Method Of Target Molecule Characterisation Using A Molecular Pore

Abstract

The invention relates to a new method of determining the presence, absence or one or more characteristics of multiple analytes. The invention concerns coupling a first analyte to a membrane containing a detector and investigating the first analyte using the detector. The invention also concerns coupling a second analyte to the membrane and investigating the second analyte. The first analyte is uncoupled from the membrane prior to investigating the second analyte. The invention also relates to polynucleotide sequencing.

Description

FIELD OF THE INVENTION

[0001] The invention relates to a new method of determining the presence, absence or one or more characteristics of multiple analytes. The invention concerns coupling a first analyte to a membrane containing a detector and investigating the first analyte using the detector. The invention also concerns coupling a second analyte to the membrane and investigating the second analyte. The first analyte is uncoupled from the membrane prior to investigating the second analyte. The invention also relates to polynucleotide sequencing.

BACKGROUND OF THE INVENTION

[0002] There is currently a need for rapid and cheap polynucleotide (e.g. DNA or RNA) sequencing and identification technologies across a wide range of applications. Existing technologies are slow and expensive mainly because they rely on amplification techniques to produce large volumes of polynucleotide and require a high quantity of specialist fluorescent chemicals for signal detection.

[0003] Transmembrane pores (nanopores) have great potential as direct, electrical biosensors for polymers and a variety of small molecules. In particular, recent focus has been given to nanopores as a potential DNA sequencing technology.

[0004] When a potential is applied across a nanopore, there is a change in the current flow when an analyte, such as a nucleotide, resides transiently in the barrel for a certain period of time. Nanopore detection of the nucleotide gives a current change of known signature and duration. In the strand sequencing method, a single polynucleotide strand is passed through the pore and the identities of the nucleotides are derived. Strand sequencing can involve the use of a polynucleotide binding protein to control the movement of the polynucleotide through the pore.

[0005] It has previously been demonstrated that ultra low concentration analyte delivery can be achieved by coupling the analyte to a membrane in which the relevant detector is present. This lowers by several orders of magnitude the amount of analyte required in order to be detected (WO 2012/164270).

SUMMARY OF THE INVENTION

[0006] The inventors have surprisingly demonstrated that it is possible to investigate multiple analytes in multiple samples by successively coupling the analytes to a membrane in which a detector is present. The first analyte is uncoupled from the membrane prior to investigating the second analyte.

[0007] Accordingly, the invention provides a method for determining the presence, absence or one or more characteristics of two or more analytes in two or more samples, comprising: [0008] (a) coupling a first analyte in a first sample to a membrane using one or more anchors; [0009] (b) allowing the first analyte to interact with a detector present in the membrane and thereby determining the presence, absence or one or more characteristics of the first analyte; [0010] (c) uncoupling the first analyte from the membrane; [0011] (d) coupling a second analyte in a second sample to the membrane using one or more anchors; and [0012] (e) allowing the second analyte to interact with a detector in the membrane and thereby determining the presence, absence or one or more characteristics of the second analyte.

[0013] The invention also provides: [0014] a method for uncoupling from a membrane an analyte coupled to the membrane using cholesterol, comprising contacting the analyte with a cyclodextrin or a derivative thereof and thereby uncoupling the analyte from the membrane; and [0015] a kit for determining the presence, absence or one or more characteristics of two or more analytes in two or more samples comprising (a) a membrane, (b) two or more anchors which are capable of coupling the two or more analytes to the membrane and (c) one or more agents which are capable of uncoupling at least one of the two or more analytes from the membrane.

DESCRIPTION OF THE FIGURES

[0016] FIG. 1 shows in section (1) the DNA template (SEQ ID NO: 31, labelled A1 and SEQ ID NO: 47 labelled A2) used to prepare the DNA used in Examples 2-4. Section (2) shows a cartoon representation of construct X (described in full in Example 2 materials and methods)--iSpC3 spacers are shown as crosses and four 5-nitroindoles as a grey box and the cholesterol tether as a grey oval; label b=SEQ ID NO: 34, label c=SEQ ID NO: 35, label d=SEQ ID NO: 39, label e=SEQ ID NO: 41. Section (3) shows a cartoon representation of construct Y (described in full in Example 2 materials and methods)--iSpC3 spacers are shown as crosses and four 5-nitroindoles as a grey box and the cholesterol tether as a grey oval; label b=SEQ ID NO: 34, label f=SEQ ID NO: 37, label g=SEQ ID NO: 40, label h=SEQ ID NO: 30.

[0017] FIG. 2 shows the experimental time course (x-axis label=time (s), y-axis label=percentage (%)) with the percentage of time the nanopores are present in their unblocked state (shown as light grey) compared to when a helicase DNA movement was occurring and the nanopores were partially blocked by the DNA strand (shown as black). DNA construct X was added at 2400 seconds as indicated by the arrow labelled X. DNA construct Y was added at 7200 seconds as indicated by the arrow labelled Y.

[0018] FIG. 3 shows part of the experimental time course (x-axis label=time (s), y-axis label=percentage (%)) with the percentage of time the nanopores are present in their unblocked state (shown as light grey) compared to when a helicase DNA movement was occurring and the nanopores were partially blocked by the DNA strand (shown as black). DNA construct X was added at 2700 seconds as indicated by the arrow labelled X. The buffer flush (10 mL) was at 7500 seconds as indicated by the arrow labelled F.

[0019] FIG. 4 shows part of the experimental time course (x-axis label=time (s), y-axis label=percentage (%)) with the percentage of time the nanopores are present in their unblocked state (shown as light grey) compared to when a helicase DNA movement was occurring and the nanopores were partially blocked by the DNA strand (shown as black). DNA construct X was added at 2700 seconds as indicated by the arrow labelled X. The 1 min methyl-.beta.-cyclodextrin incubation and then flush (100 .mu.M, 150 .mu.L) was at 6900 seconds as indicated by the arrow labelled F.

[0020] FIG. 5 shows part of the experimental time course (x-axis label=time (s), y-axis label=percentage (%)) with the percentage of time the nanopores are present in their unblocked state (shown as light grey) compared to when a helicase DNA movement was occurring and the nanopores were partially blocked by the DNA strand (shown as black). DNA construct X was added at 2400 seconds as indicated by the arrow labelled X. The 10 min methyl-.beta.-cyclodextrin incubation and then flush (100 .mu.M, 150 .mu.L) was between 6600 and 6900 seconds as indicated by the arrow labelled F and shown as white boxes.

[0021] FIG. 6 shows part of the experimental time course (x-axis label=time (s), y-axis label=percentage (%)) with the percentage of time the nanopores are present in their unblocked state (shown as light grey) compared to when a helicase DNA movement was occurring and the nanopores were partially blocked by the DNA strand (shown as black). DNA construct X was added at 2400 seconds as indicated by the arrow labelled X. The 30 min methyl-.beta.-cyclodextrin incubation and then flush (100 .mu.M, 150 .mu.L) was between 6300 and 8100 seconds as indicated by the arrow labelled F and shown as white boxes.

[0022] FIG. 7 shows how the DNA construct used in Example 5 was tethered to the membrane (labelled i). The strand of DNA which translocated through the nanopore is labelled a (SEQ ID NO: 42 attached at its 3' end to four iSpC3 spacers (labelled as crosses) which are attached at the opposite end to the 5' end of SEQ ID NO: 43). It was hybridised to two strands labelled b and c (SEQ ID NO: 44 and 45 respectively). SEQ ID NO: 45 was attached by its 3' end to six iSp18 spacers (labelled d and shown as a dotted line) which were attached at the opposite end to two thymines and a biotin group (labelled f). The biotin group was bound to streptavidin (labelled e) which also bound desthiobiotin (labelled g). Desthiobiotin was attached to the 5' end of SEQ ID NO: 46 which had a 3' cholesterol TEG (labelled h) at the opposite end.

[0023] FIG. 8 shows the current trace (y-axis label=Current (pA), x-axis label=Time (s)) of the experiment described in Example 5. The trace shows the coupling steps and the removal of the coupled DNA using free biotin. *1 label corresponds to the addition of the desthiobiotin extender, *2 corresponds to the addition of DNA construct P, *3 corresponds to the addition of free biotin and *4 corresponds to the addition of the buffer flush.

[0024] FIG. 9 shows three zoomed in regions of the current trace (all three traces have the following axes labels--y-axis label=Current (pA), x-axis label=Time (s)) shown in FIG. 8. Traces A, B and C are consecutive snap shots of part of the trace shown in FIG. 8. *1 label corresponds to the addition of the desthiobiotin extender, *2 corresponds to the addition of DNA construct P, *3 corresponds to the addition of free biotin and *4 corresponds to the addition of the buffer flush.

DESCRIPTION OF THE SEQUENCE LISTING

[0025] SEQ ID NO: 1 shows the codon optimised polynucleotide sequence encoding the MS-B1 mutant MspA monomer. This mutant lacks the signal sequence and includes the following mutations: D90N, D91N, D93N, D118R, D134R and E139K.

[0026] SEQ ID NO: 2 shows the amino acid sequence of the mature form of the MS-B1 mutant of the MspA monomer. This mutant lacks the signal sequence and includes the following mutations: D90N, D91N, D93N, D118R, D134R and E139K.

[0027] SEQ ID NO: 3 shows the polynucleotide sequence encoding one monomer of .alpha.-hemolysin-E111N/K147N (.alpha.-HL-NN; Stoddart et al., PNAS, 2009; 106(19): 7702-7707).

[0028] SEQ ID NO: 4 shows the amino acid sequence of one monomer of .alpha.-HL-NN.

[0029] SEQ ID NOs: 5 to 7 show the amino acid sequences of MspB, C and D.

[0030] SEQ ID NO: 8 shows the polynucleotide sequence encoding the Phi29 DNA polymerase.

[0031] SEQ ID NO: 9 shows the amino acid sequence of the Phi29 DNA polymerase.

[0032] SEQ ID NO: 10 shows the codon optimised polynucleotide sequence derived from the sbcB gene from E. coli. It encodes the exonuclease I enzyme (EcoExo I) from E. coli.

[0033] SEQ ID NO: 11 shows the amino acid sequence of exonuclease I enzyme (EcoExo I) from E. coli.

[0034] SEQ ID NO: 12 shows the codon optimised polynucleotide sequence derived from the xthA gene from E. coli. It encodes the exonuclease III enzyme from E. coli.

[0035] SEQ ID NO: 13 shows the amino acid sequence of the exonuclease III enzyme from E. coli. This enzyme performs distributive digestion of 5' monophosphate nucleosides from one strand of double stranded DNA (dsDNA) in a 3'-5' direction. Enzyme initiation on a strand requires a 5' overhang of approximately 4 nucleotides.

[0036] SEQ ID NO: 14 shows the codon optimised polynucleotide sequence derived from the recJ gene from T. thermophilus. It encodes the RecJ enzyme from T. thermophilus (TthRecJ-cd).

[0037] SEQ ID NO: 15 shows the amino acid sequence of the RecJ enzyme from T. thermophilus (TthRecJ-cd). This enzyme performs processive digestion of 5' monophosphate nucleosides from ssDNA in a 5'-3' direction. Enzyme initiation on a strand requires at least 4 nucleotides.

[0038] SEQ ID NO: 16 shows the codon optimised polynucleotide sequence derived from the bacteriophage lambda exo (redX) gene. It encodes the bacteriophage lambda exonuclease.

[0039] SEQ ID NO: 17 shows the amino acid sequence of the bacteriophage lambda exonuclease. The sequence is one of three identical subunits that assemble into a trimer. The enzyme performs highly processive digestion of nucleotides from one strand of dsDNA, in a 5'-3' direction (http://www.neb.com/nebecomm/products/productM0262.asp). Enzyme initiation on a strand preferentially requires a 5' overhang of approximately 4 nucleotides with a 5' phosphate.

[0040] SEQ ID NO: 18 shows the amino acid sequence of Hel308 Mbu.

[0041] SEQ ID NO: 19 shows the amino acid sequence of Hel308 Csy.

[0042] SEQ ID NO: 20 shows the amino acid sequence of Hel308 Tga.

[0043] SEQ ID NO: 21 shows the amino acid sequence of Hel308 Mhu.

[0044] SEQ ID NO: 22 shows the amino acid sequence of TraI Eco.

[0045] SEQ ID NO: 23 shows the amino acid sequence of XPD Mbu.

[0046] SEQ ID NO: 24 shows the amino acid sequence of Dda 1993.

[0047] SEQ ID NO: 25 shows the amino acid sequence of Trwc Cba.

[0048] SEQ ID NO: 26 shows a polynucleotide sequence used in Example 1.

[0049] SEQ ID NO: 27 shows a polynucleotide sequence used in Example 1. SEQ ID NO: 27 is attached at the 3' end to four iSp18 spacers which are attached at the opposite end to the 5' end of SEQ ID NO: 28.

[0050] SEQ ID NO: 28 shows a polynucleotide sequence used in Example 1. SEQ ID NO: 28 is attached at its 5' end to four iSp18 spacers which are attached at the opposite end to the 3' end of SEQ ID NO: 27.

[0051] SEQ ID NO: 29 shows a polynucleotide sequence used in Example 1.

[0052] SEQ ID NOs: 30 to 41 shows polynucleotide sequences used in Example 2.

[0053] SEQ ID NO: 42 to 46 shows polynucleotide sequences used in Example 5.

[0054] SEQ ID NO: 47 shows a polynucleotide sequence used in Example 2.

DETAILED DESCRIPTION OF THE INVENTION

[0055] It is to be understood that different applications of the disclosed products and methods may be tailored to the specific needs in the art. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

[0056] In addition as used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "an analyte" includes two or more analytes, reference to "a polynucleotide" includes two or more polynucleotides, reference to "an anchor" refers to two or more anchors, reference to "a helicase" includes two or more helicases, reference to "a transmembrane pore" includes two or more pores and the like.

[0057] All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

Method of the Invention

[0058] The invention provides a method for determining the presence, absence or one or more characteristics of two or more analytes. The method comprises coupling a first analyte in a first sample to a membrane using one or more anchors and allowing the analyte to interact with a detector present in the membrane. The presence, absence or one or more characteristics of the first analyte is thereby determined. The method also comprises coupling a second analyte in a second sample to the membrane using one or more anchors and allowing the second analyte to interact with a detector present in the membrane. The presence, absence or one or more characteristics of the second analyte is thereby determined. The first analyte may be uncoupled from the membrane before, after or at the same time as the second analyte is coupled to the membrane.

[0059] The inventors have surprisingly demonstrated that ultra low concentration analyte delivery to a detector can be achieved by coupling analytes to a membrane in which detector is present. This lowers by several orders of magnitude the amount of analyte required in order to be detected. The extent to which the amount of analyte needed is reduced could not have been predicted.

[0060] In particular, the inventors surprisingly report an increase in the capture of single stranded polynucleotide by .about.4 orders of magnitude over that previously reported. As both the detector and analyte are now on the same plane, then .about.10.sup.3 M s.sup.-1 more interactions occur per second, as diffusion of both molecules is in two dimensions rather than three dimensions. This has dramatic implications on the sample preparation requirements that are of key concern for diagnostic devices such as next-generation sequencing systems.

[0061] In addition, coupling the analyte to a membrane has added advantages for various nanopore-enzyme sequencing applications. In strand sequencing, when the polynucleotide analyte is introduced the pore may become blocked permanently or temporarily, preventing the sequencing of the polynucleotide. When one end of the polynucleotide analyte is localised away from the pore, for example by coupling or tethering to the membrane, surprisingly it was found that this temporary or permanent blocking is no longer observed. By occupying one end of the polynucleotide by coupling it to the membrane it also acts to effectively increase the analyte concentration over the detector and so increase the sequencing systems duty cycle.

[0062] The method is of course advantageous for detecting multiple analytes that are present at low concentrations. The method preferably allows the presence or one or more characteristics of the two or more analytes to be determined when each analyte is present at a concentration of from about 0.001 pM to about 1 nM, such as less than 0.01 pM, less than 0.1 pM, less than 1 pM, less than 10 pM or less than 100 pM.

[0063] The method of the invention is particularly advantageous for polynucleotide sequencing because only small amounts of purified polynucleotide can be obtained from human blood. The method preferably allows estimating the sequence of, or allows sequencing of, a polynucleotide that is present at a concentration of from about 0.001 pM to about 1 nM, such as less than 0.01 pM, less than 0.1 pM, less than 1 pM, less than 10 pM or less than 100 pM. As discussed in more detail below, the two or more analytes may be two or more instances of the same analyte. This is advantageous in polynucleotide sequencing because it allows the sequence of a polynucleotide to be investigated more than once. This leads to increased sequencing efficiency and accuracy.

[0064] Coupling one end of a polynucleotide to the membrane (even temporarily) also means that the end will be prevented from interfering with the nanopore-based sequencing process.

[0065] The method of the invention also has other advantages. The method provides an alternative to the simultaneous measurement of two or more analytes which removes the need to decouple the measurement signals obtained from each analyte. The method enables the sequential determination of two or more analytes wherein, for example, the conditions required to determine each analyte differ, thus making simultaneous measurement impractical. The method also conveniently enables the measurement of two or more analytes using the same membrane thus providing the possibility for multiple use and extending the lifetime of the membrane.

Analytes

[0066] The method of the invention concerns determining the presence, absence or one or more characteristics of two or more analytes. Any number of analytes can be investigated. For instance, the method of the invention may concern determining the presence, absence or one or more characteristics of 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 100 or more analytes. If three or more analytes are investigated using the method of the invention, the second analyte is also uncoupled from the membrane and the requisite number of steps are added for the third analyte. The same is true for four or more analytes.

[0067] The method of the invention may comprise determining or measuring one or more characteristics of each analyte. The method may involve determining or measuring two, three, four or five or more characteristics of each analyte. The one or more characteristics are preferably selected from (i) the size of the analyte, (ii) the identity of the analyte, (iii) the secondary structure of the analyte and (iv) whether or not the analyte is modified. Any combination of (i) to (iv) may be measured in accordance with the invention, such as {i}, {ii}, {iii}, {iv}, {i,ii}, {i,iii}, {i,iv}, {ii,iii}, {ii,iv}, {iii,iv}, {i,ii,iii}, {i,ii,iv}, {i,iii,iv}{ii,iii,iv} or {i,ii,iii,iv}. Different combinations of (i) to (iv) may be measured for the first analyte compared with the second analyte, including any of those combinations listed above. The method preferably comprises estimating the sequence of or sequencing a first polynucleotide and/or a second polynucleotide.

[0068] Each analyte can be any substance. Suitable analytes include, but are not limited to, metal ions, inorganic salts, polymers, such as a polymeric acids or bases, dyes, bleaches, pharmaceuticals, diagnostic agents, recreational drugs, explosives and environmental pollutants.

[0069] The first analyte and/or second analyte can be an analyte that is secreted from cells. Alternatively, the first analyte and/or second analyte can be an analyte that is present inside cells such that the analyte(s) must be extracted from the cells before the invention can be carried out.

[0070] The first analyte and/or second analyte is preferably an amino acid, peptide, polypeptide, a protein or a polynucleotide. The amino acid, peptide, polypeptide or protein can be naturally-occurring or non-naturally-occurring. The polypeptide or protein can include within it synthetic or modified amino acids. A number of different types of modification to amino acids are known in the art. For the purposes of the invention, it is to be understood that the first analyte and/or second analyte can be modified by any method available in the art.

[0071] The protein can be an enzyme, antibody, hormone, growth factor or growth regulatory protein, such as a cytokine. The cytokine may be selected from an interleukin, preferably IFN-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 or IL-13, an interferon, preferably IL-.gamma. or other cytokines such as TNF-.alpha.. The protein may be a bacterial protein, fungal protein, virus protein or parasite-derived protein. Before it is contacted with the detector, the protein may be unfolded to form a polypeptide chain.

[0072] The first analyte and/or second analyte is most preferably a polynucleotide, such as a nucleic acid. Polynucleotides are discussed in more detail below. A polynucleotide may be coupled to the membrane at its 5' end or 3' end or at one or more intermediate points along the strand. The polynucleotide can be single stranded or double stranded as discussed below. The polynucleotide may be circular. The polynucleotide may be an aptamer, a probe which hybridises to microRNA or microRNA itself (Wang, Y. et al, Nature Nanotechnology, 2011, 6, 668-674). The two polynucleotide analytes may be polynucleotides which bind two proteins and may be used to characterise the proteins, for instance to determine their concentration.

[0073] When the analyte is a probe which hybridises to microRNA, the probe may be coupled permanently or transiently to the membrane. This is discussed in more detail below. The probe itself may be adapted to couple directly to the membrane or may hybridise to a complementary polynucleotide which has been adapted to couple to the membrane. The analyte may be a complex of microRNA hybridised to a probe where the probe has distinctive sequences or barcodes enabling it to be identified unambiguously.

[0074] When the first analyte and/or second analyte is an aptamer, the aptamer may be coupled permanently or transiently to the membrane. The aptamer itself may be adapted to couple directly to the membrane or may hybridise to a complementary polynucleotide which has been adapted to couple to the membrane. The aptamer may be bound or unbound to a protein analyte and the ultimate purpose of detecting the aptamer may be to detect the presence, absence or one or more characteristics of a protein analyte to which it binds.

[0075] The first analyte and second analyte may be different from one another. For instance, the first analyte may be a protein and the second analyte may be a polynucleotide. Alternatively, the first and second analytes may be different polynucleotides. In such instances, there may be no need to remove at least part of the first sample before adding the second sample. This is discussed in more detail below. If the method concerns investigating three or more analytes, they may all be different from one another or some of them may be different from one another.

[0076] The first analyte and the second analyte may be two instances of the same analyte. The first analyte may be identical to the second analyte. This allows proofreading, particularly if the analytes are polynucleotides. If the method concerns investigating three or more analytes, they may all be three or more instances of the same analyte or some of them may be separate instances of the same analyte.

Polynucleotide

[0077] The first and/or second analyte is preferably a polynucleotide. A polynucleotide, such as a nucleic acid, is a macromolecule comprising two or more nucleotides. The polynucleotide or nucleic acid may comprise any combination of any nucleotides. The nucleotides can be naturally occurring or artificial. One or more nucleotides in the polynucleotide can be oxidized or methylated. One or more nucleotides in the polynucleotide may be damaged. For instance, the polynucleotide may comprise a pyrimidine dimer. Such dimers are typically associated with damage by ultraviolet light and are the primary cause of skin melanomas. One or more nucleotides in the polynucleotide may be modified, for instance with a label or a tag. Suitable labels are described below. The polynucleotide may comprise one or more spacers.

[0078] A nucleotide typically contains a nucleobase, a sugar and at least one phosphate group. The nucleobase and sugar form a nucleoside.

[0079] The nucleobase is typically heterocyclic. Nucleobases include, but are not limited to, purines and pyrimidines and more specifically adenine (A), guanine (G), thymine (T), uracil (U) and cytosine (C).

[0080] The sugar is typically a pentose sugar. Nucleotide sugars include, but are not limited to, ribose and deoxyribose. The sugar is preferably a deoxyribose.

[0081] The polynucleotide preferably comprises the following nucleosides: deoxyadenosine (dA), deoxyuridine (dU) and/or thymidine (dT), deoxyguanosine (dG) and deoxycytidine (dC).

[0082] The nucleotide is typically a ribonucleotide or deoxyribonucleotide. The nucleotide typically contains a monophosphate, diphosphate or triphosphate. The nucleotide may comprise more than three phosphates, such as 4 or 5 phosphates. Phosphates may be attached on the 5' or 3' side of a nucleotide. Nucleotides include, but are not limited to, adenosine monophosphate (AMP), guanosine monophosphate (GMP), thymidine monophosphate (TMP), uridine monophosphate (UMP), 5-methylcytidine monophosphate, 5-hydroxymethylcytidine monophosphate, cytidine monophosphate (CMP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), deoxyadenosine monophosphate (dAMP), deoxyguanosine monophosphate (dGMP), deoxythymidine monophosphate (dTMP), deoxyuridine monophosphate (dUMP), deoxycytidine monophosphate (dCMP) and deoxymethylcytidine monophosphate. The nucleotides are preferably selected from AMP, TMP, GMP, CMP, UMP, dAMP, dTMP, dGMP, dCMP and dUMP.

[0083] A nucleotide may be abasic (i.e. lack a nucleobase). A nucleotide may also lack a nucleobase and a sugar (i.e. is a C3 spacer).

[0084] The nucleotides in the polynucleotide may be attached to each other in any manner. The nucleotides are typically attached by their sugar and phosphate groups as in nucleic acids. The nucleotides may be connected via their nucleobases as in pyrimidine dimers.

[0085] The polynucleotide may be single stranded or double stranded. At least a portion of the polynucleotide is preferably double stranded.

[0086] The polynucleotide can be a nucleic acid, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The polynucleotide can comprise one strand of RNA hybridised to one strand of DNA. The polynucleotide may be any synthetic nucleic acid known in the art, such as peptide nucleic acid (PNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA), locked nucleic acid (LNA), bridged nucleic acid (BNA) or other synthetic polymers with nucleotide side chains. The PNA backbone is composed of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. The GNA backbone is composed of repeating glycol units linked by phosphodiester bonds. The TNA backbone is composed of repeating threose sugars linked together by phosphodiester bonds. LNA is formed from ribonucleotides as discussed above having an extra bridge connecting the 2' oxygen and 4' carbon in the ribose moiety.

[0087] The polynucleotide is most preferably ribonucleic nucleic acid (RNA) or deoxyribonucleic acid (DNA).

[0088] The polynucleotide can be any length. For example, the polynucleotide can be at least 10, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400 or at least 500 nucleotides or nucleotide pairs in length. The polynucleotide can be 1000 or more nucleotides or nucleotide pairs, 5000 or more nucleotides or nucleotide pairs in length or 100000 or more nucleotides or nucleotide pairs in length.

Sample

[0089] Each analyte is typically present in any suitable sample. The invention is typically carried out on two or more samples that are known to contain or suspected to contain the analytes. Alternatively, the invention may be carried out on two or more samples to confirm the identity of two or more analytes whose presence in the samples is known or expected.

[0090] The first sample and/or second sample may be a biological sample. The invention may be carried out in vitro using at least one sample obtained from or extracted from any organism or microorganism. The organism or microorganism is typically archaeal, prokaryotic or eukaryotic and typically belongs to one of the five kingdoms: plantae, animalia, fungi, monera and protista. The invention may be carried out in vitro on at least one sample obtained from or extracted from any virus. The first sample and/or second sample is preferably a fluid sample. The first sample and/or second sample typically comprises a body fluid of the patient. The first sample and/or second sample may be urine, lymph, saliva, mucus or amniotic fluid but is preferably blood, plasma or serum. Typically, the first sample and/or second sample is human in origin, but alternatively it may be from another mammal animal such as from commercially farmed animals such as horses, cattle, sheep, fish, chickens or pigs or may alternatively be pets such as cats or dogs. Alternatively, the first sample and/or second sample may be of plant origin, such as a sample obtained from a commercial crop, such as a cereal, legume, fruit or vegetable, for example wheat, barley, oats, canola, maize, soya, rice, rhubarb, bananas, apples, tomatoes, potatoes, grapes, tobacco, beans, lentils, sugar cane, cocoa, cotton.

[0091] The first sample and/or second sample may be a non-biological sample. The non-biological sample is preferably a fluid sample. Examples of non-biological samples include surgical fluids, water such as drinking water, sea water or river water, and reagents for laboratory tests.

[0092] The first sample and/or second sample is typically processed prior to being used in the invention, for example by centrifugation or by passage through a membrane that filters out unwanted molecules or cells, such as red blood cells. The first sample and/or second sample may be measured immediately upon being taken. The first sample and/or second sample may also be typically stored prior to assay, preferably below -70.degree. C.

[0093] The first sample and second sample may be different from one another. For instance, the first sample may be derived from a human and the second sample may be derived from a virus. If the first and second samples are different from one another, they may contain or be suspected of containing the same first and second analytes. If the method concerns investigating three or more samples, they may all be different from one another or some of them may be different from one another.

[0094] The first sample and the second sample are preferably two instances of the same sample. The first sample is preferably identical to the second sample. This allows proofreading, particularly if the analytes are polynucleotides. If the method concerns investigating three or more samples, they may all be three or more instances of the same sample or some of them may be separate instances of the same sample.

Membrane

[0095] Any membrane may be used in accordance with the invention. Suitable membranes are well-known in the art. The membrane is preferably an amphiphilic layer. An amphiphilic layer is a layer formed from amphiphilic molecules, such as phospholipids, which have both hydrophilic and lipophilic properties. The amphiphilic molecules may be synthetic or naturally occurring. Non-naturally occurring amphiphiles and amphiphiles which form a monolayer are known in the art and include, for example, block copolymers (Gonzalez-Perez et al., Langmuir, 2009, 25, 10447-10450). Block copolymers are polymeric materials in which two or more monomer sub-units are polymerized together to create a single polymer chain. Block copolymers typically have properties that are contributed by each monomer sub-unit. However, a block copolymer may have unique properties that polymers formed from the individual sub-units do not possess. Block copolymers can be engineered such that one of the monomer sub-units is hydrophobic (i.e. lipophilic), whilst the other sub-unit(s) are hydrophilic whilst in aqueous media. In this case, the block copolymer may possess amphiphilic properties and may form a structure that mimics a biological membrane. The block copolymer may be a diblock (consisting of two monomer sub-units), but may also be constructed from more than two monomer sub-units to form more complex arrangements that behave as amphiphiles. The copolymer may be a triblock, tetrablock or pentablock copolymer. The membrane is preferably a triblock copolymer membrane.

[0096] Archaebacterial bipolar tetraether lipids are naturally occurring lipids that are constructed such that the lipid forms a monolayer membrane. These lipids are generally found in extremophiles that survive in harsh biological environments, thermophiles, halophiles and acidophiles. Their stability is believed to derive from the fused nature of the final bilayer. It is straightforward to construct block copolymer materials that mimic these biological entities by creating a triblock polymer that has the general motif hydrophilic-hydrophobic-hydrophilic. This material may form monomeric membranes that behave similarly to lipid bilayers and encompasses a range of phase behaviours from vesicles through to laminar membranes. Membranes formed from these triblock copolymers hold several advantages over biological lipid membranes. Because the triblock copolymer is synthesized, the exact construction can be carefully controlled to provide the correct chain lengths and properties required to form membranes and to interact with pores and other proteins.

[0097] Block copolymers may also be constructed from sub-units that are not classed as lipid sub-materials; for example a hydrophobic polymer may be made from siloxane or other non-hydrocarbon based monomers. The hydrophilic sub-section of block copolymer can also possess low protein binding properties, which allows the creation of a membrane that is highly resistant when exposed to raw biological samples. This head group unit may also be derived from non-classical lipid head-groups.

[0098] Triblock copolymer membranes also have increased mechanical and environmental stability compared with biological lipid membranes, for example a much higher operational temperature or pH range. The synthetic nature of the block copolymers provides a platform to customize polymer based membranes for a wide range of applications.

[0099] In a preferred embodiment, the invention provides a method for determining the presence, absence or one or more characteristics of two or more analytes in two or more samples, comprising (a) coupling a first analyte in a first sample to a membrane using one or more anchors comprising a triblock copolymer, optionally wherein the membrane is modified to facilitate the coupling; (b) allowing the first analyte to interact with a detector present in the membrane and thereby determining the presence, absence or one or more characteristics of the first analyte; (c) uncoupling the first analyte from the membrane; (d) coupling a second analyte in a second sample to the membrane using one or more anchors; and (e) allowing the second analyte to interact with a detector in the membrane and thereby determining the presence, absence or one or more characteristics of the second analyte.

[0100] The membrane is most preferably one of the membranes disclosed in International Application No. PCT/GB2013/052766 or PCT/GB2013/052767.

[0101] The amphiphilic molecules may be chemically-modified or functionalised to facilitate coupling of the analyte.

[0102] The amphiphilic layer may be a monolayer or a bilayer. The amphiphilic layer is typically planar. The amphiphilic layer may be curved. The amphiphilic layer may be supported.

[0103] Amphiphilic membranes are typically naturally mobile, essentially acting as two dimensional fluids with lipid diffusion rates of approximately 10.sup.-8 cm s-1. This means that the detector and coupled analyte can typically move within an amphiphilic membrane.

[0104] The membrane may be a lipid bilayer. Lipid bilayers are models of cell membranes and serve as excellent platforms for a range of experimental studies. For example, lipid bilayers can be used for in vitro investigation of membrane proteins by single-channel recording. Alternatively, lipid bilayers can be used as biosensors to detect the presence of a range of substances. The lipid bilayer may be any lipid bilayer. Suitable lipid bilayers include, but are not limited to, a planar lipid bilayer, a supported bilayer or a liposome. The lipid bilayer is preferably a planar lipid bilayer. Suitable lipid bilayers are disclosed in International Application No. PCT/GB08/000563 (published as WO 2008/102121), International Application No. PCT/GB08/004127 (published as WO 2009/077734) and International Application No. PCT/GB2006/001057 (published as WO 2006/100484).

[0105] Methods for forming lipid bilayers are known in the art. Suitable methods are disclosed in the Example. Lipid bilayers are commonly formed by the method of Montal and Mueller (Proc. Natl. Acad. Sci. USA., 1972; 69: 3561-3566), in which a lipid monolayer is carried on aqueous solution/air interface past either side of an aperture which is perpendicular to that interface. The lipid is normally added to the surface of an aqueous electrolyte solution by first dissolving it in an organic solvent and then allowing a drop of the solvent to evaporate on the surface of the aqueous solution on either side of the aperture. Once the organic solvent has evaporated, the solution/air interfaces on either side of the aperture are physically moved up and down past the aperture until a bilayer is formed. Planar lipid bilayers may be formed across an aperture in a membrane or across an opening into a recess.

[0106] The method of Montal & Mueller is popular because it is a cost-effective and relatively straightforward method of forming good quality lipid bilayers that are suitable for protein pore insertion. Other common methods of bilayer formation include tip-dipping, painting bilayers and patch-clamping of liposome bilayers.

[0107] Tip-dipping bilayer formation entails touching the aperture surface (for example, a pipette tip) onto the surface of a test solution that is carrying a monolayer of lipid. Again, the lipid monolayer is first generated at the solution/air interface by allowing a drop of lipid dissolved in organic solvent to evaporate at the solution surface. The bilayer is then formed by the Langmuir-Schaefer process and requires mechanical automation to move the aperture relative to the solution surface.

[0108] For painted bilayers, a drop of lipid dissolved in organic solvent is applied directly to the aperture, which is submerged in an aqueous test solution. The lipid solution is spread thinly over the aperture using a paintbrush or an equivalent. Thinning of the solvent results in formation of a lipid bilayer. However, complete removal of the solvent from the bilayer is difficult and consequently the bilayer formed by this method is less stable and more prone to noise during electrochemical measurement.

[0109] Patch-clamping is commonly used in the study of biological cell membranes. The cell membrane is clamped to the end of a pipette by suction and a patch of the membrane becomes attached over the aperture. The method has been adapted for producing lipid bilayers by clamping liposomes which then burst to leave a lipid bilayer sealing over the aperture of the pipette. The method requires stable, giant and unilamellar liposomes and the fabrication of small apertures in materials having a glass surface.

[0110] Liposomes can be formed by sonication, extrusion or the Mozafari method (Colas et al. (2007) Micron 38:841-847).

[0111] In a preferred embodiment, the lipid bilayer is formed as described in International Application No. PCT/GB08/004127 (published as WO 2009/077734). Advantageously in this method, the lipid bilayer is formed from dried lipids. In a most preferred embodiment, the lipid bilayer is formed across an opening as described in WO2009/077734 (PCT/GB08/004127).

[0112] A lipid bilayer is formed from two opposing layers of lipids. The two layers of lipids are arranged such that their hydrophobic tail groups face towards each other to form a hydrophobic interior. The hydrophilic head groups of the lipids face outwards towards the aqueous environment on each side of the bilayer. The bilayer may be present in a number of lipid phases including, but not limited to, the liquid disordered phase (fluid lamellar), liquid ordered phase, solid ordered phase (lamellar gel phase, interdigitated gel phase) and planar bilayer crystals (lamellar sub-gel phase, lamellar crystalline phase).

[0113] Any lipid composition that forms a lipid bilayer may be used. The lipid composition is chosen such that a lipid bilayer having the required properties, such surface charge, ability to support membrane proteins, packing density or mechanical properties, is formed. The lipid composition can comprise one or more different lipids. For instance, the lipid composition can contain up to 100 lipids. The lipid composition preferably contains 1 to 10 lipids. The lipid composition may comprise naturally-occurring lipids and/or artificial lipids.

[0114] The lipids typically comprise a head group, an interfacial moiety and two hydrophobic tail groups which may be the same or different. Suitable head groups include, but are not limited to, neutral head groups, such as diacylglycerides (DG) and ceramides (CM); zwitterionic head groups, such as phosphatidylcholine (PC), phosphatidylethanolamine (PE) and sphingomyelin (SM); negatively charged head groups, such as phosphatidylglycerol (PG); phosphatidylserine (PS), phosphatidylinositol (PI), phosphatic acid (PA) and cardiolipin (CA); and positively charged headgroups, such as trimethylammonium-Propane (TAP). Suitable interfacial moieties include, but are not limited to, naturally-occurring interfacial moieties, such as glycerol-based or ceramide-based moieties. Suitable hydrophobic tail groups include, but are not limited to, saturated hydrocarbon chains, such as lauric acid (n-Dodecanolic acid), myristic acid (n-Tetradecononic acid), palmitic acid (n-Hexadecanoic acid), stearic acid (n-Octadecanoic) and arachidic (n-Eicosanoic); unsaturated hydrocarbon chains, such as oleic acid (cis-9-Octadecanoic); and branched hydrocarbon chains, such as phytanoyl. The length of the chain and the position and number of the double bonds in the unsaturated hydrocarbon chains can vary. The length of the chains and the position and number of the branches, such as methyl groups, in the branched hydrocarbon chains can vary. The hydrophobic tail groups can be linked to the interfacial moiety as an ether or an ester. The lipids may be mycolic acid.

[0115] The lipids can also be chemically-modified. The head group or the tail group of the lipids may be chemically-modified. Suitable lipids whose head groups have been chemically-modified include, but are not limited to, PEG-modified lipids, such as 1,2-Diacyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000]; functionalised PEG Lipids, such as 1,2-Distearoyl-sn-Glycero-3 Phosphoethanolamine-N-[Biotinyl(Polyethylene Glycol)2000]; and lipids modified for conjugation, such as 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-(succinyl) and 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-(Biotinyl). Suitable lipids whose tail groups have been chemically-modified include, but are not limited to, polymerisable lipids, such as 1,2-bis(10,12-tricosadiynoyl)-sn-Glycero-3-Phosphocholine; fluorinated lipids, such as 1-Palmitoyl-2-(16-Fluoropalmitoyl)-sn-Glycero-3-Phosphocholine; deuterated lipids, such as 1,2-Dipalmitoyl-D62-sn-Glycero-3-Phosphocholine; and ether linked lipids, such as 1,2-Di-O-phytanyl-sn-Glycero-3-Phosphocholine. The lipids may be chemically-modified or functionalised to facilitate coupling of the analyte.

[0116] The amphiphilic layer, for example the lipid composition, typically comprises one or more additives that will affect the properties of the layer. Suitable additives include, but are not limited to, fatty acids, such as palmitic acid, myristic acid and oleic acid; fatty alcohols, such as palmitic alcohol, myristic alcohol and oleic alcohol; sterols, such as cholesterol, ergosterol, lanosterol, sitosterol and stigmasterol; lysophospholipids, such as 1-Acyl-2-Hydroxy-sn-Glycero-3-Phosphocholine; and ceramides.

[0117] In another preferred embodiment, the membrane is a solid state layer. Solid state layers can be formed from both organic and inorganic materials including, but not limited to, microelectronic materials, insulating materials such as Si.sub.3N.sub.4, Al.sub.2O.sub.3, and SiO, organic and inorganic polymers such as polyamide, plastics such as Teflon.RTM. or elastomers such as two-component addition-cure silicone rubber, and glasses. The solid state layer may be formed from graphene. Suitable graphene layers are disclosed in International Application No. PCT/US2008/010637 (published as WO 2009/035647).

[0118] The method is typically carried out using (i) an artificial amphiphilic layer comprising a pore, (ii) an isolated, naturally-occurring lipid bilayer comprising a pore, or (iii) a cell having a pore inserted therein. The method is typically carried out using an artificial amphiphilic layer, such as an artificial triblock copolymer layer. The layer may comprise other transmembrane and/or intramembrane proteins as well as other molecules in addition to the pore. Suitable apparatus and conditions are discussed below. The method of the invention is typically carried out in vitro.

Coupling

[0119] Each analyte may be coupled to the membrane using any known method. Each analyte is coupled to the membrane using one or more anchors.

[0120] Coupling means that the analyte is intentionally linked with the membrane using the one or more anchors. The method preferably comprises specifically coupling the first analyte to the membrane using the one or more anchors. The method preferably comprises specifically coupling the second analyte to the membrane using the one or more anchors. The first analyte and/or the second analyte is preferably not coupled with the membrane via non-specific interactions.

[0121] Each anchor comprises a group which couples (or binds) to the adaptor and a group which couples (or binds) to the membrane. Each anchor may covalently couple (or bind) to the adaptor and/or the membrane.

[0122] Each analyte may be coupled to the membrane using any number of anchors, such as 2, 3, 4 or more anchors. For instance, one analyte may be coupled to the membrane using two anchors each of which separately couples (or binds) to both the analyte and membrane.

[0123] The one or more anchors may comprise one or more polynucleotide binding proteins. Each anchor may comprise one or more polynucleotide binding proteins. The polynucleotide binding protein(s) may be any of those discussed below.

[0124] In some embodiments, the second analyte is coupled to the membrane using the one or more anchors that were left behind in the membrane following the uncoupling of the first analyte. Alternatively, the second analyte is coupled to the membrane using other (or separate) one or more anchors. The one or more anchors used to couple the second analyte may be the same type of anchor used to couple the first analyte or may be a different type of anchor. This is discussed in more detail below.

[0125] If the membrane is an amphiphilic layer, such as a triblock copolymer membrane, the one or more anchors preferably comprise a polypeptide anchor present in the membrane and/or a hydrophobic anchor present in the membrane. The hydrophobic anchor is preferably a lipid, fatty acid, sterol, carbon nanotube, polypeptide, protein or amino acid, for example cholesterol, palmitate or tocopherol. In preferred embodiments, the one or more anchors are not the detector.

[0126] The components of the membrane, such as the amphiphilic molecules, copolymer or lipids, may be chemically-modified or functionalised to form the one or more anchors. Examples of suitable chemical modifications and suitable ways of functionalising the components of the membrane are discussed in more detail below. Any proportion of the membrane components may be functionalized, for example at least 0.01%, at least 0.1%, at least 1%, at least 10%, at least 25%, at least 50% or 100%.

[0127] The first and/or second analyte may be coupled directly to the membrane. The one or more anchors used to couple the first analyte and/or the second analyte to the membrane preferably comprise a linker. The one or more anchors may comprise one or more, such as 2, 3, 4 or more, linkers. One linker may be used couple more than one, such as 2, 3, 4 or more, analytes to the membrane.

[0128] Preferred linkers include, but are not limited to, polymers, such as polynucleotides, polyethylene glycols (PEGs), polysaccharides and polypeptides. These linkers may be linear, branched or circular. For instance, the linker may be a circular polynucleotide. If the analyte is itself a polynucleotide, it may hybridise to a complementary sequence on the circular polynucleotide linker.

[0129] The one or more anchors or one or more linkers may comprise a component that can be cut or broken down, such as a restriction site or a photolabile group.

[0130] Functionalised linkers and the ways in which they can couple molecules are known in the art. For instance, linkers functionalised with maleimide groups will react with and attach to cysteine residues in proteins. In the context of this invention, the protein may be present in the membrane, may be the analyte itself or may be used to couple (or bind) to the analyte. This is discussed in more detail below.

[0131] Crosslinkage of analytes can be avoided using a "lock and key" arrangement. Only one end of each linker may react together to form a longer linker and the other ends of the linker each react with the analyte or membrane respectively. Such linkers are described in International Application No. PCT/GB10/000132 (published as WO 2010/086602).

[0132] The use of a linker is preferred in the sequencing embodiments discussed below. If a polynucleotide analyte is permanently coupled directly to the membrane in the sense that it does not uncouple when interacting with the detector (i.e. does not uncouple in step (b) or (e)), then some sequence data will be lost as the sequencing run cannot continue to the end of the polynucleotide due to the distance between the membrane and the detector. If a linker is used, then the polynucleotide analyte can be processed to completion.

[0133] The coupling may be permanent or stable. In other words, the coupling may be such that the analyte remains coupled to the membrane when interacting with the detector (i.e. does not uncouple in step (b) or (e)).

[0134] The coupling may be transient. In other words, the coupling may be such that the analyte may decouple from the membrane when interacting with the detector (i.e. may uncouple in step (b) or (e)). Typically, some instances of the first analyte remain coupled to the membrane, for instance, because they do not interact with the detector and so need to be uncoupled in step (c). For certain applications, such as aptamer detection and polynucleotide sequencing, the transient nature of the coupling is preferred. If a permanent or stable linker is attached directly to either the 5' or 3' end of a polynucleotide and the linker is shorter than the distance between the membrane and the transmembrane pore's channel, then some sequence data will be lost as the sequencing run cannot continue to the end of the polynucleotide. If the coupling is transient, then when the coupled end randomly becomes free of the membrane, then the polynucleotide can be processed to completion. Chemical groups that form permanent/stable or transient links are discussed in more detail below. The analyte may be transiently coupled to an amphiphilic layer or triblock copolymer membrane using cholesterol or a fatty acyl chain. Any fatty acyl chain having a length of from 6 to 30 carbon atom, such as hexadecanoic acid, may be used.

[0135] In preferred embodiments, a polynucleotide analyte, such as a nucleic acid, is coupled to an amphiphilic layer such as a triblock copolymer membrane or lipid bilayer. Coupling of nucleic acids to synthetic lipid bilayers has been carried out previously with various different tethering strategies. These are summarised in Table 1 below.

TABLE-US-00001 TABLE 1 Anchor comprising Type of coupling Reference Thiol Stable Yoshina-Ishii, C. and S. G. Boxer (2003). "Arrays of mobile tethered vesicles on supported lipid bilayers." J Am Chem Soc 125(13): 3696-7. Biotin Stable Nikolov, V., R. Lipowsky, et al. (2007). "Behavior of giant vesicles with anchored DNA molecules." Biophys J 92(12): 4356-68 Cholesterol Transient Pfeiffer, I. and F. Hook (2004). "Bivalent cholesterol-based coupling of oligonucletides to lipid membrane assemblies." J Am Chem Soc 126(33): 10224-5 Surfactant (e.g. Stable van Lengerich, B., R. J. Rawle, et al. "Covalent Lipid, Palmitate, etc) attachment of lipid vesicles to a fluid-supported bilayer allows observation of DNA-mediated vesicle interactions." Langmuir 26(11): 8666-72

[0136] Synthetic polynucleotide analytes and/or linkers may be functionalised using a modified phosphoramidite in the synthesis reaction, which is easily compatible for the direct addition of suitable anchoring groups, such as cholesterol, tocopherol, palmitate, thiol, lipid and biotin groups. These different attachment chemistries give a suite of options for attachment to polynucleotides. Each different modification group couples the polynucleotide in a slightly different way and coupling is not always permanent so giving different dwell times for the analyte to the membrane. The advantages of transient coupling are discussed above.

[0137] Coupling of polynucleotides to a linker or to a functionalised membrane can also be achieved by a number of other means provided that a complementary reactive group or an anchoring group can be added to the polynucleotide. The addition of reactive groups to either end of a polynucleotide has been reported previously. A thiol group can be added to the 5' of ssDNA or dsDNA using T4 polynucleotide kinase and ATP.gamma.S (Grant, G. P. and P. Z. Qin (2007). "A facile method for attaching nitroxide spin labels at the 5' terminus of nucleic acids." Nucleic Acids Res 35(10): e77). An azide group can be added to the 5'-phosphate of ssDNA or dsDNA using T4 polynucleotide kinase and .gamma.-[2-Azidoethyl]-ATP or .gamma.-[6-Azidohexyl]-ATP. Using thiol or Click chemistry a tether, containing either a thiol, iodoacetamide OPSS or maleimide group (reactive to thiols) or a DIBO (dibenzocyclooxtyne) or alkyne group (reactive to azides), can be covalently attached to the analyte. A more diverse selection of chemical groups, such as biotin, thiols and fluorophores, can be added using terminal transferase to incorporate modified oligonucleotides to the 3' of ssDNA (Kumar, A., P. Tchen, et al. (1988). "Nonradioactive labeling of synthetic oligonucleotide probes with terminal deoxynucleotidyl transferase." Anal Biochem 169(2): 376-82). Streptavidin/biotin and/or streptavidin/desthiobiotin coupling may be used for any other analyte. The Examples below describes how a polynucleotide can be coupled to a membrane using streptavidin/biotin and streptavidin/desthiobiotin. It may also be possible that anchors may be directly added to polynucleotides using terminal transferase with suitably modified nucleotides (e.g. cholesterol or palmitate).

[0138] The one or more anchors preferably couple the first analyte and/or the second analyte to the membrane via hybridisation. The hybridisation may be present in any part of the one or more anchors, such as between the one or more anchors and the analyte, within the one or more anchors or between the one or more anchors and the membrane. Hybridisation in the one or more anchors allows coupling in a transient manner as discussed above. For instance, a linker may comprise two or more polynucleotides, such as 3, 4 or 5 polynucleotides, hybridised together. If the first analyte and/or second analyte are themselves polynucleotides, the one or more anchors may hybridise to the first polynucleotide analyte and/or the second polynucleotide analyte. The one or more anchors may hybridise directly to the polynucleotide analyte, directly to a Y adaptor and/or leader sequence attached to the polynucleotide analyte or directly to a hairpin loop adaptor attached to the polynucleotide analyte (as discussed in more detail below). Alternatively, the one or more anchors may be hybridised to one or more, such as 2 or 3, intermediate polynucleotides (or "splints") which are hybridised to the polynucleotide analyte, to a Y adaptor and/or leader sequence attached to the polynucleotide analyte or to a hairpin loop adaptor attached to the polynucleotide analyte (as discussed in more detail below).

[0139] The one or more anchors may comprise a single stranded or double stranded polynucleotide. One part of the anchor may be ligated to a single stranded or double stranded polynucleotide analyte. Ligation of short pieces of ssDNA have been reported using T4 RNA ligase I (Troutt, A. B., M. G. McHeyzer-Williams, et al. (1992). "Ligation-anchored PCR: a simple amplification technique with single-sided specificity." Proc Natl Acad Sci USA 89(20): 9823-5). Alternatively, either a single stranded or double stranded polynucleotide can be ligated to a double stranded polynucleotide analyte and then the two strands separated by thermal or chemical denaturation. To a double stranded polynucleotide, it is possible to add either a piece of single stranded polynucleotide to one or both of the ends of the duplex, or a double stranded polynucleotide to one or both ends. For addition of single stranded polynucleotides to the a double stranded polynucleotide, this can be achieved using T4 RNA ligase I as for ligation to other regions of single stranded polynucleotides. For addition of double stranded polynucleotides to a double stranded polynucleotide analyte then ligation can be "blunt-ended", with complementary 3' dA/dT tails on the analyte and added polynucleotide respectively (as is routinely done for many sample prep applications to prevent concatemer or dimer formation) or using "sticky-ends" generated by restriction digestion of the analyte and ligation of compatible adapters. Then, when the duplex is melted, each single strand will have either a 5' or 3' modification if a single stranded polynucleotide was used for ligation or a modification at the 5' end, the 3' end or both if a double stranded polynucleotide was used for ligation.

[0140] If the polynucleotide analyte is a synthetic strand, the one or more anchors can be incorporated during the chemical synthesis of the polynucleotide. For instance, the polynucleotide can be synthesised using a primer having a reactive group attached to it.

[0141] Adenylated polynucleotides are intermediates in ligation reactions, where an adenosine-monophosphate is attached to the 5'-phosphate of the polynucleotide. Various kits are available for generation of this intermediate, such as the 5' DNA Adenylation Kit from NEB. By substituting ATP in the reaction for a modified nucleotide triphosphate, then addition of reactive groups (such as thiols, amines, biotin, azides, etc) to the 5' of a polynucleotide can be possible. It may also be possible that anchors could be directly added to polynucleotides using a 5' DNA adenylation kit with suitably modified nucleotides (e.g. cholesterol or palmitate).

[0142] A common technique for the amplification of sections of genomic DNA is using polymerase chain reaction (PCR). Here, using two synthetic oligonucleotide primers, a number of copies of the same section of DNA can be generated, where for each copy the 5' of each strand in the duplex will be a synthetic polynucleotide. Single or multiple nucleotides can be added to 3' end of single or double stranded DNA by employing a polymerase. Examples of polymerases which could be used include, but are not limited to, Terminal Transferase, Klenow and E. coli Poly(A) polymerase). By substituting ATP in the reaction for a modified nucleotide triphosphate then anchors, such as cholesterol, thiol, amine, azide, biotin or lipid, can be incorporated into double stranded polynucleotides. Therefore, each copy of the amplified polynucleotide will contain an anchor.

[0143] Ideally, the analyte is coupled to the membrane without having to functionalise the analyte. This can be achieved by coupling the one or more anchors, such as a polynucleotide binding protein or a chemical group, to the membrane and allowing the one or more anchors to interact with the analyte or by functionalizing the membrane. The one or more anchors may be coupled to the membrane by any of the methods described herein. In particular, the one or more anchors may comprise one or more linkers, such as maleimide functionalised linkers.

[0144] In this embodiment, the analyte is typically RNA, DNA, PNA, TNA or LNA and may be double or single stranded. This embodiment is particularly suited to genomic DNA analytes.

[0145] The one or more anchors can comprise any group that couples to, binds to or interacts with single or double stranded polynucleotides, specific nucleotide sequences within the analyte or patterns of modified nucleotides within the analyte, or any other ligand that is present on the polynucleotide.

[0146] Suitable binding proteins for use in anchors include, but are not limited to, E. coli single stranded binding protein, P5 single stranded binding protein, T4 gp32 single stranded binding protein, the TOPO V dsDNA binding region, human histone proteins, E. coli HU DNA binding protein and other archaeal, prokaryotic or eukaryotic single stranded or double stranded polynucleotide (or nucleic acid) binding proteins, including those listed below.

[0147] The specific nucleotide sequences could be sequences recognised by transcription factors, ribosomes, endonucleases, topoisomerases or replication initiation factors. The patterns of modified nucleotides could be patterns of methylation or damage.

[0148] The one or more anchors can comprise any group which couples to, binds to, intercalates with or interacts with a polynucleotide analyte. The group may intercalate or interact with the polynucleotide analyte via electrostatic, hydrogen bonding or Van der Waals interactions. Such groups include a lysine monomer, poly-lysine (which will interact with ssDNA or dsDNA), ethidium bromide (which will intercalate with dsDNA), universal bases or universal nucleotides (which can hybridise with any polynucleotide analyte) and osmium complexes (which can react to methylated bases). A polynucleotide analyte may therefore be coupled to the membrane using one or more universal nucleotides attached to the membrane. Each universal nucleotide may be coupled to the membrane using one or more linkers. The universal nucleotide preferably comprises one of the following nucleobases: hypoxanthine, 4-nitroindole, 5-nitroindole, 6-nitroindole, formylindole, 3-nitropyrrole, nitroimidazole, 4-nitropyrazole, 4-nitrobenzimidazole, 5-nitroindazole, 4-aminobenzimidazole or phenyl (C6-aromatic ring). The universal nucleotide more preferably comprises one of the following nucleosides: 2'-deoxyinosine, inosine, 7-deaza-2'-deoxyinosine, 7-deaza-inosine, 2-aza-deoxyinosine, 2-aza-inosine, 2-O'-methylinosine, 4-nitroindole 2'-deoxyribonucleoside, 4-nitroindole ribonucleoside, 5-nitroindole 2'-deoxyribonucleoside, 5-nitroindole ribonucleoside, 6-nitroindole 2'-deoxyribonucleoside, 6-nitroindole ribonucleoside, 3-nitropyrrole 2'-deoxyribonucleoside, 3-nitropyrrole ribonucleoside, an acyclic sugar analogue of hypoxanthine, nitroimidazole 2'-deoxyribonucleoside, nitroimidazole ribonucleoside, 4-nitropyrazole 2'-deoxyribonucleoside, 4-nitropyrazole ribonucleoside, 4-nitrobenzimidazole 2'-deoxyribonucleoside, 4-nitrobenzimidazole ribonucleoside, 5-nitroindazole 2'-deoxyribonucleoside, 5-nitroindazole ribonucleoside, 4-aminobenzimidazole 2'-deoxyribonucleoside, 4-aminobenzimidazole ribonucleoside, phenyl C-ribonucleoside, phenyl C-2'-deoxyribosyl nucleoside, 2'-deoxynebularine, 2'-deoxyisoguanosine, K-2'-deoxyribose, P-2'-deoxyribose and pyrrolidine. The universal nucleotide more preferably comprises 2'-deoxyinosine. The universal nucleotide is more preferably IMP or dIMP. The universal nucleotide is most preferably dPMP (2'-Deoxy-P-nucleoside monophosphate) or dKMP (N6-methoxy-2, 6-diaminopurine monophosphate).

[0149] The one or more anchors may couple to (or bind to) the polynucleotide analyte via Hoogsteen hydrogen bonds (where two nucleobases are held together by hydrogen bonds) or reversed Hoogsteen hydrogen bonds (where one nucleobase is rotated through 180.degree. with respect to the other nucleobase). For instance, the one or more anchors may comprise one or more nucleotides, one or more oligonucleotides or one or more polynucleotides which form Hoogsteen hydrogen bonds or reversed Hoogsteen hydrogen bonds with the polynucleotide analyte. These types of hydrogen bonds allow a third polynucleotide strand to wind around a double stranded helix and form a triplex. The one or more anchors may couple to (or bind to) a double stranded polynucleotide analyte by forming a triplex with the double stranded duplex.

[0150] In this embodiment at least 1%, at least 10%, at least 25%, at least 50% or 100% of the membrane components may be functionalized.

[0151] Where the one or more anchors comprise a protein, they may be able to anchor directly into the membrane without further functonalisation, for example if it already has an external hydrophobic region which is compatible with the membrane. Examples of such proteins include, but are not limited to, transmembrane proteins, intramembrane proteins and membrane proteins. Alternatively the protein may be expressed with a genetically fused hydrophobic region which is compatible with the membrane. Such hydrophobic protein regions are known in the art.

[0152] The one or more anchors are preferably mixed with the analyte before contacting with the membrane, but the one or more anchors may be contacted with the membrane and subsequently contacted with the analyte.

[0153] In another aspect the analyte may be functionalised, using methods described above, so that it can be recognised by a specific binding group. Specifically the analyte may be functionalised with a ligand such as biotin (for binding to streptavidin), amylose (for binding to maltose binding protein or a fusion protein), Ni-NTA (for binding to poly-histidine or poly-histidine tagged proteins) or peptides (such as an antigen).

[0154] According to a preferred embodiment, the one or more anchors may be used to couple a polynucleotide analyte to the membrane when the analyte is attached to a leader sequence which preferentially threads into the pore. Leader sequences are discussed in more detail below. Preferably, the polynucleotide analyte is attached (such as ligated) to a leader sequence which preferentially threads into the pore. Such a leader sequence may comprise a homopolymeric polynucleotide or an abasic region. The leader sequence is typically designed to hybridise to the one or more anchors either directly or via one or more intermediate polynucleotides (or splints). In such instances, the one or more anchors typically comprise a polynucleotide sequence which is complementary to a sequence in the leader sequence or a sequence in the one or more intermediate polynucleotides (or splints). In such instances, the one or more splints typically comprise a polynucleotide sequence which is complementary to a sequence in the leader sequence.

[0155] Any of the methods discussed above for coupling polynucleotides to membranes, such as amphiphilic layers, can of course be applied to other analyte and membrane combinations. In some embodiments, an amino acid, peptide, polypeptide or protein is coupled to an amphiphilic layer, such as a triblock copolymer layer or lipid bilayer. Various methodologies for the chemical attachment of such analytes are available. An example of a molecule used in chemical attachment is EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride). Reactive groups can also be added to the 5' of polynucleotides using commercially available kits (Thermo Pierce, Part No. 22980). Suitable methods include, but are not limited to, transient affinity attachment using histidine residues and Ni-NTA, as well as more robust covalent attachment by reactive cysteines, lysines or non natural amino acids.

Detector

[0156] Steps (b) and (e) comprise allowing the first analyte and second analyte respectively to interact with a detector present in the membrane and thereby determining the presence, absence or one or more characteristics of the first analyte and second analyte respectively. The detector in each step may be different. The detector in each step is typically the same. For instance, both the first and second analytes are preferably allowed to interact with a transmembrane pore, preferably the same transmembrane pore.

[0157] The coupling of the first analyte and/or the second analyte is not essential for the analyte to interact with the detector. The coupling allows ultra low concentration analyte delivery to the detector.

[0158] The detector can be any structure that provides a readable signal in response to the presence, the absence or the one or more characteristics of the first and/or second analyte. The detector can be any structure that provides a readable signal in response to the presence or the absence of the first and/or second analyte. Suitable detectors are known in the art. They include, but are not limited to transmembrane pores, tunnelling electrodes, classis electrodes, nanotubes, FETs (field-effect transistors) and optical detectors, such as atomic force microscopes (AFMs) and scanning tunneling microscopes (STMs).

[0159] A variety of different types of measurements may be made. This includes without limitation: electrical measurements and optical measurements. Possible electrical measurements include: current measurements, impedance measurements, tunnelling measurements (Ivanov A P et al., Nano Lett. 2011 Jan. 12; 11(1):279-85), and FET measurements (International Application WO 2005/124888). Optical measurements may be combined with electrical measurements (Soni G V et al., Rev Sci Instrum. 2010 January; 81(1):014301). The measurement may be a transmembrane current measurement such as measurement of ionic current flowing through the pore.

[0160] Electrical measurements may be made using standard single channel recording equipment as describe in Stoddart D et al., Proc Natl Acad Sci, 12; 106(19):7702-7, Lieberman K R et al, J Am Chem Soc. 2010; 132(50):17961-72, and International Application WO 2000/28312. Alternatively, electrical measurements may be made using a multi-channel system, for example as described in International Application WO 2009/077734 and International Application WO 2011/067559.

[0161] The method is preferably carried out with a potential applied across the membrane. The applied potential may be a voltage potential. Alternatively, the applied potential may be a chemical potential. An example of this is using a salt gradient across a membrane, such as an amphiphilic layer. A salt gradient is disclosed in Holden et al., J Am Chem Soc. 2007 Jul. 11; 129(27):8650-5. In some instances, the current passing through the detector (or pore) as a polynucleotide analyte moves with respect to the pore is used to estimate or determine the sequence of the polynucleotide. This is strand sequencing.

[0162] In other preferred embodiments, the detector does not detect the analyte using fluorescent means.

[0163] The detector preferably comprises a transmembrane pore. A transmembrane pore is a structure that crosses the membrane to some degree. It permits hydrated ions driven by an applied potential to flow across or within the membrane. The transmembrane pore typically crosses the entire membrane so that hydrated ions may flow from one side of the membrane to the other side of the membrane. However, the transmembrane pore does not have to cross the membrane. It may be closed at one end. For instance, the pore may be a well, gap, channel, trench or slit in the membrane along which or into which hydrated ions may flow.

[0164] If the detector is a pore, step (b) preferably comprises (i) allowing the first analyte to interact with the detector and (ii) measuring the current passing through the detector during the interaction and thereby determining the presence, absence or one or more characteristics of the first analyte and/or step (e) comprises (i) allowing the second analyte to interact with the detector and (ii) measuring the current passing through the detector during the interaction and thereby determining the presence, absence or one or more characteristics of the second analyte.

[0165] The first or second analyte is present if the current flows through the pore in a manner specific for the analyte (i.e. if a distinctive current associated with the analyte is detected flowing through the pore). The first or second analyte is absent if the current does not flow through the pore in a manner specific for the analyte. Similarly, the characteristics of the analyte can be determined using the current flowing through the pore during the interaction.

[0166] The invention therefore involves nanopore sensing of an analyte. The invention can be used to differentiate analytes of similar structure on the basis of the different effects they have on the current passing through the pore. The invention can also be used to measure the concentration of a particular analyte in a sample.

[0167] The invention may also be used in a sensor that uses many or thousands of pores in bulk sensing applications.

[0168] During the interaction between the first or second analyte and the pore, the analyte affects the current flowing through the pore in a manner specific for that analyte. For example, a particular analyte will reduce the current flowing through the pore for a particular mean time period and to a particular extent. In other words, the current flowing through the pore is distinctive for a particular analyte. Control experiments may be carried out to determine the effect a particular analyte has on the current flowing through the pore. Results from carrying out the method of the invention on a test sample can then be compared with those derived from such a control experiment in order to identify a particular analyte in the sample, determine whether a particular analyte is present in the sample or determine the characteristics of each analyte. The frequency at which the current flowing through the pore is affected in a manner indicative of a particular analyte can be used to determine the concentration of that analyte in the sample.

[0169] Any transmembrane pore may be used in the invention. The pore may be biological or artificial. Suitable pores include, but are not limited to, protein pores, polynucleotide pores and solid state pores. The pore may be a DNA origami pore (Langecker et al., Science, 2012; 338: 932-936).

[0170] The transmembrane pore is preferably a transmembrane protein pore. A transmembrane protein pore is a polypeptide or a collection of polypeptides that permits hydrated ions, such as analyte, to flow from one side of a membrane to the other side of the membrane. In the present invention, the transmembrane protein pore is capable of forming a pore that permits hydrated ions driven by an applied potential to flow from one side of the membrane to the other. The transmembrane protein pore preferably permits analyte such as nucleotides to flow from one side of the membrane, such as a triblock copolymer membrane, to the other. The transmembrane protein pore allows a polynucleotide, such as DNA or RNA, to be moved through the pore.

[0171] The transmembrane protein pore may be a monomer or an oligomer. The pore is preferably made up of several repeating subunits, such as at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13 or at least 14 subunits, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 subunits. The pore is preferably a hexameric, heptameric, octameric or nonameric pore. The pore may be a homo-oligomer or a hetero-oligomer.

[0172] The transmembrane protein pore typically comprises a barrel or channel through which the ions may flow. The subunits of the pore typically surround a central axis and contribute strands to a transmembrane .beta. barrel or channel or a transmembrane .alpha.-helix bundle or channel.

[0173] The barrel or channel of the transmembrane protein pore typically comprises amino acids that facilitate interaction with analyte, such as nucleotides, polynucleotides or nucleic acids. These amino acids are preferably located near a constriction of the barrel or channel. The transmembrane protein pore typically comprises one or more positively charged amino acids, such as arginine, lysine or histidine, or aromatic amino acids, such as tyrosine or tryptophan. These amino acids typically facilitate the interaction between the pore and nucleotides, polynucleotides or nucleic acids.

[0174] Transmembrane protein pores for use in accordance with the invention can be derived from .beta.-barrel pores or .alpha.-helix bundle pores. .beta.-barrel pores comprise a barrel or channel that is formed from .beta.-strands. Suitable .beta.-barrel pores include, but are not limited to, .beta.-toxins, such as .alpha.-hemolysin, anthrax toxin and leukocidins, and outer membrane proteins/porins of bacteria, such as Mycobacterium smegmatis porin (Msp), for example MspA, MspB, MspC or MspD, lysenin, outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A and Neisseria autotransporter lipoprotein (NalP). .alpha.-helix bundle pores comprise a barrel or channel that is formed from .alpha.-helices. Suitable .alpha.-helix bundle pores include, but are not limited to, inner membrane proteins and .alpha., outer membrane proteins, such as WZA and ClyA toxin. The transmembrane pore may be derived from lysenin. Suitable pores derived from lysenin are disclosed in International Application No. PCT/GB2013/050667 (published as WO 2013/153359). The transmembrane pore may be derived from Msp or from .alpha.-hemolysin (.alpha.-HL).

[0175] The transmembrane protein pore is preferably derived from Msp, preferably from MspA. Such a pore will be oligomeric and typically comprises 7, 8, 9 or 10 monomers derived from Msp. The pore may be a homo-oligomeric pore derived from Msp comprising identical monomers. Alternatively, the pore may be a hetero-oligomeric pore derived from Msp comprising at least one monomer that differs from the others. Preferably the pore is derived from MspA or a homolog or paralog thereof.

[0176] A monomer derived from Msp typically comprises the sequence shown in SEQ ID NO: 2 or a variant thereof. SEQ ID NO: 2 is the MS-(B1)8 mutant of the MspA monomer. It includes the following mutations: D90N, D91N, D93N, D118R, D134R and E139K. A variant of SEQ ID NO: 2 is a polypeptide that has an amino acid sequence which varies from that of SEQ ID NO: 2 and which retains its ability to form a pore. The ability of a variant to form a pore can be assayed using any method known in the art. For instance, the variant may be inserted into an amphiphilic layer along with other appropriate subunits and its ability to oligomerise to form a pore may be determined. Methods are known in the art for inserting subunits into membranes, such as amphiphilic layers. For example, subunits may be suspended in a purified form in a solution containing a triblock copolymer membrane such that it diffuses to the membrane and is inserted by binding to the membrane and assembling into a functional state. Alternatively, subunits may be directly inserted into the membrane using the "pick and place" method described in M. A. Holden, H. Bayley. J. Am. Chem. Soc. 2005, 127, 6502-6503 and International Application No. PCT/GB2006/001057 (published as WO 2006/100484).

[0177] Over the entire length of the amino acid sequence of SEQ ID NO: 2, a variant will preferably be at least 50% homologous to that sequence based on amino acid identity. More preferably, the variant may be at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% and more preferably at least 95%, 97% or 99% homologous based on amino acid identity to the amino acid sequence of SEQ ID NO: 2 over the entire sequence. There may be at least 80%, for example at least 85%, 90% or 95%, amino acid identity over a stretch of 100 or more, for example 125, 150, 175 or 200 or more, contiguous amino acids ("hard homology").

[0178] Standard methods in the art may be used to determine homology. For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology, for example used on its default settings (Devereux et al (1984) Nucleic Acids Research 12, p 387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent residues or corresponding sequences (typically on their default settings)), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S. F et al (1990) J Mol Biol 215:403-10. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/).

[0179] SEQ ID NO: 2 is the MS-(B1)8 mutant of the MspA monomer. The variant may comprise any of the mutations in the MspB, C or D monomers compared with MspA. The mature forms of MspB, C and D are shown in SEQ ID NOs: 5 to 7. In particular, the variant may comprise the following substitution present in MspB: A138P. The variant may comprise one or more of the following substitutions present in MspC: A96G, N102E and A138P. The variant may comprise one or more of the following mutations present in MspD: Deletion of G1, L2V, E5Q, L8V, D13G, W21A, D22E, K47T, I49H, I68V, D91G, A96Q, N102D, S103T, V104I, S136K and G141A. The variant may comprise combinations of one or more of the mutations and substitutions from Msp B, C and D. The variant preferably comprises the mutation L88N. A variant of SEQ ID NO: 2 has the mutation L88N in addition to all the mutations of MS-B1 and is called MS-(B2)8. The pore used in the invention is preferably MS-(B2)8. A variant of SEQ ID NO: 2 has the mutations G75S/G77S/L88N/Q126R in addition to all the mutations of MS-B1 and is called MS-B2C. The pore used in the invention is preferably MS-(B2)8 or MS-(B2C)8.

[0180] Amino acid substitutions may be made to the amino acid sequence of SEQ ID NO: 2 in addition to those discussed above, for example up to 1, 2, 3, 4, 5, 10, 20 or 30 substitutions. Conservative substitutions replace amino acids with other amino acids of similar chemical structure, similar chemical properties or similar side-chain volume. The amino acids introduced may have similar polarity, hydrophilicity, hydrophobicity, basicity, acidity, neutrality or charge to the amino acids they replace. Alternatively, the conservative substitution may introduce another amino acid that is aromatic or aliphatic in the place of a pre-existing aromatic or aliphatic amino acid.

[0181] One or more amino acid residues of the amino acid sequence of SEQ ID NO: 2 may additionally be deleted from the polypeptides described above. Up to 1, 2, 3, 4, 5, 10, 20 or 30 residues may be deleted, or more.

[0182] Variants may include fragments of SEQ ID NO: 2. Such fragments retain pore forming activity. Fragments may be at least 50, 100, 150 or 200 amino acids in length. Such fragments may be used to produce the pores. A fragment preferably comprises the pore forming domain of SEQ ID NO: 2. Fragments must include one of residues 88, 90, 91, 105, 118 and 134 of SEQ ID NO: 2. Typically, fragments include all of residues 88, 90, 91, 105, 118 and 134 of SEQ ID NO: 2.

[0183] One or more amino acids may be alternatively or additionally added to the polypeptides described above. An extension may be provided at the amino terminal or carboxy terminal of the amino acid sequence of SEQ ID NO: 2 or polypeptide variant or fragment thereof. The extension may be quite short, for example from 1 to 10 amino acids in length. Alternatively, the extension may be longer, for example up to 50 or 100 amino acids. A carrier protein may be fused to an amino acid sequence according to the invention. Other fusion proteins are discussed in more detail below.

[0184] As discussed above, a variant is a polypeptide that has an amino acid sequence which varies from that of SEQ ID NO: 2 and which retains its ability to form a pore. A variant typically contains the regions of SEQ ID NO: 2 that are responsible for pore formation. The pore forming ability of Msp, which contains a .beta.-barrel, is provided by .beta.-sheets in each subunit. A variant of SEQ ID NO: 2 typically comprises the regions in SEQ ID NO: 2 that form .beta.-sheets. One or more modifications can be made to the regions of SEQ ID NO: 2 that form .beta.-sheets as long as the resulting variant retains its ability to form a pore. A variant of SEQ ID NO: 2 preferably includes one or more modifications, such as substitutions, additions or deletions, within its .alpha.-helices and/or loop regions.

[0185] The monomer derived from Msp contains one or more specific modifications to facilitate nucleotide discrimination. The monomer derived from Msp may also contain other non-specific modifications as long as they do not interfere with pore formation. A number of non-specific side chain modifications are known in the art and may be made to the side chains of the monomer derived from Msp. Such modifications include, for example, reductive alkylation of amino acids by reaction with an aldehyde followed by reduction with NaBH.sub.4, amidination with methylacetimidate or acylation with acetic anhydride.

[0186] The monomer derived from Msp can be produced using standard methods known in the art. The monomer derived from Msp may be made synthetically or by recombinant means. For example, the pore may be synthesized by in vitro translation and transcription (IVTT). Suitable methods for producing pores are discussed in International Application Nos. PCT/GB09/001690 (published as WO 2010/004273), PCT/GB09/001679 (published as WO 2010/004265) or PCT/GB10/000133 (published as WO 2010/086603). Methods for inserting pores into membranes are discussed.

[0187] The transmembrane protein pore is also preferably derived from .alpha.-hemolysin (.alpha.-HL). The wild type .alpha.-HL pore is formed of seven identical monomers or subunits (i.e. it is heptameric). The sequence of one monomer or subunit of .alpha.-hemolysin-NN is shown in SEQ ID NO: 4.

[0188] In some embodiments, the transmembrane protein pore is chemically modified. The pore can be chemically modified in any way and at any site. The transmembrane protein pore is preferably chemically modified by attachment of a molecule to one or more cysteines (cysteine linkage), attachment of a molecule to one or more lysines, attachment of a molecule to one or more non-natural amino acids, enzyme modification of an epitope or modification of a terminus. Suitable methods for carrying out such modifications are well-known in the art. The transmembrane protein pore may be chemically modified by the attachment of any molecule. For instance, the pore may be chemically modified by attachment of a dye or a fluorophore.

[0189] Any number of the monomers in the pore may be chemically modified. One or more, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10, of the monomers is preferably chemically modified as discussed above.

[0190] The reactivity of cysteine residues may be enhanced by modification of the adjacent residues. For instance, the basic groups of flanking arginine, histidine or lysine residues will change the pKa of the cysteines thiol group to that of the more reactive S.sup.- group. The reactivity of cysteine residues may be protected by thiol protective groups such as dTNB. These may be reacted with one or more cysteine residues of the pore before a linker is attached.

[0191] The molecule (with which the pore is chemically modified) may be attached directly to the pore or attached via a linker as disclosed in International Application Nos. PCT/GB09/001690 (published as WO 2010/004273), PCT/GB09/001679 (published as WO 2010/004265) or PCT/GB10/000133 (published as WO 2010/086603).

[0192] Any of the proteins described herein, such as the transmembrane protein pores, can be produced using standard methods known in the art. Polynucleotide sequences encoding a pore or construct may be derived and replicated using standard methods in the art. Polynucleotide sequences encoding a pore or construct may be expressed in a bacterial host cell using standard techniques in the art. The pore may be produced in a cell by in situ expression of the polypeptide from a recombinant expression vector. The expression vector optionally carries an inducible promoter to control the expression of the polypeptide. These methods are described in Sambrook, J. and Russell, D. (2001). Molecular Cloning: A Laboratory Manual, 3rd Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

[0193] The pore may be produced in large scale following purification by any protein liquid chromatography system from protein producing organisms or after recombinant expression. Typical protein liquid chromatography systems include FPLC, AKTA systems, the Bio-Cad system, the Bio-Rad BioLogic system and the Gilson HPLC system.

Uncoupling

[0194] The method of the invention involves uncoupling the first analyte from the membrane. The method of the invention may involve uncoupling the second analyte from the membrane, for instance if three or more analytes are being investigated.

[0195] Step (c) (i.e. uncoupling of the first analyte) may be performed before step (d) (i.e. before coupling the second analyte to the membrane). Step (d) may be performed before step (c). If the second analyte is coupled to the membrane before the first analyte is uncoupled, step (c) preferably comprises selectively uncoupling the first analyte from the membrane (i.e. uncoupling the first analyte but not the second analyte from the membrane). A skilled person can design a system in which selective uncoupling is achieved. Steps (c) and (d) may be performed at the same time. This is discussed in more detail below.

[0196] In step (c), at least 10% of the first analyte is preferably uncoupled from the membrane. For instance, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% at least 90% or at least 95% of the first analyte may be uncoupled from the membrane. Preferably, all of the first analyte is uncoupled from the membrane. The amount of the first analyte uncoupled from the membrane can be determined using the detector. This is disclosed in the Examples.

[0197] The first analyte can be uncoupled from the membrane using any known method. The first analyte is preferably not uncoupled from the membrane in step (c) using the detector, such as a transmembrane pore. The first analyte is preferably not uncoupled from the membrane using a voltage or an applied potential.

[0198] Step (c) preferably comprises uncoupling the first analyte from the membrane by removing the one or more anchors from the membrane. In such embodiments, the second analyte is coupled to the membrane using other (or separate) one or more anchors. The one or more anchors used to couple the second analyte may be the same type of anchor used to couple the first analyte or a different type of anchor.

[0199] Step (c) more preferably comprises contacting the one or more anchors with an agent which has a higher affinity for the one or more anchors than the one or more anchors have for the membrane. A variety of protocols for competitive binding or immunoradiometric assays to determine the specific binding capability of molecules are well known in the art (see for example Maddox et al, J. Exp. Med. 158, 1211-1226, 1993). The agent removes the one or more anchors from the membrane and thereby uncouples the first analyte. The agent is preferably a sugar. Any sugar which binds to the one or more anchors with a higher affinity than the one or more anchors have for the membrane may be used. The sugar may be a cyclodextrin or derivative thereof as discussed below.

[0200] The one or more anchors preferably comprise a hydrophobic anchor, such as cholesterol, and the agent is preferably a cyclodextrin or a derivative thereof or a lipid. The cyclodextrin or derivative thereof may be any of those disclosed in Eliseev, A. V., and Schneider, H-J. (1994) J. Am. Chem. Soc. 116, 6081-6088. The agent is more preferably heptakis-6-amino-.beta.-cyclodextrin (am.sub.7-.beta.CD), 6-monodeoxy-6-monoamino-.beta.-cyclodextrin (am.sub.1-.beta.CD), heptakis-(6-deoxy-6-guanidino)-cyclodextrin (gu.sub.7-.beta.CD), heptakis(2,3,6-tri-O-methyl)-.beta.-cyclodextrin or (2-hydroxypropyl)-.beta.-cyclodextrin. Any of the lipids disclosed herein may be used.

[0201] The one or more anchors preferably comprise streptavidin, biotin or desthiobiotin and the agent is preferably biotin, desthiobiotin or streptavidin. Both biotin and desthiobiotin bind to streptavidin with a higher affinity than streptavidin binds to the membrane. Biotin has a stronger affinity for streptavidin than desthiobiotin. An anchor comprising streptavidin may therefore be removed from the membrane using biotin or desthiobiotin, depending on the composition of the anchor e.g. as shown in Example 5 and FIG. 7.

[0202] The one or more anchors preferably comprise a protein and the agent is preferably an antibody or fragment thereof which specifically binds to the protein. An antibody specifically binds to a protein if it binds to the protein with preferential or high affinity, but does not bind or binds with only low affinity to other or different proteins. An antibody binds with preferential or high affinity if it binds with a Kd of 1.times.10.sup.-6 M or less, more preferably 1.times.10.sup.-7 M or less, 5.times.10.sup.-8 M or less, more preferably 1.times.10.sup.-8 M or less or more preferably 5.times.10.sup.-9M or less. An antibody binds with low affinity if it binds with a Kd of 1.times.10.sup.-6 M or more, more preferably 1.times.10.sup.-5 M or more, more preferably 1.times.10.sup.-4 M or more, more preferably 1.times.10.sup.-3 M or more, even more preferably 1.times.10.sup.-2 M or more. Any method may be used to detect binding or specific binding. Methods of quantitatively measuring the binding of an antibody to a protein are well known in the art. The antibody may be a monoclonal antibody or a polyclonal antibody. Suitable fragments of antibodies include, but are not limited to, Fv, F(ab') and F(ab')2 fragments, as well as single chain antibodies. Furthermore, the antibody or fragment thereof may be a chimeric antibody or fragment thereof, a CDR-grafted antibody or fragment thereof or a humanised antibody or fragment thereof.

[0203] Step (c) preferably comprises contacting the one or more anchors with an agent which reduces their ability to couple to the membrane. For instance, the agent could interfere with the structure and/or hydrophobicity of the one or more anchors and thereby reduce their ability to couple to the membrane. The one or more anchors preferably comprise cholesterol and the agent is preferably cholesterol dehydrogenase. The one or more anchors preferably comprise a lipid and the agent is preferably a phospholipase. The one or more anchors preferably comprise a protein and the agent is preferably a proteinase or urea. Other combination of suitable anchors and agents will be clear to a person skilled in the art.

[0204] Step (c) preferably comprises uncoupling the first analyte from the membrane by separating the first analyte from the one or more anchors. This can be done in any manner. For instance, the linker could be cut in one or more anchors comprising a linker. This embodiment is particularly applicable to one or more anchors which involve linkage via hybridisation. Such anchors are discussed above.

[0205] Step (c) more preferably comprises uncoupling the first analyte from the membrane by contacting the first analyte and the one or more anchors with an agent which competes with the first analyte for binding to the one or more anchors. Methods for determining and measuring competitive binding are known in the art. The agent is preferably a polynucleotide which competes with the first analyte for hybridisation to the one or more anchors. For instance, if the first analyte is coupled to the membrane using one or more anchors which involve hybridisation, the analyte can be uncoupled by contacting the one or more anchors with a polynucleotide which also hybridises to the site of hybridisation. The polynucleotide agent is typically added at a concentration that is higher than the concentration of the first analyte and one or more anchors. Alternatively, the polynucleotide agent may hybridise more strongly to the one or more anchors than the first analyte.

[0206] Step (c) more preferably comprises (i) contacting the first analyte and the one or more anchors with urea, tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT), streptavidin or biotin, UV light, an enzyme or a binding agent; (ii) heating the first analyte and one or more anchors; or (iii) altering the pH. Urea, tris(2-carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT) are capable of disrupting anchors and separating the first analyte from the membrane. If an anchor comprises a streptavidin-biotin link, then a streptavidin agent will compete for binding to the biotin. If an anchor comprises a streptavidin-desthiobiotin link, then a biotin agent will compete for binding to the streptavidin. UV light can be used to breakdown photolabile groups. Enzymes and binding agents can be used to cut, breakdown or unravel the anchor. Preferred enzymes include, but are not limited to, an exonuclease, an endonuclease or a helicase. Preferred binding agents include, but are not limited to, an enzyme, an antibody or a fragment thereof or a single-stranded binding protein (SSB). Any of the enzymes discussed below or antibodies discussed above may be used. Heat and pH can be used to disrupt hybridisation and other linkages.

[0207] If the first analyte is uncoupled from the membrane by separating the first analyte from the one or more anchors, the one or more anchors will remain in the membrane. Step (d) preferably comprises coupling the second analyte to the membrane using the one or more anchors that were separated from the first analyte. For instance, the second analyte may also be provided with a polynucleotide which hybridises to the one or more anchors that remain in the membrane. Alternatively, step (d) preferably comprises coupling the second analyte to the membrane using separate one or more anchors from the ones separated from the first analyte (i.e. other one or more anchors). The separate one or more anchors may be the same type of anchor used to couple the first analyte to the membrane or may be a different type of anchor. Step (d) preferably comprises coupling the second analyte to the membrane using a different one or more anchors from the ones separated from the first analyte.

[0208] In a preferred embodiment, steps (c) and (d) comprise uncoupling the first analyte from the membrane by contacting the membrane with the second analyte such that the second analyte competes with the first analyte for binding to the one or more anchors and replaces the first analyte. For instance, if the first analyte is coupled to the membrane using one or more anchors which involve hybridisation, the analyte can be uncoupled by contacting the one or more anchors with the second analyte attached to a polynucleotide which also hybridises to the sites of hybridisation in the one or more anchors. The second analyte is typically added at a concentration that is higher than the concentration of the first analyte and one or more anchors. Alternatively, the second analyte may hybridise more strongly to the one or more anchors than the first analyte.

Removal or Washing

[0209] Although the first analyte is uncoupled from the membrane in step (c), it is not necessarily removed or washed away. If the second analyte can be easily distinguished from the first analyte, there is no need to remove the first analyte.

[0210] Between steps (c) and (d), the method preferably further comprises removing at least some of the first sample from the membrane. At least 10% of the first sample may be removed, such as at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the first sample may be removed. The method more preferably further comprises removing all of the first sample from the membrane. This can be done in any way. For instance, the membrane can be washed with a buffer after the first analyte has been uncoupled. Suitable buffers are discussed below.

Polynucleotide Characterisation

[0211] The method of the invention preferably involves measuring one or more characteristics of two or more polynucleotides. The two or more polynucleotides may be different polynucleotides or two instances of the same polynucleotide.

[0212] Any number of polynucleotides can be investigated. For instance, the method of the invention may concern determining the presence, absence or one or more characteristics of 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 100 or more polynucleotides. If three or more polynucleotides are investigated using the method of the invention, the second polynucleotide is also uncoupled from the membrane and the requisite number of steps are added for the third polynucleotide. The same is true for four or more polynucleotides.

[0213] The polynucleotides can be naturally occurring or artificial. For instance, the method may be used to verify the sequence of two or more manufactured oligonucleotides. The methods are typically carried out in vitro.

[0214] The method may involve measuring two, three, four or five or more characteristics of each polynucleotide. The one or more characteristics are preferably selected from (i) the length of the polynucleotide, (ii) the identity of the polynucleotide, (iii) the sequence of the polynucleotide, (iv) the secondary structure of the polynucleotide and (v) whether or not the polynucleotide is modified. Any combination of (i) to (v) may be measured in accordance with the invention, such as {i}, {ii}, {iii}, {iv}, {v}, {i,ii}, {i,iii}, {i,iv}, {i,v}, {ii,iii}, {ii,iv}, {ii,v}, {iii,iv}, {iii,v}, {iv,v}, {i,ii,iii}, {i,ii,iv}, {i,ii,v}, {i,iii,iv}, {i,iii,v}, {i,iv,v}, {ii,iii,iv}, {ii,iii,v}, {ii,iv,v}, {iii,iv,v}, {i,ii,iii,iv}, {i,ii,iii,v}, {i,ii,iv,v}, {i,iii,iv,v}, {ii,iii,iv,v} or {i,ii,iii,iv,v}. Different combinations of (i) to (v) may be measured for the first polynucleotide compared with the second polynucleotide, including any of those combinations listed above.

[0215] For (i), the length of the polynucleotide may be measured for example by determining the number of interactions between the polynucleotide and the pore or the duration of interaction between the polynucleotide and the pore.

[0216] For (ii), the identity of the polynucleotide may be measured in a number of ways. The identity of the polynucleotide may be measured in conjunction with measurement of the sequence of the polynucleotide or without measurement of the sequence of the polynucleotide. The former is straightforward; the polynucleotide is sequenced and thereby identified. The latter may be done in several ways. For instance, the presence of a particular motif in the polynucleotide may be measured (without measuring the remaining sequence of the polynucleotide). Alternatively, the measurement of a particular electrical and/or optical signal in the method may identify the polynucleotide as coming from a particular source.

[0217] For (iii), the sequence of the polynucleotide can be determined as described previously. Suitable sequencing methods, particularly those using electrical measurements, are described in Stoddart D et al., Proc Natl Acad Sci, 12; 106(19):7702-7, Lieberman K R et al, J Am Chem Soc. 2010; 132(50):17961-72, and International Application WO 2000/28312.

[0218] For (iv), the secondary structure may be measured in a variety of ways. For instance, if the method involves an electrical measurement, the secondary structure may be measured using a change in dwell time or a change in current flowing through the pore. This allows regions of single-stranded and double-stranded polynucleotide to be distinguished.

[0219] For (v), the presence or absence of any modification may be measured. The method preferably comprises determining whether or not the polynucleotide is modified by methylation, by oxidation, by damage, with one or more proteins or with one or more labels, tags or spacers. Specific modifications will result in specific interactions with the pore which can be measured using the methods described below. For instance, methylcytosine may be distinguished from cytosine on the basis of the current flowing through the pore during its interaction with each nucleotide.

[0220] The methods may be carried out using any apparatus that is suitable for investigating a membrane/pore system in which a pore is present in a membrane. The method may be carried out using any apparatus that is suitable for transmembrane pore sensing. For example, the apparatus comprises a chamber comprising an aqueous solution and a barrier that separates the chamber into two sections. The barrier typically has an aperture in which the membrane containing the pore is formed. Alternatively the barrier forms the membrane in which the pore is present.

[0221] The methods may be carried out using the apparatus described in International Application No. PCT/GB08/000562 (WO 2008/102120).

[0222] The methods may involve measuring the current passing through the pore as the polynucleotide moves with respect to the pore. Therefore the apparatus may also comprise an electrical circuit capable of applying a potential and measuring an electrical signal across the membrane and pore. The methods may be carried out using a patch clamp or a voltage clamp. The methods preferably involve the use of a voltage clamp.

[0223] The methods of the invention may involve the measuring of a current passing through the pore as the polynucleotide moves with respect to the pore. Suitable conditions for measuring ionic currents through transmembrane protein pores are known in the art and disclosed in the Example. The method is typically carried out with a voltage applied across the membrane and pore. The voltage used is typically from +5 V to -5 V, such as from +4 V to -4 V, +3 V to -3 V or +2 V to -2 V. The voltage used is typically from -600 mV to +600 mV or -400 mV to +400 mV. The voltage used is preferably in a range having a lower limit selected from -400 mV, -300 mV, -200 mV, -150 mV, -100 mV, -50 mV, -20 mV and 0 mV and an upper limit independently selected from +10 mV, +20 mV, +50 mV, +100 mV, +150 mV, +200 mV, +300 mV and +400 mV. The voltage used is more preferably in the range 100 mV to 240 mV and most preferably in the range of 120 mV to 220 mV. It is possible to increase discrimination between different nucleotides by a pore by using an increased applied potential.

[0224] The methods are typically carried out in the presence of any charge carriers, such as metal salts, for example alkali metal salt, halide salts, for example chloride salts, such as alkali metal chloride salt. Charge carriers may include ionic liquids or organic salts, for example tetramethyl ammonium chloride, trimethylphenyl ammonium chloride, phenyltrimethyl ammonium chloride, or 1-ethyl-3-methyl imidazolium chloride. In the exemplary apparatus discussed above, the salt is present in the aqueous solution in the chamber. Potassium chloride (KCl), sodium chloride (NaCl), caesium chloride (CsCl) or a mixture of potassium ferrocyanide and potassium ferricyanide is typically used. KCl, NaCl and a mixture of potassium ferrocyanide and potassium ferricyanide are preferred. The charge carriers may be asymmetric across the membrane. For instance, the type and/or concentration of the charge carriers may be different on each side of the membrane.

[0225] The salt concentration may be at saturation. The salt concentration may be 3 M or lower and is typically from 0.1 to 2.5 M, from 0.3 to 1.9 M, from 0.5 to 1.8 M, from 0.7 to 1.7 M, from 0.9 to 1.6 M or from 1 M to 1.4 M. The salt concentration is preferably from 150 mM to 1 M. The method is preferably carried out using a salt concentration of at least 0.3 M, such as at least 0.4 M, at least 0.5 M, at least 0.6 M, at least 0.8 M, at least 1.0 M, at least 1.5 M, at least 2.0 M, at least 2.5 M or at least 3.0 M. High salt concentrations provide a high signal to noise ratio and allow for currents indicative of the presence of a nucleotide to be identified against the background of normal current fluctuations.

[0226] The methods are typically carried out in the presence of a buffer. In the exemplary apparatus discussed above, the buffer is present in the aqueous solution in the chamber. Any buffer may be used in the method of the invention. Typically, the buffer is phosphate buffer. Other suitable buffers are HEPES and Tris-HCl buffer. The methods are typically carried out at a pH of from 4.0 to 12.0, from 4.5 to 10.0, from 5.0 to 9.0, from 5.5 to 8.8, from 6.0 to 8.7 or from 7.0 to 8.8 or 7.5 to 8.5. The pH used is preferably about 7.5.

[0227] The methods may be carried out at from 0.degree. C. to 100.degree. C., from 15.degree. C. to 95.degree. C., from 16.degree. C. to 90.degree. C., from 17.degree. C. to 85.degree. C., from 18.degree. C. to 80.degree. C., 19.degree. C. to 70.degree. C., or from 20.degree. C. to 60.degree. C. The methods are typically carried out at room temperature. The methods are optionally carried out at a temperature that supports enzyme function, such as about 37.degree. C.

[0228] Step (b) preferably comprises allowing the first polynucleotide to interact with a polynucleotide binding protein which controls the interaction of the first polynucleotide with the detector present in the membrane and/or step (e) preferably comprises allowing the second polynucleotide to interact with a polynucleotide binding protein which controls the interaction of the second polynucleotide with the detector present in the membrane.

[0229] More preferably, the method comprises (a) coupling a first polynucleotide in a first sample to a membrane using one or more anchors; (b) contacting the first polynucleotide with a transmembrane pore such that the first polynucleotide moves through the pore; (c) taking one or more measurements as the first polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the first polynucleotide and thereby characterising the first polynucleotide; (d) uncoupling the first polynucleotide from the membrane; (e) coupling a second polynucleotide in a second sample to the membrane using one or more anchors; (f) contacting the second polynucleotide with a transmembrane pore such that the second polynucleotide moves through the pore; and (g) taking one or more measurements as the second polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the second polynucleotide and thereby characterising the second polynucleotide. In this embodiment, step (b) preferably comprises contacting the first polynucleotide with a transmembrane pore and a polynucleotide binding protein such that the protein controls the movement of the first polynucleotide through the pore and/or step (f) preferably comprises contacting the second polynucleotide with a transmembrane pore and a polynucleotide binding protein such that the protein controls the movement of the second polynucleotide through the pore.

[0230] The polynucleotide binding protein may be any protein that is capable of binding to the polynucleotide and controlling its movement through the pore. It is straightforward in the art to determine whether or not a protein binds to a polynucleotide. The protein typically interacts with and modifies at least one property of the polynucleotide. The protein may modify the polynucleotide by cleaving it to form individual nucleotides or shorter chains of nucleotides, such as di- or trinucleotides. The moiety may modify the polynucleotide by orienting it or moving it to a specific position, i.e. controlling its movement.

[0231] The polynucleotide binding protein is preferably derived from a polynucleotide handling enzyme. A polynucleotide handling enzyme is a polypeptide that is capable of interacting with and modifying at least one property of a polynucleotide. The enzyme may modify the polynucleotide by cleaving it to form individual nucleotides or shorter chains of nucleotides, such as di- or trinucleotides. The enzyme may modify the polynucleotide by orienting it or moving it to a specific position. The polynucleotide handling enzyme does not need to display enzymatic activity as long as it is capable of binding the polynucleotide and controlling its movement through the pore. For instance, the enzyme may be modified to remove its enzymatic activity or may be used under conditions which prevent it from acting as an enzyme. Such conditions are discussed in more detail below.

[0232] The polynucleotide handling enzyme is preferably derived from a nucleolytic enzyme. The polynucleotide handling enzyme used in the construct of the enzyme is more preferably derived from a member of any of the Enzyme Classification (EC) groups 3.1.11, 3.1.13, 3.1.14, 3.1.15, 3.1.16, 3.1.21, 3.1.22, 3.1.25, 3.1.26, 3.1.27, 3.1.30 and 3.1.31. The enzyme may be any of those disclosed in International Application No. PCT/GB10/000133 (published as WO 2010/086603).

[0233] Preferred enzymes are polymerases, exonucleases, helicases and topoisomerases, such as gyrases. Suitable enzymes include, but are not limited to, exonuclease I from E. coli (SEQ ID NO: 11), exonuclease III enzyme from E. coli (SEQ ID NO: 13), RecJ from T. thermophilus (SEQ ID NO: 15) and bacteriophage lambda exonuclease (SEQ ID NO: 17) and variants thereof. Three subunits comprising the sequence shown in SEQ ID NO: 15 or a variant thereof interact to form a trimer exonuclease. The enzyme is preferably Phi29 DNA polymerase (SEQ ID NO: 9) or a variant thereof. The topoisomerase is preferably a member of any of the Moiety Classification (EC) groups 5.99.1.2 and 5.99.1.3.

[0234] The enzyme is most preferably derived from a helicase, such as Hel308 Mbu (SEQ ID NO: 18), Hel308 Csy (SEQ ID NO: 19), Hel308 Mhu (SEQ ID NO: 20), TraI Eco (SEQ ID NO: 21), XPD Mbu (SEQ ID NO: 22) or a variant thereof. Any helicase may be used in the invention. The helicase may be or be derived from a Hel308 helicase, a RecD helicase, such as TraI helicase or a TrwC helicase, a XPD helicase or a Dda helicase. The helicase may be any of the helicases, modified helicases or helicase constructs disclosed in International Application Nos. PCT/GB2012/052579 (published as WO 2013/057495); PCT/GB2012/053274 (published as WO 2013/098562); PCT/GB2012/053273 (published as WO2013098561); PCT/GB2013/051925 (published as WO 2014/013260); PCT/GB2013/051924 (published as WO 2014/013259); PCT/GB2013/051928 (published as WO 2014/013262) and PCT/GB2014/052736.

[0235] The helicase preferably comprises the sequence shown in SEQ ID NO: 25 (Trwc Cba) or a variant thereof, the sequence shown in SEQ ID NO: 18 (Hel308 Mbu) or a variant thereof or the sequence shown in SEQ ID NO: 24 (Dda) or a variant thereof. Variants may differ from the native sequences in any of the ways discussed below for transmembrane pores. A preferred variant of SEQ ID NO: 24 comprises E94C/A360C and then (.DELTA.M1)G1G2 (i.e. deletion of M1 and then addition G1 and G2) or E94C/A360C/C109A/C136A and then (.DELTA.M1)G1G2.

[0236] Any number of helicases may be used in accordance with the invention. For instance, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more helicases may be used. In some embodiments, different numbers of helicases may be used.

[0237] The method of the invention preferably comprises contacting the first polynucleotide analyte and/or the second polynucleotide analyte with two or more helicases. The two or more helicases are typically the same helicase. The two or more helicases may be different helicases.

[0238] The two or more helicases may be any combination of the helicases mentioned above. The two or more helicases may be two or more Dda helicases. The two or more helicases may be one or more Dda helicases and one or more TrwC helicases. The two or more helicases may be different variants of the same helicase.

[0239] The two or more helicases are preferably attached to one another. The two or more helicases are more preferably covalently attached to one another. The helicases may be attached in any order and using any method. Preferred helicase constructs for use in the invention are described in International Application Nos. PCT/GB2013/051925 (published as WO 2014/013260); PCT/GB2013/051924 (published as WO 2014/013259); PCT/GB2013/051928 (published as WO 2014/013262) and PCT/GB2014/052736.

[0240] A variant of SEQ ID NOs: 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, 23, 24 or 25 is an enzyme that has an amino acid sequence which varies from that of SEQ ID NO: 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, 23, 24 or 25 and which retains polynucleotide binding ability. This can be measured using any method known in the art. For instance, the variant can be contacted with a polynucleotide and its ability to bind to and move along the polynucleotide can be measured. The variant may include modifications that facilitate binding of the polynucleotide and/or facilitate its activity at high salt concentrations and/or room temperature. Variants may be modified such that they bind polynucleotides (i.e. retain polynucleotide binding ability) but do not function as a helicase (i.e. do not move along polynucleotides when provided with all the necessary components to facilitate movement, e.g. ATP and Mg.sup.2+). Such modifications are known in the art. For instance, modification of the Mg.sup.2+ binding domain in helicases typically results in variants which do not function as helicases. These types of variants may act as molecular brakes (see below).

[0241] Over the entire length of the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, 23, 24 or 25, a variant will preferably be at least 50% homologous to that sequence based on amino acid identity. More preferably, the variant polypeptide may be at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% and more preferably at least 95%, 97% or 99% homologous based on amino acid identity to the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, 23, 24 or 25 over the entire sequence. There may be at least 80%, for example at least 85%, 90% or 95%, amino acid identity over a stretch of 200 or more, for example 230, 250, 270, 280, 300, 400, 500, 600, 700, 800, 900 or 1000 or more, contiguous amino acids ("hard homology"). Homology is determined as described above. The variant may differ from the wild-type sequence in any of the ways discussed above with reference to SEQ ID NO: 2 and 4 above. The enzyme may be covalently attached to the pore. Any method may be used to covalently attach the enzyme to the pore.

[0242] A preferred molecular brake is TrwC Cba-Q594A (SEQ ID NO: 25 with the mutation Q594A). This variant does not function as a helicase (i.e. binds polynucleotides but does not move along them when provided with all the necessary components to facilitate movement, e.g. ATP and Mg.sup.2+).

[0243] In strand sequencing, the polynucleotide is translocated through the pore either with or against an applied potential. Exonucleases that act progressively or processively on double stranded polynucleotides can be used on the cis side of the pore to feed the remaining single strand through under an applied potential or the trans side under a reverse potential. Likewise, a helicase that unwinds the double stranded DNA can also be used in a similar manner. A polymerase may also be used. There are also possibilities for sequencing applications that require strand translocation against an applied potential, but the DNA must be first "caught" by the enzyme under a reverse or no potential. With the potential then switched back following binding the strand will pass cis to trans through the pore and be held in an extended conformation by the current flow. The single strand DNA exonucleases or single strand DNA dependent polymerases can act as molecular motors to pull the recently translocated single strand back through the pore in a controlled stepwise manner, trans to cis, against the applied potential.

Helicase(s) and Molecular Brake(s)

[0244] In a preferred embodiment, the method comprises: [0245] (a) providing a first polynucleotide in a first sample with one or more helicases attached to the first polynucleotide and one or more molecular brakes attached to the first polynucleotide; [0246] (b) providing a second polynucleotide in a second sample with one or more helicases attached to the second polynucleotide and one or more molecular brakes attached to the second polynucleotide; [0247] (c) coupling the first polynucleotide in the first sample to a membrane using one or more anchors; [0248] (d) contacting the first polynucleotide with a transmembrane pore and applying a potential across the pore such that the one or more helicases and the one or more molecular brakes are brought together and both control the movement of the first polynucleotide through the pore; [0249] (e) taking one or more measurements as the first polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the first polynucleotide and thereby characterising the first polynucleotide; [0250] (f) uncoupling the first polynucleotide from the membrane; [0251] (g) coupling the second polynucleotide in the second sample to the membrane using one or more anchors; [0252] (h) contacting the second polynucleotide with a transmembrane pore and applying a potential across the pore such that the one or more helicases and the one or more molecular brakes are brought together and both control the movement of the second polynucleotide through the pore; and [0253] (i) taking one or more measurements as the second polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the second polynucleotide and thereby characterising the second polynucleotide.

[0254] This type of method is discussed in detail in the International Application PCT/GB2014/052737.

[0255] Step (f) (i.e. uncoupling of the first polynucleotide) may be performed before step (g) (i.e. before coupling the second polynucleotide to the membrane). Step (g) may be performed before step (f). If the second polynucleotide is coupled to the membrane before the first polynucleotide is uncoupled, step (f) preferably comprises selectively uncoupling the first polynucleotide from the membrane (i.e. uncoupling the first polynucleotide but not the second polynucleotide from the membrane). A skilled person can design a system in which selective uncoupling is achieved. Steps (f) and (g) may be performed at the same time. This is discussed in more detail below.

[0256] The one or more helicases may be any of those discussed above. The one or more molecular brakes may be any compound or molecule which binds to the polynucleotide and slow the movement of the polynucleotide through the pore. The one or more molecular brakes are preferably one or more polynucleotide binding proteins. The polynucleotide binding protein may be any protein that is capable of binding to the polynucleotide and controlling its movement through the pore. It is straightforward in the art to determine whether or not a protein binds to a polynucleotide. The protein typically interacts with and modifies at least one property of the polynucleotide. The protein may modify the polynucleotide by cleaving it to form individual nucleotides or shorter chains of nucleotides, such as di- or trinucleotides. The moiety may modify the polynucleotide by orienting it or moving it to a specific position, i.e. controlling its movement.

[0257] The polynucleotide binding protein is preferably derived from a polynucleotide handling enzyme. The one or more molecular brakes may be derived from any of the polynucleotide handling enzymes discussed above. Modified versions of Phi29 polymerase (SEQ ID NO: 8) which act as molecular brakes are disclosed in U.S. Pat. No. 5,576,204. The one or more molecular brakes are preferably derived from a helicase.

Spacers in Polynucleotide Analytes

[0258] The one or more helicases may be stalled at one or more spacers as discussed in International Application No. PCT/GB2014/050175 (published as WO 2014/135838). Any configuration of one or more helicases and one or more spacers disclosed in the International Application may be used in this invention.

Double Stranded Polynucleotide

[0259] The first polynucleotide analyte and/or the second polynucleotide analyte may be double stranded. If the analyte polynucleotide is double stranded, the method preferably further comprises before the coupling step ligating a hairpin adaptor to one end of the polynucleotide and separating the two strands of the polynucleotide to form a single stranded polynucleotide construct. The single stranded polynucleotide construct may then be allowed to interact with the detector in accordance with the invention. Linking and interrogating both strands on a double stranded construct in this way increases the efficiency and accuracy of characterization. Sequencing using hairpin adaptors is disclosed in International Application Nos. PCT/GB2010/000160 (published as WO 2010/086622) and PCT/GB2012/051786 (published as WO 2013/014451).

Leader Sequence

[0260] Before the coupling step, the method preferably comprises attaching to the first and/or second polynucleotide analyte a leader sequence which preferentially threads into the pore. The leader sequence facilitates the method of the invention. The leader sequence is designed to preferentially thread into the transmembrane pore and thereby facilitate the movement of polynucleotide analyte through the pore. The leader sequence can also be used to link the polynucleotide to the one or more anchors as discussed above.

[0261] The leader sequence typically comprises a polymer. The polymer is preferably negatively charged. The polymer is preferably a polynucleotide, such as DNA or RNA, a modified polynucleotide (such as abasic DNA), PNA, LNA, polyethylene glycol (PEG) or a polypeptide. The leader preferably comprises a polynucleotide and more preferably comprises a single stranded polynucleotide. The leader sequence can comprise any of the polynucleotides discussed above. The single stranded leader sequence most preferably comprises a single strand of DNA, such as a poly dT section. The leader sequence preferably comprises the one or more spacers.

[0262] The leader sequence can be any length, but is typically 10 to 150 nucleotides in length, such as from 20 to 150 nucleotides in length. The length of the leader typically depends on the transmembrane pore used in the method.

Double Coupling

[0263] The method of the invention may involve double coupling of multiple double stranded polynucleotides. In a preferred embodiment, the invention involves characterising multiple double stranded polynucleotides. The method preferably comprises: [0264] (a) providing a first double stranded polynucleotide in a first sample with a Y adaptor at one end and a hairpin loop adaptor at the other end, wherein the Y adaptor comprises one or more first anchors for coupling the polynucleotide to the membrane, wherein the hairpin loop adaptor comprises one or more second anchors for coupling the polynucleotide to the membrane and wherein the strength of coupling of the hairpin loop adaptor to the membrane is greater than the strength of coupling of the Y adaptor to the membrane; [0265] (b) providing a second double stranded polynucleotide in a second sample in a form as defined in step (a); [0266] (c) coupling the first polynucleotide provided in step (a) to a membrane; [0267] (d) contacting the first polynucleotide coupled in step (c) with a transmembrane pore such that at least one strand of the first polynucleotide moves through the pore; [0268] (e) taking one or more measurements as the at least one strand of the first polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the at least one strand of the first polynucleotide and thereby characterising the first polynucleotide; [0269] (f) uncoupling the first polynucleotide from the membrane; [0270] (g) coupling the second polynucleotide provided in step (b) to the membrane; [0271] (h) contacting the second polynucleotide coupled in step (g) with a transmembrane pore such that at least one strand of the second polynucleotide moves through the pore; and [0272] (i) taking one or more measurements as the at least one strand of the second polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the at least one strand of the second polynucleotide and thereby characterising the first polynucleotide.

[0273] This type of method is discussed in detail in the UK Applications 1406147.7 and 1407815.8 and in the International application being filed concurrently with this application.

[0274] The double stranded polynucleotide is provided with a Y adaptor at one end and a hairpin loop adaptor at the other end. The Y adaptor and/or the hairpin adaptor are typically polynucleotide adaptors. They may be formed from any of the polynucleotides discussed above.

[0275] The Y adaptor typically comprises (a) a double stranded region and (b) a single stranded region or a region that is not complementary at the other end. The Y adaptor may be described as having an overhang if it comprises a single stranded region. The presence of a non-complementary region in the Y adaptor gives the adaptor its Y shape since the two strands typically do not hybridise to each other unlike the double stranded portion. The Y adaptor comprises the one or more first anchors. Anchors are discussed in more detail above.

[0276] The Y adaptor preferably comprises a leader sequence which preferentially threads into the pore. Leader sequences are discussed above.

[0277] The hairpin adaptor preferably comprises a selectable binding moiety as discussed above. The hairpin adaptor and/or the selectable binding moiety may comprise a region that can be cut, nicked, cleaved or hydrolysed as discussed above.

[0278] The Y adaptor and/or the hairpin adaptor may be ligated to the polynucleotide using any method known in the art. One or both of the adaptors may be ligated using a ligase, such as T4 DNA ligase, E. coli DNA ligase, Taq DNA ligase, Tma DNA ligase and 9.degree. N DNA ligase. Alternatively, the adaptors may be added to the polynucleotide using the methods of the invention discussed below.

[0279] In a preferred embodiment, step a) of the method comprises modifying the double stranded polynucleotide so that it comprises the Y adaptor at one end and the hairpin loop adaptor at the other end. Any manner of modification can be used. The method preferably comprises modifying the double stranded polynucleotide in accordance with the invention. This is discussed in more detail below. The methods of modification and characterisation may be combined in any way.

[0280] The strength of coupling (or binding) of the hairpin adaptor to the membrane is greater than the strength of coupling (or binding) of the Y adaptor to the membrane. This can be measured in any way. A suitable method for measuring the strength of coupling (or binding) is disclosed in the Examples of the UK Applications 1406147.7 and 1407815.8 and in the International application which is being filed concurrently.

[0281] The strength of coupling (or binding) of the hairpin loop adaptor is preferably at least 1.5 times the strength of coupling (or binding) of the hairpin loop adaptor, such as at least twice, at least three times, at least four times, at least five or at least ten times the strength of coupling (or binding) of the anchor adaptor. The affinity constant (Kd) of the hairpin loop adaptor for the membrane is preferably at least 1.5 times the affinity constant of the Y adaptor, such as at least twice, at least three times, at least four times, at least five or at least ten times the strength of coupling of the Y adaptor.

[0282] There are several ways in which the hairpin loop adaptor couples (or binds) more strongly to the membrane than the Y adaptor. For instance, the hairpin loop adaptor may comprise more anchors that than the Y adaptor. For instance, the hairpin loop adaptor may comprise 2, 3 or more second anchors whereas the Y adaptor may comprise one first anchor.

[0283] The strength of coupling (or binding) of the one or more second anchors to the membrane may be greater than the strength of coupling (or binding) of the one or more first anchors to the membrane. The strength of coupling (or binding) of the one or more second anchors to the hairpin loop adaptor may be greater than the strength of coupling (or binding) of the one or more first anchors to the Y adaptor. The one or more first anchors and the one or more second anchors may be attached to their respective adaptors via hybridisation and the strength of hybridisation is greater in the one or more second anchors than in the one or more first anchors. Any combination of these embodiments may also be used in the invention. Strength of coupling (or binding) may be measure using known techniques in the art.

[0284] The one or more second anchors preferably comprise one or more groups which couples(s) (or bind(s)) to the membrane with a greater strength than the one or more groups in the one or more first anchors which couple(s) (or bind(s)) to the membrane. In preferred embodiments, the hairpin loop adaptor/one or more second anchors couple (or bind) to the membrane using cholesterol and the Y adaptor/one or more first anchors couple (or bind) to the membrane using palmitate. Cholesterol binds to triblock copolymer membranes and lipid membranes more strongly than palmitate. In an alternative embodiment, the hairpin loop adaptor/one or more second anchors couple (or bind) to the membrane using a mono-acyl species, such as palmitate, and the Y adaptor/one or more first anchors couple (or bind) to the membrane using a diacyl species, such as dipalmitoylphosphatidylcholine.

Adding Hairpin Loops and Leader Sequences

[0285] Before the coupling step, a double stranded polynucleotide analyte is preferably contacted with a MuA transposase and a population of double stranded MuA substrates, wherein a proportion of the substrates in the population are Y adaptors comprising the leader sequence and wherein a proportion of the substrates in the population are hairpin loop adaptors. The transposase fragments the double stranded polynucleotide analyte and ligates MuA substrates to one or both ends of the fragments. This produces a plurality of modified double stranded polynucleotides comprising the leader sequence at one end and the hairpin loop at the other. The modified double stranded polynucleotides may then be investigated using the method of the invention.

[0286] These MuA based methods are disclosed in the International Application No. PCT/GB2014/052505 (published as WO2015022544). They are also discussed in detail in the UK Applications 1406147.7 and 1407815.8 and the International application being filed concurrently with this application (ONT IP 056).

Modified Polynucleotide Analytes

[0287] Before characterisation, the first polynucleotide analyte and/or the second polynucleotide analyte may modified by contacting the polynucleotide analyte with a polymerase and a population of free nucleotides under conditions in which the polymerase forms a modified polynucleotide analyte using the polynucleotide analyte as a template, wherein the polymerase replaces one or more of the nucleotide species in the polynucleotide analyte with a different nucleotide species when forming the modified polynucleotide analyte. The modified polynucleotide analyte may then be coupled to the membrane as in step a) and/or d). This type of modification is described in International Application No. PCT/GB2015/050483. Any of the polymerases discussed above may be used. The polymerase is preferably Klenow or 90 North.

[0288] The template polynucleotide is contacted with the polymerase under conditions in which the polymerase forms a modified polynucleotide using the template polynucleotide as a template. Such conditions are known in the art. For instance, the polynucleotide is typically contacted with the polymerase in commercially available polymerase buffer, such as buffer from New England Biolabs.RTM.. The temperature is preferably from 20 to 37.degree. C. for Klenow or from 60 to 75.degree. C. for 9o North. A primer or a 3' hairpin is typically used as the nucleation point for polymerase extension.

[0289] Characterisation, such as sequencing, of a polynucleotide using a transmembrane pore typically involves analyzing polymer units made up of k nucleotides where k is a positive integer (i.e. `k-mers`). This is discussed in International Application No. PCT/GB2012/052343 (published as WO 2013/041878). While it is desirable to have clear separation between current measurements for different k-mers, it is common for some of these measurements to overlap. Especially with high numbers of polymer units in the k-mer, i.e. high values of k, it can become difficult to resolve the measurements produced by different k-mers, to the detriment of deriving information about the polynucleotide, for example an estimate of the underlying sequence of the polynucleotide.

[0290] By replacing one or more nucleotide species in the template polynucleotide analyte with different nucleotide species in the modified polynucleotide analyte, the modified polynucleotide analyte contains k-mers which differ from those in the template polynucleotide analyte. The different k-mers in the modified polynucleotide analyte are capable of producing different current measurements from the k-mers in the template polynucleotide analyte and so the modified polynucleotide analyte provides different information from the template polynucleotide analyte. The additional information from the modified polynucleotide analyte can make it easier to characterise the template polynucleotide analyte. In some instances, the modified polynucleotide analyte itself may be easier to characterise. For instance, the modified polynucleotide may be designed to include k-mers with an increased separation or a clear separation between their current measurements or k-mers which have a decreased noise.

Preferred Embodiment

[0291] The invention provides a method of characterising two or more double stranded polynucleotides, comprising [0292] (a) providing a first double stranded polynucleotide in a first sample with a first Y adaptor at one end and a first hairpin loop adaptor at the other end, wherein the first Y adaptor comprises one or more first helicases and one or more first anchors for coupling the polynucleotide to the membrane, wherein the first hairpin loop adaptor comprises the one or more first molecular brakes and one or more second anchors for coupling the first polynucleotide to the membrane and wherein the strength of coupling of the first hairpin loop adaptor to the membrane is greater than the strength of coupling of the first Y adaptor to the membrane; [0293] (b) providing a second double stranded polynucleotide in a second sample with a second Y adaptor at one end and a second hairpin loop adaptor at the other end, wherein the second Y adaptor comprises one or more second helicases and one or more third anchors for coupling the polynucleotide to the membrane, wherein the second hairpin loop adaptor comprises one or more second molecular brakes and one or more fourth anchors for coupling the second polynucleotide to the membrane and wherein the strength of coupling of the second hairpin loop adaptor to the membrane is greater than the strength of coupling of the second Y adaptor to the membrane; [0294] (c) coupling the first polynucleotide in the first sample to a membrane; [0295] (d) contacting the first polynucleotide with a transmembrane pore and applying a potential across the pore such that the one or more helicases and the one or more molecular brakes are brought together and both control the movement of the first polynucleotide through the pore; [0296] (e) taking one or more measurements as the first polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the first polynucleotide and thereby characterising the first polynucleotide; [0297] (f) uncoupling the first polynucleotide from the membrane; [0298] (g) coupling the second polynucleotide in the second sample to the membrane; [0299] (h) contacting the second polynucleotide with a transmembrane pore and applying a potential across the pore such that the one or more helicases and the one or more molecular brakes are brought together and both control the movement of the second polynucleotide through the pore; and [0300] (i) taking one or more measurements as the second polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the second polynucleotide and thereby characterising the second polynucleotide [0301] This combines the methods disclosed in the UK Applications 1406155.0, 1406147.7, 1407815.8 and 1406151.9 and International Application PCT/GB2014/052737 and the International application being co-filed at this time (ONT IP 056). Any of the embodiments disclosed herein and therein may be applied to the preferred embodiment.

Other Characterisation Method

[0302] In another embodiment, a first polynucleotide analyte and/or a second polynucleotide analyte is characterised by detecting labelled species that are released as a polymerase incorporates nucleotides into the polynucleotide. The polymerase uses the first and/or second polynucleotide analyte as a template. Each labelled species is specific for each nucleotide. The first and/or second polynucleotide analyte is contacted with a transmembrane pore, a polymerase and labelled nucleotides such that phosphate labelled species are sequentially released when nucleotides are added to the polynucleotide(s) by the polymerase, wherein the phosphate species contain a label specific for each nucleotide. The polymerase may be any of those discussed above. The phosphate labelled species are detected using the pore and thereby characterising the first and/or second polynucleotide analyte. This type of method is disclosed in European Application No. 13187149.3 (published as EP 2682460). Any of the embodiments discussed above equally apply to this method.

Method Involving Cholesterol and Cyclodextrin

[0303] The invention also provides a method for uncoupling from a membrane an analyte coupled to the membrane using an anchor comprising cholesterol, comprising contacting the analyte with a cyclodextrin or a derivative thereof and thereby uncoupling the analyte from the membrane. Any of the embodiments discussed above, particularly those concerning the analyte, anchor, cyclodextrin or a derivative thereof and membrane, are equally applicable to this method. The analyte is preferably a polynucleotide. The polynucleotide preferably comprises a leader sequence as defined above. The cholesterol anchor preferably comprises a polynucleotide sequence which is hybridised to the leader sequence. The polynucleotide sequence is preferably covalently attached to the cholesterol in the anchor.

Kits

[0304] The present invention also provides a kit for determining the presence, absence or one or more characteristics of two or more analytes in two or more samples comprising (a) a membrane, (b) one or more anchors which are capable of coupling the two or more analytes to the membrane, such as one or more first anchors which are capable of coupling a first analyte to the membrane and one or more second anchors which are capable of coupling a second analyte to the membrane and (c) one or more agents which are capable of uncoupling at least one of, such as both of, the two or more analytes from the membrane. The one or more anchors and one or more agents may be any of those discussed above with reference to the method of the invention.

[0305] The kit preferably further comprises a detector, such as a transmembrane pore. Any of the detectors discussed above may be in the kit.

[0306] The kit preferably further comprises a hairpin loop and/or a leader sequence which is capable of preferentially threading into a transmembrane pore. The kit preferably further comprises a polynucleotide binding protein. Preferred hairpin loops, leader sequences and polynucleotide binding proteins are discussed above.

[0307] Any of the embodiments discussed above with reference to the method of the invention equally apply to the kits. The kit may further comprise the components of a membrane, such as the components of an amphiphilic layer or a triblock copolymer membrane.

[0308] The kit of the invention may additionally comprise one or more other reagents or instruments which enable any of the embodiments mentioned above to be carried out. Such reagents or instruments include one or more of the following: suitable buffer(s) (aqueous solutions), means to obtain a sample from a subject (such as a vessel or an instrument comprising a needle), means to amplify and/or express polynucleotides, a membrane as defined above or voltage or patch clamp apparatus. Reagents may be present in the kit in a dry state such that a fluid sample resuspends the reagents. The kit may also, optionally, comprise instructions to enable the kit to be used in the method of the invention or details regarding for which organism the method may be used.

[0309] The following Examples illustrate the invention.

Examples

Example 1

[0310] This example shows a control experiment which illustrated that free DNA in solution, which had not been coupled to the membrane, was not prevented from entering the nanopore by the presence of methyl-.beta.-cyclodextrin in the experimental system.

Materials and Methods

[0311] Electrical measurements were acquired from single MspA nanopores MS(B1-G75S/G77S/L88N/Q126R)8 MspA (MspA-B2C) (SEQ ID NO: 2 with mutations G75S/G77S/L88N/Q126R) inserted in block co-polymer in buffer (600 mM KCl, 25 mM potassium phosphate, 75 mM potassium ferrocyanide (II), 25 mM potassium ferricyanide (III) pH 8.0) at a temperature of 15.degree. C. After achieving a single pore inserted in the block co-polymer, then buffer (1 mL, 600 mM KCl, 25 mM potassium phosphate, 75 mM potassium ferrocyanide (II), 25 mM potassium ferricyanide (III) pH 8.0) was flowed through the system to remove any excess MspA-B2C nanopores. Two DNA samples (100 nM, 1--SEQ ID NO: 26 and SEQ ID NO: 29 and 2--SEQ ID NO: 27 attached at its 5' end to four iSp18 spacers which are attached at the opposite end to the 3' end of SEQ ID NO: 28) were added to the system and the experiment was run at an applied potential of 120 mV for 30 minutes. The system was then flushed with methyl-.beta.-cyclodextrin (100 .mu.M) and the DNA samples 1 and 2 at a concentration of 100 nM in a total volume of 500 .mu.L and the experiment run at an applied potential of 120 mV for a further 30 minutes. The system was then flushed with two 1 mL flushes of methyl-.beta.-cyclodextrin (100 .mu.M) and the DNA samples 1 and 2 at a concentration of 100 nM.

[0312] A similar control experiment to the one described previously was carried out except that for all the steps which had contained methyl-.beta.-cyclodextrin only DNA samples were added and no methyl-.beta.-cyclodextrin was flushed through the system.

Results

[0313] The control experiment where only free DNA was added to the system consistently exhibited short spikes in the current trace which corresponded to the DNA translocating through the nanopore under the applied potential. This illustrated that DNA translocation was seen for each flush of the nanopore system with DNA samples 1 and 2.

[0314] These controls were undertaken to confirm that the reduction in the number of DNA translocations observed (see Example 4) was due to the methyl-.beta.-cyclodextrin removing the cholesterol from the membrane surface, rather than preventing the strand from entering the pore. The controls tested whether the cyclodextrin could have bound along the length of the DNA, impeding its ability to thread through the pore, and thus preventing the strand from being detected despite the fact that it was still attached to the membrane. In these experiments, free DNA was used, which had no anchor to couple it to the membrane, if the interaction of the cyclodextrin was confined specifically to the cholesterol, the cyclodextrin should have had no effect on the DNA in this case. Any reduction in number of DNA translocations observed would, therefore, have been due to binding of the body of the DNA. No difference in the number of DNA translocations was observed in the presence or absence of cyclodextrin, suggesting that the cyclodextrin present in the system did not bind to the free DNA and prevent its translocation through the nanopore.

Example 2

[0315] This example shows a further control experiment which illustrated that when a first sample of coupled DNA was added to the nanopore system followed by a second sample, without flushing the system with a de-coupling agent or buffer with no DNA present, then the number of helicase-controlled DNA movements detected over a defined period remained fairly constant and helicase controlled DNA movements were observed for both samples.

Materials and Methods

[0316] The strands used in this study were from a region of the lambda genome, between 45,042 bp and 48,487 bp. Analytes were made by the polymerase PCR method to include hybridisation sites at defined ends of each of the template and template compliment strands as desired. PCR was carried out from lambda genomic DNA.

[0317] The DNA template (SEQ ID NO: 31 which corresponds to the sequence of the strand labelled Alwhich was hybridised to SEQ ID NO: 47 which corresponds to the sequence for the strand labelled A2, see FIG. 1(1)) was made using KAPA HiFi 2.times. Master mix, lambda DNA (NEB) and primers SEQ ID NO: 32 and SEQ ID NO: 33. Reactions were cycled 20 times and product of the correct size was purified by Gel Filtration on Sephacryl S1000 column and concentrated to 0.25 mg/ml using Millipore Ultracel 15 50 kDa concentrators.

[0318] DNA constructs (X and Y) for electrophysiology experiments were made according to the same reaction mix; 2.times. LongAmp Taq master mix, 300 nM of primers 1 and 2 or 3 and 4, 1.2 ng ul.sup.-1 DNA template (SEQ ID NO: 31 which corresponds to the sequence for the strand labelled Alwhich was hybridised to SEQ ID NO: 47 which corresponds to the sequence for the strand labelled A2, see FIG. 1(1)). DNA constructs were all amplified according to the same cycling program; 94.degree. C. for 2 mins, [94.degree. C. for 15 secs, 58.degree. C. for 30 secs, 65.degree. C. for 2 mins].sub.12 and 65.degree. C. for 5 mins. DNA constructs were all purified from a 0.8% agarose gel according to manufacturer's instructions (Qiagen Gel Extraction kit) and then SPRI purified (Agencourt AMPure beads) according to manufacturer's instructions.

[0319] For DNA construct X=SEQ ID NO: 34 attached at its 3' end to four iSpC3 spacers which are attached at the opposite end to the 5' end of SEQ ID NO: 35; SEQ ID NO: 35 is attached at the 3' end to four iSpC3 spacers which are attached at the opposite end to four 5-nitroindoles which are attached to the 3' end of SEQ ID NO: 39. The primers used to produce construct X are primer 1--SEQ ID NO: 34 attached at the 3' end to four iSpC3 spacers which are attached at the opposite end to the 5' end of SEQ ID NO: 35; SEQ ID NO: 35 is also attached at the 3' end to four iSpC3 spacers which are attached at the opposite end to four 5-nitroindoles which are attached to the 5' end of SEQ ID NO: 36 and primer 2--SEQ ID NO: 37 is attached at the 3' end to four 5-nitroindoles which are attached at the opposite end to the 5' end of SEQ ID NO: 38.

[0320] Construct X was then hybridised to SEQ ID NO: 41 and SEQ ID NO: 41 which is attached at the 3' end to six iSp18 spacers which are attached at the opposite end to two thymines and a 3' cholesterol TEG (FIG. 1(2) shows a cartoon representation of construct X). The tethers were annealed at a five-fold excess at room temperature for ten minutes in 25 mM potassium phosphate buffer, 151 mM potassium chloride, pH 8.0.

[0321] For DNA construct Y=SEQ ID NO: 34 attached at its 3' end to four iSpC3 spacers which are attached at the opposite end to the 5' end of SEQ ID NO: 37; SEQ ID NO: 37 is attached at the 3' end to four iSpC3 spacers which are attached at the opposite end to four 5-nitroindoles which are attached to the 5' end of SEQ ID NO: 40. The primers used to produce construct Y are primer 3--SEQ ID NO: 34 attached at the 3' end to four iSpC3 spacers which are attached at the opposite end to the 5' end of SEQ ID NO: 37; SEQ ID NO: 37 is attached at the 3' end to four iSpC3 spacers which are attached at the opposite end to four 5-nitroindoles which are attached to the 5' end of SEQ ID NO: 38 and primer 4--SEQ ID NO: 35 is attached at the 3' end to four 5-nitroindoles which are attached at the opposite end to the 5' end of SEQ ID NO: 36.

[0322] Construct Y was then hybridised to SEQ ID NO: 30 and SEQ ID NO: 30 which is attached at the 3' end to six iSp18 spacers which are attached at the opposite end to two thymines and a 3' cholesterol TEG (FIG. 1(3) shows a cartoon representation of construct Y). The tethers were annealed at a five-fold excess at room temperature for ten minutes in 25 mM potassium phosphate buffer, 151 mM potassium chloride, pH 8.0.

[0323] Prior to setting up the experiment, the DNA constructs X and Y with their appropriate tethers (stock concentration 20 nM, final concentration added to nanopore system 0.1 nM) were separately incubated with reagents as described. Firstly the DNA was pre-incubated at room temperature for five minutes with T4 Dda-E94C/A360C (stock concentration 250 nM, final concentration added to nanopore system 1 nM, SEQ ID NO: 24 with mutations E94C/A360C) in buffer (151 mM KCl, 25 mM phosphate, 2 mM EDTA, pH8.0). After five minutes TMAD (500 .mu.M) was added to the pre-mix and the mixture incubated for a further 5 minutes. Finally, MgCl2 (10 mM final concentration), ATP (2.5 mM final concentration) and buffer (150 mM potassium ferrocyanide (II), 150 mM potassium ferricyanide and 25 mM potassium phosphate pH 8.0) were added to the pre-mix.

[0324] Electrical measurements were acquired from single MspA nanopores (MspA-B2C) inserted in block co-polymer in buffer (25 mM potassium phosphate, 150 mM potassium ferrocyanide (II), 150 mM potassium ferricyanide (III), pH 8.0). After achieving a single pore inserted in the block co-polymer, then buffer (2 mL, 25 mM potassium phosphate pH 8.0, 150 mM potassium ferrocyanide (II) and 150 mM potassium ferricyanide (III)) was flowed through the system to remove any excess MspA nanopores. The enzyme (T4 Dda-E94C/A360C, 1 nM final concentration), DNA construct X (0.1 nM final concentration), fuel (MgCl2 10 mM final concentration, ATP 2.5 mM final concentration) pre-mix (150 .mu.L total) was then added to the single nanopore experimental system and the experiment was run at a holding potential of 120 mV for 2 hours and helicase-controlled DNA movement was monitored. After two hours, the experimental protocol was stopped, the potential set to zero and the DNA construct Y/enzyme pre-mix (150 .mu.L total) was then added directly to the system with no de-coupling agents or flushes of buffer included. The experiment was then run for a further 2 hours at a holding potential of 120 mV and helicase controlled DNA movement monitored.

Results and Discussion

[0325] DNA contructs X and Y (shown in FIGS. 1 (a) and (b) respectively) were prepared from the same 3.8 kB section of the lambda phage genome. Adaptors were attached to give an overhanging "leader" at one end of the duplex, which allowed capture and threading by the pore as well as providing an enzyme binding site. The other end was left blunt so only the strand with the leader on was captured and sequenced. The two samples had the adaptor ligated to opposite ends, such that the leader was joined to strand A1 (shown in FIG. 1(2)) in DNA construct X and to strand A2 (shown in FIG. 1(3)) in DNA construct Y. This meant that DNA constructs X and Y gave detectable strand movements with sequences that mapped only to distinct regions of the lambda genome. These movements were easily distinguished, so provided a convenient way of identifying two different test samples; however any other samples with different sequences could have been used just as well.

[0326] Helicase controlled DNA movement was observed for both DNA constructs X and Y, with T4 Dda-E94C/A360C. Figure two shows the experimental time course with the percentage of time the nanopores were present in their unblocked state (shown as light grey) compared to when a helicase DNA movement was occurring and the nanopores were partially blocked by the DNA strand (shown as black). For the first 2100 seconds no DNA was present in the system, therefore, the nanopores were in an unblocked state. DNA construct X was added at 2400 seconds and helicase controlled DNA movements were occurring through the nanopore around 80% of the time. DNA construct Y was then flowed into the nanopore system at 7200 seconds and again helicase controlled DNA movement through the nanopore was observed for approximately 80% of the time.

[0327] Upon the addition of construct X, the helicase controlled DNA movements observed were all identified as corresponding to this construct. When construct Y was flowed into the system helicase controlled DNA movements corresponding to Y were detected as well as a significant number of movements which corresponded to construct X. Experimental data showed that the rate of helicase controlled DNA movements detected remained fairly constant throughout the experiment and that by adding construct Y to the system, with no additional flushing or de-coupling agents, helicase controlled DNA movements were detected for both samples.

Example 3

[0328] This example illustrates that when coupled DNA construct X was added to the nanopore system it was not possible to remove the sample simply by flushing the system with a large volume of buffer.

Materials and Methods

[0329] DNA constructs X and Y were prepared as described in Example 2. The DNA constructs were pre-incubated with enzyme as described in Example 2 producing the construct X and construct Y pre-mixes.

[0330] The nanopore experimental system was set up as described in Example 2. DNA construct X/enzyme pre-mix (300 .mu.L total) was added to the experimental system and the experiment run at a holding potential of 120 mV for two hours and helicase controlled DNA movement was monitored. After two hours, the experimental protocol was stopped, the potential set to zero and buffer (10 mL of 150 mM potassium ferrocyanide (II), 150 mM potassium ferricyanide (III), 25 mM potassium phosphate pH 8.0) was flowed through the nanopore system in order to try and remove coupled DNA construct X. After the buffer flush, the experiment was run with no additional DNA added to the system at a holding potential of 120 mV for two hours and helicase controlled DNA movement was monitored. Finally, DNA construct Y/enzyme pre-mix (300 .mu.L total) was added to the experimental system and the experiment run at a holding potential of 120 mV for two hours and helicase controlled DNA movement was monitored.

Results and Discussion

[0331] Helicase controlled DNA movement was observed for both DNA constructs X and Y, with T4 Dda-E94C/A360C. FIG. 3 shows part of the experimental time course with the percentage of time the nanopores were present in their unblocked state (shown as light grey) compared to when a helicase DNA movement was occurring and the nanopores were partially blocked by the DNA strand (shown as black). For the first 2400 seconds no DNA was present in the system, therefore, the nanopores were in an unblocked state. DNA construct X was added at 2700 seconds and helicase controlled DNA movements were occurring through the nanopore around 80% of the time. Buffer (10 mL) was flowed across the system, at 7500 seconds and then the percentage of time the nanopore was partially blocked owing to helicase controlled DNA movement was then monitored. After flushing with buffer, helicase controlled DNA movements were occurring through the nanopore around 50% of the time. This indicated that the amount of coupled DNA construct X present in the system had been reduced by the buffer flush, however, a large number of helicase controlled DNA movements were still detected. Upon the addition of DNA construct Y, helicase controlled DNA movements corresponding to Y were detected as well as a significant number of helicase controlled DNA movements which corresponded to construct X which was still present in the system.

Example 4

[0332] This example illustrates how methyl-.beta.-cyclodextrin was used to decouple DNA, which was coupled to the membrane using a cholesterol TEG, from the membrane. A solution of methyl-.beta.-cyclodextrin was added to the nanopore system for 1, 10 and 30 mins and the number of helicase-controlled DNA movements detected over a defined period was monitored after each incubation. This experiment illustrated that even using an incubation period of only one minute significant decoupling of the DNA from the membrane was detected.

Materials and Methods

[0333] DNA constructs X and Y were prepared as described in Example 2. The DNA constructs were pre-incubated with enzyme as described in Example 2 producing the construct X and construct Y pre-mixes.

[0334] The nanopore experimental system was set up as described in Example 2. DNA construct X/enzyme pre-mix (150 .mu.L total) was added to the experimental system and the experiment run at a holding potential of 120 mV for two hours and helicase controlled DNA movement was monitored. After two hours, the experimental protocol was stopped, the potential set to zero and methyl-.beta.-cyclodextrin (150 .mu.L of 100 .mu.M) was flowed onto the nanopore system and incubated for 1, 10 or 30 minutes in order to try and remove coupled DNA construct X. After the appropriate incubation period, buffer (150 .mu.L, 150 mM potassium ferrocyanide (II), 150 mM potassium ferricyanide (III), 25 mM potassium phosphate, pH 8.0) was flushed through the system to remove any de-coupled DNA and excess methyl-.beta.-cyclodextrin. After the buffer flush, the experiment was run with no additional DNA added to the system at a holding potential of 120 mV for two hours and helicase controlled DNA movement was monitored. Finally, DNA construct Y/enzyme pre-mix (150 .mu.L total) was added to the experimental system and the experiment run at a holding potential of 120 mV for two hours and helicase controlled DNA movement was monitored. The same de-coupling procedure was then repeated for DNA construct Y.

Results and Discussion

[0335] Helicase controlled DNA movement was observed for both DNA constructs X and Y, with T4 Dda-E94C/A360C. FIGS. 4, 5 and 6 show part of the experimental time course with the percentage of time the nanopores were present in their unblocked state (shown as light grey) compared to when a helicase DNA movement was occurring and the nanopores were partially blocked by the DNA strand (shown as black). FIGS. 4, 5 and 6 correspond to incubation periods of 1, 10 and 30 minutes with methyl-.beta.-cyclodextrin respectively. For all three experiments, prior to addition of DNA, little or no helicase controlled DNA movements were observed. Upon the addition of construct X helicase controlled DNA movements were occurring through the nanopore around 80% of the time. After the addition of methyl-.beta.-cyclodextrin for various incubation periods and the corresponding buffer flush, the percentage of time the nanopore was partially blocked owing to helicase controlled DNA movement was drastically reduced to around 20% and for the 30 minute incubation to less than 10%. This indicated that methyl-.beta.-cyclodextrin successfully decoupled DNA, which had been coupled to a membrane using cholesterol, from the membrane. The methyl-.beta.-cyclodextrin decoupled significantly more coupled DNA than flushing with buffer.

[0336] Upon the addition of DNA construct Y to the system, helicase controlled DNA movements which corresponded to construct Y were identified. A small proportion of movements were identified as corresponding to construct X, however, the proportion of events identified as X was significantly reduced in comparison to experiments where either construct X was not flushed from the system (see Example 2) or where tethered construct X was treated with 10 mL of buffer in an attempt to remove it from the system (see Example 3). The methyl-.beta.-cyclodextrin decoupling process was repeated for construct Y and it was also shown that it was possible to successfully decouple construct Y from the membrane using this method.

Example 5

[0337] This example illustrates how DNA, which has had a biotin-tether hybridised onto it and has been pre-incubated with streptavidin, has been coupled to the membrane by the streptavidin binding a 5' desthiobiotin of an extender (which also has a cholesterol at the 3' end) (see FIG. 7 for cartoon representation). This DNA construct can then be decoupled from the membrane by flushing the system, with free biotin. As biotin has a stronger binding affinity for streptavidin than desthiobiotin when the biotin was added to the system it out competed the desthiobiotin, which ensured efficient removal of the strand. This left the extenders coupled to the bilayer and available for coupling of a second DNA construct to the membrane.

Materials and Methods

[0338] The DNA construct used in Example 5 is shown in FIG. 7. The DNA construct was prepared by hybridising SEQ ID NO: 45 (50 nM, which has six iSp18 spacers attached to its 3' end which are attached at the opposite end to two thymines and a 3'biotin TEG) to the DNA strand which was made up of SEQ ID NO: 42 which is attached at its 3' end to four iSpC3 spacers which are attached at the opposite end to the 5' end of SEQ ID NO: 43 (50 nM) at 50.degree. C. for ten minutes and then slow cooled. Streptavidin (final concentration 50 nM) was added to the DNA mixture (final concentration 25 nM) and incubated at room temperature for 10 minutes. This complex will be referred to as DNA construct P.

[0339] The nanopore experimental system was set up as described in Example 2. A control experiment was run, with no DNA added to the system for 15 minutes at an applied potential of 120 mV. The desthiobiotin extender (SEQ ID NO: 46 which has a desthiobiotin attached at the 5' end and a cholesterol TEG attached at the 3' end) was then added to the nanopore system and the experiment run for 15 mins allowing it to couple to the membrane. DNA construct P was added to the experimental system (25 nM) and the experiment run at an applied potential of 120 mV for 30 minutes. Free biotin (50 .mu.M) was then added to the system and the experiment run for a further 30 minutes. After the biotin incubation, buffer was flowed through the system (1 mL, 625 mM KCl, 100 mM HEPES, pH8) to remove any excess biotin and de-coupled DNA.

Results and Discussion

[0340] This experiment illustrates another method for de-coupling DNA constructs from a membrane. FIG. 8 shows the current trace of the full experiment described above. FIG. 9 shows several continuous snap shots of the experimental steps described previously. FIG. 9(A) initially shows that the nanopore was open and exhibited a couple of blocks when no DNA was present in the system. *1 marks the point in the experiment when the desthiobiotin extended was added to the system, current blocks corresponding to this short fragment were not observed. *2 marks the point where DNA construct P was added to the system. The addition of DNA resulted in DNA current blocks which were consistently between 70 and 100 pA (see FIG. 9A (last portion of the trace and 9B the first portion of the trace). *3 marks the point where biotin (50 .mu.M) was added to the system. It was clear that upon addition of biotin there was a drastic reduction in the number of DNA current blocks observed. Finally, *4 corresponds to the buffer flush step where the DNA and biotin were removed from the system. This experiment illustrated that by flushing biotin into the system DNA construct P could be de-coupled from the membrane. As biotin has a stronger binding affinity for streptavidin than desthiobiotin when the biotin was added to the system it out competed the desthiobiotin, which ensured efficient removal of the strand. The biotin also bound to the other free binding sites on the streptavidin and the whole-streptavidin DNA complex was removed from the system. This left the extenders coupled to the bilayer and available for coupling of a second DNA construct to the membrane.

Example 6

[0341] This example illustrates how (2-hydroxypropyl)-.beta.-cyclodextrin was used to decouple DNA, which was coupled to the membrane using a cholesterol TEG, from the membrane. Various different concentrations of (2-hydroxypropyl)-.beta.-cyclodextrin were added to the nanopore system and the % change in the number of helicase controlled DNA movements that were detected per nanopore over a defined period was monitored. This experiment illustrated that concentrations as low as 20 mM (2-hydroxypropyl)-.beta.-cyclodextrin resulted in a reduction in the number of helicase controlled DNA movements detected per nanopore, after incubation (see Table 2).

Materials and Methods

[0342] DNA construct X was prepared as described in Example 2. The DNA construct was pre-incubated with enzyme as described in Example 2 producing the construct X pre-mix.

[0343] The nanopore experimental system was set up as described in Example 2. DNA construct X/enzyme pre-mix (150 .mu.L total) was added to the experimental system and the experiment run at a holding potential of 140 mV for two hours and helicase controlled DNA movement was monitored. After two hours, the experimental protocol was stopped, the potential set to zero and (2-hydroxypropyl)-.beta.-cyclodextrin (150 .mu.L of either 20 mM, 50 mM, 100 mM or 200 mM in 500 mM KCl, 25 mM K Phosphate pH8) was flowed onto the nanopore system and incubated for 10 minutes in order to try to remove coupled DNA construct X. After the incubation period, buffer (150 .mu.L, 500 mM KCl, 25 mM K Phosphate pH8) was flushed through the system to remove any de-coupled DNA and excess (2-hydroxypropyl)-.beta.-cyclodextrin. After the buffer flush, buffer (containing fuel) was added to the system (150 uL of 500 mM KCl, 25 mM K Phosphate 2 mM ATP, 2 mM MgCl2 pH8) with no additional DNA at a holding potential of 140 mV for two hours and helicase controlled DNA movement was monitored.

Results and Discussion

[0344] Helicase controlled DNA movement was observed for DNA construct X, with T4 Dda-E94C/A360C. Table 2 below shows the average % change in the number of helicase controlled DNA movements that were detected per nanopore, after the system had been incubated with (2-hydroxypropyl)-.beta.-cyclodextrin at various concentrations. For all experiments, prior to addition of DNA, few or no helicase controlled DNA movements were observed. Upon the addition of construct X, helicase controlled DNA movements were occurring through the nanopore. After the addition of (2-hydroxypropyl)-.beta.-cyclodextrin at various concentrations and the corresponding buffer flush, the average percentage change in the number of helicase controlled DNA movements that were detected per nanopore was at least 50% and was as much as 90% when incubated at 200 mM concentration. This indicated that (2-hydroxypropyl)-.beta.-cyclodextrin successfully decoupled DNA, which had been coupled to a membrane using cholesterol, from the membrane.

TABLE-US-00002 TABLE 2 Reduction in the number of helicase controlled DNA movements detected (Average % change per nanopore) Concentration Experiment 1 Experiment 2 20 mM -53.73 -52.39 50 mM -59.23 -79.10 100 mM -84.06 -83.38 200 mM -90.90 -96.20

Sequence CWU 1

1

471558DNAArtificial SequenceMycobacterium smegmatis porin A mutant (D90N/D91N/D93N/D118R/D134R/E193K) 1atgggtctgg ataatgaact gagcctggtg gacggtcaag atcgtaccct gacggtgcaa 60caatgggata cctttctgaa tggcgttttt ccgctggatc gtaatcgcct gacccgtgaa 120tggtttcatt ccggtcgcgc aaaatatatc gtcgcaggcc cgggtgctga cgaattcgaa 180ggcacgctgg aactgggtta tcagattggc tttccgtggt cactgggcgt tggtatcaac 240ttctcgtaca ccacgccgaa tattctgatc aacaatggta acattaccgc accgccgttt 300ggcctgaaca gcgtgattac gccgaacctg tttccgggtg ttagcatctc tgcccgtctg 360ggcaatggtc cgggcattca agaagtggca acctttagtg tgcgcgtttc cggcgctaaa 420ggcggtgtcg cggtgtctaa cgcccacggt accgttacgg gcgcggccgg cggtgtcctg 480ctgcgtccgt tcgcgcgcct gattgcctct accggcgaca gcgttacgac ctatggcgaa 540ccgtggaata tgaactaa 5582184PRTArtificial SequenceMycobacterium smegmatis porin A mutant (D90N/D91N/D93N/D118R/D134R/E139K) 2Gly Leu Asp Asn Glu Leu Ser Leu Val Asp Gly Gln Asp Arg Thr Leu 1 5 10 15 Thr Val Gln Gln Trp Asp Thr Phe Leu Asn Gly Val Phe Pro Leu Asp 20 25 30 Arg Asn Arg Leu Thr Arg Glu Trp Phe His Ser Gly Arg Ala Lys Tyr 35 40 45 Ile Val Ala Gly Pro Gly Ala Asp Glu Phe Glu Gly Thr Leu Glu Leu 50 55 60 Gly Tyr Gln Ile Gly Phe Pro Trp Ser Leu Gly Val Gly Ile Asn Phe 65 70 75 80 Ser Tyr Thr Thr Pro Asn Ile Leu Ile Asn Asn Gly Asn Ile Thr Ala 85 90 95 Pro Pro Phe Gly Leu Asn Ser Val Ile Thr Pro Asn Leu Phe Pro Gly 100 105 110 Val Ser Ile Ser Ala Arg Leu Gly Asn Gly Pro Gly Ile Gln Glu Val 115 120 125 Ala Thr Phe Ser Val Arg Val Ser Gly Ala Lys Gly Gly Val Ala Val 130 135 140 Ser Asn Ala His Gly Thr Val Thr Gly Ala Ala Gly Gly Val Leu Leu 145 150 155 160 Arg Pro Phe Ala Arg Leu Ile Ala Ser Thr Gly Asp Ser Val Thr Thr 165 170 175 Tyr Gly Glu Pro Trp Asn Met Asn 180 3885DNAArtificial Sequencealpha-hemolysin mutant (E111N/K147N) 3atggcagatt ctgatattaa tattaaaacc ggtactacag atattggaag caatactaca 60gtaaaaacag gtgatttagt cacttatgat aaagaaaatg gcatgcacaa aaaagtattt 120tatagtttta tcgatgataa aaatcacaat aaaaaactgc tagttattag aacaaaaggt 180accattgctg gtcaatatag agtttatagc gaagaaggtg ctaacaaaag tggtttagcc 240tggccttcag cctttaaggt acagttgcaa ctacctgata atgaagtagc tcaaatatct 300gattactatc caagaaattc gattgataca aaaaactata tgagtacttt aacttatgga 360ttcaacggta atgttactgg tgatgataca ggaaaaattg gcggccttat tggtgcaaat 420gtttcgattg gtcatacact gaactatgtt caacctgatt tcaaaacaat tttagagagc 480ccaactgata aaaaagtagg ctggaaagtg atatttaaca atatggtgaa tcaaaattgg 540ggaccatacg atcgagattc ttggaacccg gtatatggca atcaactttt catgaaaact 600agaaatggtt ctatgaaagc agcagataac ttccttgatc ctaacaaagc aagttctcta 660ttatcttcag ggttttcacc agacttcgct acagttatta ctatggatag aaaagcatcc 720aaacaacaaa caaatataga tgtaatatac gaacgagttc gtgatgatta ccaattgcat 780tggacttcaa caaattggaa aggtaccaat actaaagata aatggacaga tcgttcttca 840gaaagatata aaatcgattg ggaaaaagaa gaaatgacaa attaa 8854293PRTArtificial Sequencealpha-hemolysin mutant (E111N/K147N) 4Ala Asp Ser Asp Ile Asn Ile Lys Thr Gly Thr Thr Asp Ile Gly Ser 1 5 10 15 Asn Thr Thr Val Lys Thr Gly Asp Leu Val Thr Tyr Asp Lys Glu Asn 20 25 30 Gly Met His Lys Lys Val Phe Tyr Ser Phe Ile Asp Asp Lys Asn His 35 40 45 Asn Lys Lys Leu Leu Val Ile Arg Thr Lys Gly Thr Ile Ala Gly Gln 50 55 60 Tyr Arg Val Tyr Ser Glu Glu Gly Ala Asn Lys Ser Gly Leu Ala Trp 65 70 75 80 Pro Ser Ala Phe Lys Val Gln Leu Gln Leu Pro Asp Asn Glu Val Ala 85 90 95 Gln Ile Ser Asp Tyr Tyr Pro Arg Asn Ser Ile Asp Thr Lys Asn Tyr 100 105 110 Met Ser Thr Leu Thr Tyr Gly Phe Asn Gly Asn Val Thr Gly Asp Asp 115 120 125 Thr Gly Lys Ile Gly Gly Leu Ile Gly Ala Asn Val Ser Ile Gly His 130 135 140 Thr Leu Asn Tyr Val Gln Pro Asp Phe Lys Thr Ile Leu Glu Ser Pro 145 150 155 160 Thr Asp Lys Lys Val Gly Trp Lys Val Ile Phe Asn Asn Met Val Asn 165 170 175 Gln Asn Trp Gly Pro Tyr Asp Arg Asp Ser Trp Asn Pro Val Tyr Gly 180 185 190 Asn Gln Leu Phe Met Lys Thr Arg Asn Gly Ser Met Lys Ala Ala Asp 195 200 205 Asn Phe Leu Asp Pro Asn Lys Ala Ser Ser Leu Leu Ser Ser Gly Phe 210 215 220 Ser Pro Asp Phe Ala Thr Val Ile Thr Met Asp Arg Lys Ala Ser Lys 225 230 235 240 Gln Gln Thr Asn Ile Asp Val Ile Tyr Glu Arg Val Arg Asp Asp Tyr 245 250 255 Gln Leu His Trp Thr Ser Thr Asn Trp Lys Gly Thr Asn Thr Lys Asp 260 265 270 Lys Trp Thr Asp Arg Ser Ser Glu Arg Tyr Lys Ile Asp Trp Glu Lys 275 280 285 Glu Glu Met Thr Asn 290 5184PRTMycobacterium smegmatis 5Gly Leu Asp Asn Glu Leu Ser Leu Val Asp Gly Gln Asp Arg Thr Leu 1 5 10 15 Thr Val Gln Gln Trp Asp Thr Phe Leu Asn Gly Val Phe Pro Leu Asp 20 25 30 Arg Asn Arg Leu Thr Arg Glu Trp Phe His Ser Gly Arg Ala Lys Tyr 35 40 45 Ile Val Ala Gly Pro Gly Ala Asp Glu Phe Glu Gly Thr Leu Glu Leu 50 55 60 Gly Tyr Gln Ile Gly Phe Pro Trp Ser Leu Gly Val Gly Ile Asn Phe 65 70 75 80 Ser Tyr Thr Thr Pro Asn Ile Leu Ile Asp Asp Gly Asp Ile Thr Ala 85 90 95 Pro Pro Phe Gly Leu Asn Ser Val Ile Thr Pro Asn Leu Phe Pro Gly 100 105 110 Val Ser Ile Ser Ala Asp Leu Gly Asn Gly Pro Gly Ile Gln Glu Val 115 120 125 Ala Thr Phe Ser Val Asp Val Ser Gly Pro Ala Gly Gly Val Ala Val 130 135 140 Ser Asn Ala His Gly Thr Val Thr Gly Ala Ala Gly Gly Val Leu Leu 145 150 155 160 Arg Pro Phe Ala Arg Leu Ile Ala Ser Thr Gly Asp Ser Val Thr Thr 165 170 175 Tyr Gly Glu Pro Trp Asn Met Asn 180 6184PRTMycobacterium smegmatis 6Gly Leu Asp Asn Glu Leu Ser Leu Val Asp Gly Gln Asp Arg Thr Leu 1 5 10 15 Thr Val Gln Gln Trp Asp Thr Phe Leu Asn Gly Val Phe Pro Leu Asp 20 25 30 Arg Asn Arg Leu Thr Arg Glu Trp Phe His Ser Gly Arg Ala Lys Tyr 35 40 45 Ile Val Ala Gly Pro Gly Ala Asp Glu Phe Glu Gly Thr Leu Glu Leu 50 55 60 Gly Tyr Gln Ile Gly Phe Pro Trp Ser Leu Gly Val Gly Ile Asn Phe 65 70 75 80 Ser Tyr Thr Thr Pro Asn Ile Leu Ile Asp Asp Gly Asp Ile Thr Gly 85 90 95 Pro Pro Phe Gly Leu Glu Ser Val Ile Thr Pro Asn Leu Phe Pro Gly 100 105 110 Val Ser Ile Ser Ala Asp Leu Gly Asn Gly Pro Gly Ile Gln Glu Val 115 120 125 Ala Thr Phe Ser Val Asp Val Ser Gly Pro Ala Gly Gly Val Ala Val 130 135 140 Ser Asn Ala His Gly Thr Val Thr Gly Ala Ala Gly Gly Val Leu Leu 145 150 155 160 Arg Pro Phe Ala Arg Leu Ile Ala Ser Thr Gly Asp Ser Val Thr Thr 165 170 175 Tyr Gly Glu Pro Trp Asn Met Asn 180 7183PRTMycobacterium smegmatis 7Val Asp Asn Gln Leu Ser Val Val Asp Gly Gln Gly Arg Thr Leu Thr 1 5 10 15 Val Gln Gln Ala Glu Thr Phe Leu Asn Gly Val Phe Pro Leu Asp Arg 20 25 30 Asn Arg Leu Thr Arg Glu Trp Phe His Ser Gly Arg Ala Thr Tyr His 35 40 45 Val Ala Gly Pro Gly Ala Asp Glu Phe Glu Gly Thr Leu Glu Leu Gly 50 55 60 Tyr Gln Val Gly Phe Pro Trp Ser Leu Gly Val Gly Ile Asn Phe Ser 65 70 75 80 Tyr Thr Thr Pro Asn Ile Leu Ile Asp Gly Gly Asp Ile Thr Gln Pro 85 90 95 Pro Phe Gly Leu Asp Thr Ile Ile Thr Pro Asn Leu Phe Pro Gly Val 100 105 110 Ser Ile Ser Ala Asp Leu Gly Asn Gly Pro Gly Ile Gln Glu Val Ala 115 120 125 Thr Phe Ser Val Asp Val Lys Gly Ala Lys Gly Ala Val Ala Val Ser 130 135 140 Asn Ala His Gly Thr Val Thr Gly Ala Ala Gly Gly Val Leu Leu Arg 145 150 155 160 Pro Phe Ala Arg Leu Ile Ala Ser Thr Gly Asp Ser Val Thr Thr Tyr 165 170 175 Gly Glu Pro Trp Asn Met Asn 180 81830DNABacillus subtilis phage phi29 8atgaaacaca tgccgcgtaa aatgtatagc tgcgcgtttg aaaccacgac caaagtggaa 60gattgtcgcg tttgggccta tggctacatg aacatcgaag atcattctga atacaaaatc 120ggtaacagtc tggatgaatt tatggcatgg gtgctgaaag ttcaggcgga tctgtacttc 180cacaacctga aatttgatgg cgcattcatt atcaactggc tggaacgtaa tggctttaaa 240tggagcgcgg atggtctgcc gaacacgtat aataccatta tctctcgtat gggccagtgg 300tatatgattg atatctgcct gggctacaaa ggtaaacgca aaattcatac cgtgatctat 360gatagcctga aaaaactgcc gtttccggtg aagaaaattg cgaaagattt caaactgacg 420gttctgaaag gcgatattga ttatcacaaa gaacgtccgg ttggttacaa aatcaccccg 480gaagaatacg catacatcaa aaacgatatc cagatcatcg cagaagcgct gctgattcag 540tttaaacagg gcctggatcg catgaccgcg ggcagtgata gcctgaaagg tttcaaagat 600atcatcacga ccaaaaaatt caaaaaagtg ttcccgacgc tgagcctggg tctggataaa 660gaagttcgtt atgcctaccg cggcggtttt acctggctga acgatcgttt caaagaaaaa 720gaaattggcg agggtatggt gtttgatgtt aatagtctgt atccggcaca gatgtacagc 780cgcctgctgc cgtatggcga accgatcgtg ttcgagggta aatatgtttg ggatgaagat 840tacccgctgc atattcagca catccgttgt gaatttgaac tgaaagaagg ctatattccg 900accattcaga tcaaacgtag tcgcttctat aagggtaacg aatacctgaa aagctctggc 960ggtgaaatcg cggatctgtg gctgagtaac gtggatctgg aactgatgaa agaacactac 1020gatctgtaca acgttgaata catcagcggc ctgaaattta aagccacgac cggtctgttc 1080aaagatttca tcgataaatg gacctacatc aaaacgacct ctgaaggcgc gattaaacag 1140ctggccaaac tgatgctgaa cagcctgtat ggcaaattcg cctctaatcc ggatgtgacc 1200ggtaaagttc cgtacctgaa agaaaatggc gcactgggtt ttcgcctggg cgaagaagaa 1260acgaaagatc cggtgtatac cccgatgggt gttttcatta cggcctgggc acgttacacg 1320accatcaccg cggcccaggc atgctatgat cgcattatct actgtgatac cgattctatt 1380catctgacgg gcaccgaaat cccggatgtg attaaagata tcgttgatcc gaaaaaactg 1440ggttattggg cccacgaaag tacgtttaaa cgtgcaaaat acctgcgcca gaaaacctac 1500atccaggata tctacatgaa agaagtggat ggcaaactgg ttgaaggttc tccggatgat 1560tacaccgata tcaaattcag tgtgaaatgc gccggcatga cggataaaat caaaaaagaa 1620gtgaccttcg aaaacttcaa agttggtttc agccgcaaaa tgaaaccgaa accggtgcag 1680gttccgggcg gtgtggttct ggtggatgat acgtttacca ttaaatctgg cggtagtgcg 1740tggagccatc cgcagttcga aaaaggcggt ggctctggtg gcggttctgg cggtagtgcc 1800tggagccacc cgcagtttga aaaataataa 18309608PRTBacillus subtilis phage phi29 9Met Lys His Met Pro Arg Lys Met Tyr Ser Cys Ala Phe Glu Thr Thr 1 5 10 15 Thr Lys Val Glu Asp Cys Arg Val Trp Ala Tyr Gly Tyr Met Asn Ile 20 25 30 Glu Asp His Ser Glu Tyr Lys Ile Gly Asn Ser Leu Asp Glu Phe Met 35 40 45 Ala Trp Val Leu Lys Val Gln Ala Asp Leu Tyr Phe His Asn Leu Lys 50 55 60 Phe Asp Gly Ala Phe Ile Ile Asn Trp Leu Glu Arg Asn Gly Phe Lys 65 70 75 80 Trp Ser Ala Asp Gly Leu Pro Asn Thr Tyr Asn Thr Ile Ile Ser Arg 85 90 95 Met Gly Gln Trp Tyr Met Ile Asp Ile Cys Leu Gly Tyr Lys Gly Lys 100 105 110 Arg Lys Ile His Thr Val Ile Tyr Asp Ser Leu Lys Lys Leu Pro Phe 115 120 125 Pro Val Lys Lys Ile Ala Lys Asp Phe Lys Leu Thr Val Leu Lys Gly 130 135 140 Asp Ile Asp Tyr His Lys Glu Arg Pro Val Gly Tyr Lys Ile Thr Pro 145 150 155 160 Glu Glu Tyr Ala Tyr Ile Lys Asn Asp Ile Gln Ile Ile Ala Glu Ala 165 170 175 Leu Leu Ile Gln Phe Lys Gln Gly Leu Asp Arg Met Thr Ala Gly Ser 180 185 190 Asp Ser Leu Lys Gly Phe Lys Asp Ile Ile Thr Thr Lys Lys Phe Lys 195 200 205 Lys Val Phe Pro Thr Leu Ser Leu Gly Leu Asp Lys Glu Val Arg Tyr 210 215 220 Ala Tyr Arg Gly Gly Phe Thr Trp Leu Asn Asp Arg Phe Lys Glu Lys 225 230 235 240 Glu Ile Gly Glu Gly Met Val Phe Asp Val Asn Ser Leu Tyr Pro Ala 245 250 255 Gln Met Tyr Ser Arg Leu Leu Pro Tyr Gly Glu Pro Ile Val Phe Glu 260 265 270 Gly Lys Tyr Val Trp Asp Glu Asp Tyr Pro Leu His Ile Gln His Ile 275 280 285 Arg Cys Glu Phe Glu Leu Lys Glu Gly Tyr Ile Pro Thr Ile Gln Ile 290 295 300 Lys Arg Ser Arg Phe Tyr Lys Gly Asn Glu Tyr Leu Lys Ser Ser Gly 305 310 315 320 Gly Glu Ile Ala Asp Leu Trp Leu Ser Asn Val Asp Leu Glu Leu Met 325 330 335 Lys Glu His Tyr Asp Leu Tyr Asn Val Glu Tyr Ile Ser Gly Leu Lys 340 345 350 Phe Lys Ala Thr Thr Gly Leu Phe Lys Asp Phe Ile Asp Lys Trp Thr 355 360 365 Tyr Ile Lys Thr Thr Ser Glu Gly Ala Ile Lys Gln Leu Ala Lys Leu 370 375 380 Met Leu Asn Ser Leu Tyr Gly Lys Phe Ala Ser Asn Pro Asp Val Thr 385 390 395 400 Gly Lys Val Pro Tyr Leu Lys Glu Asn Gly Ala Leu Gly Phe Arg Leu 405 410 415 Gly Glu Glu Glu Thr Lys Asp Pro Val Tyr Thr Pro Met Gly Val Phe 420 425 430 Ile Thr Ala Trp Ala Arg Tyr Thr Thr Ile Thr Ala Ala Gln Ala Cys 435 440 445 Tyr Asp Arg Ile Ile Tyr Cys Asp Thr Asp Ser Ile His Leu Thr Gly 450 455 460 Thr Glu Ile Pro Asp Val Ile Lys Asp Ile Val Asp Pro Lys Lys Leu 465 470 475 480 Gly Tyr Trp Ala His Glu Ser Thr Phe Lys Arg Ala Lys Tyr Leu Arg 485 490 495 Gln Lys Thr Tyr Ile Gln Asp Ile Tyr Met Lys Glu Val Asp Gly Lys 500 505 510 Leu Val Glu Gly Ser Pro Asp Asp Tyr Thr Asp Ile Lys Phe Ser Val 515 520 525 Lys Cys Ala Gly Met Thr Asp Lys Ile Lys Lys Glu Val Thr Phe Glu 530 535 540 Asn Phe Lys Val Gly Phe Ser Arg Lys Met Lys Pro Lys Pro Val Gln 545 550 555 560 Val Pro Gly Gly Val Val Leu Val Asp Asp Thr Phe Thr Ile Lys Ser 565 570 575 Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser 580 585 590 Gly Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys 595 600 605 10 1390DNAEscherichia coli 10atgatgaacg atggcaaaca gcagagcacc ttcctgtttc atgattatga aaccttcggt 60acccatccgg ccctggatcg tccggcgcag tttgcggcca ttcgcaccga tagcgaattc 120aatgtgattg gcgaaccgga agtgttttat tgcaaaccgg ccgatgatta tctgccgcag 180ccgggtgcgg tgctgattac cggtattacc ccgcaggaag cgcgcgcgaa aggtgaaaac 240gaagcggcgt ttgccgcgcg cattcatagc ctgtttaccg tgccgaaaac ctgcattctg 300ggctataaca atgtgcgctt cgatgatgaa gttacccgta atatctttta tcgtaacttt 360tatgatccgt atgcgtggag ctggcagcat gataacagcc gttgggatct gctggatgtg 420atgcgcgcgt gctatgcgct gcgcccggaa ggcattaatt ggccggaaaa cgatgatggc 480ctgccgagct ttcgtctgga acatctgacc

aaagccaacg gcattgaaca tagcaatgcc 540catgatgcga tggccgatgt ttatgcgacc attgcgatgg cgaaactggt taaaacccgt 600cagccgcgcc tgtttgatta tctgtttacc caccgtaaca aacacaaact gatggcgctg 660attgatgttc cgcagatgaa accgctggtg catgtgagcg gcatgtttgg cgcctggcgc 720ggcaacacca gctgggtggc cccgctggcc tggcacccgg aaaatcgtaa cgccgtgatt 780atggttgatc tggccggtga tattagcccg ctgctggaac tggatagcga taccctgcgt 840gaacgcctgt ataccgccaa aaccgatctg ggcgataatg ccgccgtgcc ggtgaaactg 900gttcacatta acaaatgccc ggtgctggcc caggcgaaca ccctgcgccc ggaagatgcg 960gatcgtctgg gtattaatcg ccagcattgt ctggataatc tgaaaatcct gcgtgaaaac 1020ccgcaggtgc gtgaaaaagt ggtggcgatc ttcgcggaag cggaaccgtt caccccgagc 1080gataacgtgg atgcgcagct gtataacggc ttctttagcg atgccgatcg cgcggcgatg 1140aaaatcgttc tggaaaccga accgcgcaat ctgccggcgc tggatattac ctttgttgat 1200aaacgtattg aaaaactgct gtttaattat cgtgcgcgca attttccggg taccctggat 1260tatgccgaac agcagcgttg gctggaacat cgtcgtcagg ttttcacccc ggaatttctg 1320cagggttatg cggatgaact gcagatgctg gttcagcagt atgccgatga taaagaaaaa 1380gtggcgctgc 139011485PRTEscherichia coli 11Met Met Asn Asp Gly Lys Gln Gln Ser Thr Phe Leu Phe His Asp Tyr 1 5 10 15 Glu Thr Phe Gly Thr His Pro Ala Leu Asp Arg Pro Ala Gln Phe Ala 20 25 30 Ala Ile Arg Thr Asp Ser Glu Phe Asn Val Ile Gly Glu Pro Glu Val 35 40 45 Phe Tyr Cys Lys Pro Ala Asp Asp Tyr Leu Pro Gln Pro Gly Ala Val 50 55 60 Leu Ile Thr Gly Ile Thr Pro Gln Glu Ala Arg Ala Lys Gly Glu Asn 65 70 75 80 Glu Ala Ala Phe Ala Ala Arg Ile His Ser Leu Phe Thr Val Pro Lys 85 90 95 Thr Cys Ile Leu Gly Tyr Asn Asn Val Arg Phe Asp Asp Glu Val Thr 100 105 110 Arg Asn Ile Phe Tyr Arg Asn Phe Tyr Asp Pro Tyr Ala Trp Ser Trp 115 120 125 Gln His Asp Asn Ser Arg Trp Asp Leu Leu Asp Val Met Arg Ala Cys 130 135 140 Tyr Ala Leu Arg Pro Glu Gly Ile Asn Trp Pro Glu Asn Asp Asp Gly 145 150 155 160 Leu Pro Ser Phe Arg Leu Glu His Leu Thr Lys Ala Asn Gly Ile Glu 165 170 175 His Ser Asn Ala His Asp Ala Met Ala Asp Val Tyr Ala Thr Ile Ala 180 185 190 Met Ala Lys Leu Val Lys Thr Arg Gln Pro Arg Leu Phe Asp Tyr Leu 195 200 205 Phe Thr His Arg Asn Lys His Lys Leu Met Ala Leu Ile Asp Val Pro 210 215 220 Gln Met Lys Pro Leu Val His Val Ser Gly Met Phe Gly Ala Trp Arg 225 230 235 240 Gly Asn Thr Ser Trp Val Ala Pro Leu Ala Trp His Pro Glu Asn Arg 245 250 255 Asn Ala Val Ile Met Val Asp Leu Ala Gly Asp Ile Ser Pro Leu Leu 260 265 270 Glu Leu Asp Ser Asp Thr Leu Arg Glu Arg Leu Tyr Thr Ala Lys Thr 275 280 285 Asp Leu Gly Asp Asn Ala Ala Val Pro Val Lys Leu Val His Ile Asn 290 295 300 Lys Cys Pro Val Leu Ala Gln Ala Asn Thr Leu Arg Pro Glu Asp Ala 305 310 315 320 Asp Arg Leu Gly Ile Asn Arg Gln His Cys Leu Asp Asn Leu Lys Ile 325 330 335 Leu Arg Glu Asn Pro Gln Val Arg Glu Lys Val Val Ala Ile Phe Ala 340 345 350 Glu Ala Glu Pro Phe Thr Pro Ser Asp Asn Val Asp Ala Gln Leu Tyr 355 360 365 Asn Gly Phe Phe Ser Asp Ala Asp Arg Ala Ala Met Lys Ile Val Leu 370 375 380 Glu Thr Glu Pro Arg Asn Leu Pro Ala Leu Asp Ile Thr Phe Val Asp 385 390 395 400 Lys Arg Ile Glu Lys Leu Leu Phe Asn Tyr Arg Ala Arg Asn Phe Pro 405 410 415 Gly Thr Leu Asp Tyr Ala Glu Gln Gln Arg Trp Leu Glu His Arg Arg 420 425 430 Gln Val Phe Thr Pro Glu Phe Leu Gln Gly Tyr Ala Asp Glu Leu Gln 435 440 445 Met Leu Val Gln Gln Tyr Ala Asp Asp Lys Glu Lys Val Ala Leu Leu 450 455 460 Lys Ala Leu Trp Gln Tyr Ala Glu Glu Ile Val Ser Gly Ser Gly His 465 470 475 480 His His His His His 485 12804DNAEscherichia coli 12atgaaatttg tctcttttaa tatcaacggc ctgcgcgcca gacctcacca gcttgaagcc 60atcgtcgaaa agcaccaacc ggatgtgatt ggcctgcagg agacaaaagt tcatgacgat 120atgtttccgc tcgaagaggt ggcgaagctc ggctacaacg tgttttatca cgggcagaaa 180ggccattatg gcgtggcgct gctgaccaaa gagacgccga ttgccgtgcg tcgcggcttt 240cccggtgacg acgaagaggc gcagcggcgg attattatgg cggaaatccc ctcactgctg 300ggtaatgtca ccgtgatcaa cggttacttc ccgcagggtg aaagccgcga ccatccgata 360aaattcccgg caaaagcgca gttttatcag aatctgcaaa actacctgga aaccgaactc 420aaacgtgata atccggtact gattatgggc gatatgaata tcagccctac agatctggat 480atcggcattg gcgaagaaaa ccgtaagcgc tggctgcgta ccggtaaatg ctctttcctg 540ccggaagagc gcgaatggat ggacaggctg atgagctggg ggttggtcga taccttccgc 600catgcgaatc cgcaaacagc agatcgtttc tcatggtttg attaccgctc aaaaggtttt 660gacgataacc gtggtctgcg catcgacctg ctgctcgcca gccaaccgct ggcagaatgt 720tgcgtagaaa ccggcatcga ctatgaaatc cgcagcatgg aaaaaccgtc cgatcacgcc 780cccgtctggg cgaccttccg ccgc 80413268PRTEscherichia coli 13Met Lys Phe Val Ser Phe Asn Ile Asn Gly Leu Arg Ala Arg Pro His 1 5 10 15 Gln Leu Glu Ala Ile Val Glu Lys His Gln Pro Asp Val Ile Gly Leu 20 25 30 Gln Glu Thr Lys Val His Asp Asp Met Phe Pro Leu Glu Glu Val Ala 35 40 45 Lys Leu Gly Tyr Asn Val Phe Tyr His Gly Gln Lys Gly His Tyr Gly 50 55 60 Val Ala Leu Leu Thr Lys Glu Thr Pro Ile Ala Val Arg Arg Gly Phe 65 70 75 80 Pro Gly Asp Asp Glu Glu Ala Gln Arg Arg Ile Ile Met Ala Glu Ile 85 90 95 Pro Ser Leu Leu Gly Asn Val Thr Val Ile Asn Gly Tyr Phe Pro Gln 100 105 110 Gly Glu Ser Arg Asp His Pro Ile Lys Phe Pro Ala Lys Ala Gln Phe 115 120 125 Tyr Gln Asn Leu Gln Asn Tyr Leu Glu Thr Glu Leu Lys Arg Asp Asn 130 135 140 Pro Val Leu Ile Met Gly Asp Met Asn Ile Ser Pro Thr Asp Leu Asp 145 150 155 160 Ile Gly Ile Gly Glu Glu Asn Arg Lys Arg Trp Leu Arg Thr Gly Lys 165 170 175 Cys Ser Phe Leu Pro Glu Glu Arg Glu Trp Met Asp Arg Leu Met Ser 180 185 190 Trp Gly Leu Val Asp Thr Phe Arg His Ala Asn Pro Gln Thr Ala Asp 195 200 205 Arg Phe Ser Trp Phe Asp Tyr Arg Ser Lys Gly Phe Asp Asp Asn Arg 210 215 220 Gly Leu Arg Ile Asp Leu Leu Leu Ala Ser Gln Pro Leu Ala Glu Cys 225 230 235 240 Cys Val Glu Thr Gly Ile Asp Tyr Glu Ile Arg Ser Met Glu Lys Pro 245 250 255 Ser Asp His Ala Pro Val Trp Ala Thr Phe Arg Arg 260 265 141275DNAThermus thermophilus 14atgtttcgtc gtaaagaaga tctggatccg ccgctggcac tgctgccgct gaaaggcctg 60cgcgaagccg ccgcactgct ggaagaagcg ctgcgtcaag gtaaacgcat tcgtgttcac 120ggcgactatg atgcggatgg cctgaccggc accgcgatcc tggttcgtgg tctggccgcc 180ctgggtgcgg atgttcatcc gtttatcccg caccgcctgg aagaaggcta tggtgtcctg 240atggaacgcg tcccggaaca tctggaagcc tcggacctgt ttctgaccgt tgactgcggc 300attaccaacc atgcggaact gcgcgaactg ctggaaaatg gcgtggaagt cattgttacc 360gatcatcata cgccgggcaa aacgccgccg ccgggtctgg tcgtgcatcc ggcgctgacg 420ccggatctga aagaaaaacc gaccggcgca ggcgtggcgt ttctgctgct gtgggcactg 480catgaacgcc tgggcctgcc gccgccgctg gaatacgcgg acctggcagc cgttggcacc 540attgccgacg ttgccccgct gtggggttgg aatcgtgcac tggtgaaaga aggtctggca 600cgcatcccgg cttcatcttg ggtgggcctg cgtctgctgg ctgaagccgt gggctatacc 660ggcaaagcgg tcgaagtcgc tttccgcatc gcgccgcgca tcaatgcggc ttcccgcctg 720ggcgaagcgg aaaaagccct gcgcctgctg ctgacggatg atgcggcaga agctcaggcg 780ctggtcggcg aactgcaccg tctgaacgcc cgtcgtcaga ccctggaaga agcgatgctg 840cgcaaactgc tgccgcaggc cgacccggaa gcgaaagcca tcgttctgct ggacccggaa 900ggccatccgg gtgttatggg tattgtggcc tctcgcatcc tggaagcgac cctgcgcccg 960gtctttctgg tggcccaggg caaaggcacc gtgcgttcgc tggctccgat ttccgccgtc 1020gaagcactgc gcagcgcgga agatctgctg ctgcgttatg gtggtcataa agaagcggcg 1080ggtttcgcaa tggatgaagc gctgtttccg gcgttcaaag cacgcgttga agcgtatgcc 1140gcacgtttcc cggatccggt tcgtgaagtg gcactgctgg atctgctgcc ggaaccgggc 1200ctgctgccgc aggtgttccg tgaactggca ctgctggaac cgtatggtga aggtaacccg 1260gaaccgctgt tcctg 127515425PRTThermus thermophilus 15Met Phe Arg Arg Lys Glu Asp Leu Asp Pro Pro Leu Ala Leu Leu Pro 1 5 10 15 Leu Lys Gly Leu Arg Glu Ala Ala Ala Leu Leu Glu Glu Ala Leu Arg 20 25 30 Gln Gly Lys Arg Ile Arg Val His Gly Asp Tyr Asp Ala Asp Gly Leu 35 40 45 Thr Gly Thr Ala Ile Leu Val Arg Gly Leu Ala Ala Leu Gly Ala Asp 50 55 60 Val His Pro Phe Ile Pro His Arg Leu Glu Glu Gly Tyr Gly Val Leu 65 70 75 80 Met Glu Arg Val Pro Glu His Leu Glu Ala Ser Asp Leu Phe Leu Thr 85 90 95 Val Asp Cys Gly Ile Thr Asn His Ala Glu Leu Arg Glu Leu Leu Glu 100 105 110 Asn Gly Val Glu Val Ile Val Thr Asp His His Thr Pro Gly Lys Thr 115 120 125 Pro Pro Pro Gly Leu Val Val His Pro Ala Leu Thr Pro Asp Leu Lys 130 135 140 Glu Lys Pro Thr Gly Ala Gly Val Ala Phe Leu Leu Leu Trp Ala Leu 145 150 155 160 His Glu Arg Leu Gly Leu Pro Pro Pro Leu Glu Tyr Ala Asp Leu Ala 165 170 175 Ala Val Gly Thr Ile Ala Asp Val Ala Pro Leu Trp Gly Trp Asn Arg 180 185 190 Ala Leu Val Lys Glu Gly Leu Ala Arg Ile Pro Ala Ser Ser Trp Val 195 200 205 Gly Leu Arg Leu Leu Ala Glu Ala Val Gly Tyr Thr Gly Lys Ala Val 210 215 220 Glu Val Ala Phe Arg Ile Ala Pro Arg Ile Asn Ala Ala Ser Arg Leu 225 230 235 240 Gly Glu Ala Glu Lys Ala Leu Arg Leu Leu Leu Thr Asp Asp Ala Ala 245 250 255 Glu Ala Gln Ala Leu Val Gly Glu Leu His Arg Leu Asn Ala Arg Arg 260 265 270 Gln Thr Leu Glu Glu Ala Met Leu Arg Lys Leu Leu Pro Gln Ala Asp 275 280 285 Pro Glu Ala Lys Ala Ile Val Leu Leu Asp Pro Glu Gly His Pro Gly 290 295 300 Val Met Gly Ile Val Ala Ser Arg Ile Leu Glu Ala Thr Leu Arg Pro 305 310 315 320 Val Phe Leu Val Ala Gln Gly Lys Gly Thr Val Arg Ser Leu Ala Pro 325 330 335 Ile Ser Ala Val Glu Ala Leu Arg Ser Ala Glu Asp Leu Leu Leu Arg 340 345 350 Tyr Gly Gly His Lys Glu Ala Ala Gly Phe Ala Met Asp Glu Ala Leu 355 360 365 Phe Pro Ala Phe Lys Ala Arg Val Glu Ala Tyr Ala Ala Arg Phe Pro 370 375 380 Asp Pro Val Arg Glu Val Ala Leu Leu Asp Leu Leu Pro Glu Pro Gly 385 390 395 400 Leu Leu Pro Gln Val Phe Arg Glu Leu Ala Leu Leu Glu Pro Tyr Gly 405 410 415 Glu Gly Asn Pro Glu Pro Leu Phe Leu 420 425 16738DNABacteriophage lambda 16tccggaagcg gctctggtag tggttctggc atgacaccgg acattatcct gcagcgtacc 60gggatcgatg tgagagctgt cgaacagggg gatgatgcgt ggcacaaatt acggctcggc 120gtcatcaccg cttcagaagt tcacaacgtg atagcaaaac cccgctccgg aaagaagtgg 180cctgacatga aaatgtccta cttccacacc ctgcttgctg aggtttgcac cggtgtggct 240ccggaagtta acgctaaagc actggcctgg ggaaaacagt acgagaacga cgccagaacc 300ctgtttgaat tcacttccgg cgtgaatgtt actgaatccc cgatcatcta tcgcgacgaa 360agtatgcgta ccgcctgctc tcccgatggt ttatgcagtg acggcaacgg ccttgaactg 420aaatgcccgt ttacctcccg ggatttcatg aagttccggc tcggtggttt cgaggccata 480aagtcagctt acatggccca ggtgcagtac agcatgtggg tgacgcgaaa aaatgcctgg 540tactttgcca actatgaccc gcgtatgaag cgtgaaggcc tgcattatgt cgtgattgag 600cgggatgaaa agtacatggc gagttttgac gagatcgtgc cggagttcat cgaaaaaatg 660gacgaggcac tggctgaaat tggttttgta tttggggagc aatggcgatc tggctctggt 720tccggcagcg gttccgga 73817226PRTBacteriophage lambda 17Met Thr Pro Asp Ile Ile Leu Gln Arg Thr Gly Ile Asp Val Arg Ala 1 5 10 15 Val Glu Gln Gly Asp Asp Ala Trp His Lys Leu Arg Leu Gly Val Ile 20 25 30 Thr Ala Ser Glu Val His Asn Val Ile Ala Lys Pro Arg Ser Gly Lys 35 40 45 Lys Trp Pro Asp Met Lys Met Ser Tyr Phe His Thr Leu Leu Ala Glu 50 55 60 Val Cys Thr Gly Val Ala Pro Glu Val Asn Ala Lys Ala Leu Ala Trp 65 70 75 80 Gly Lys Gln Tyr Glu Asn Asp Ala Arg Thr Leu Phe Glu Phe Thr Ser 85 90 95 Gly Val Asn Val Thr Glu Ser Pro Ile Ile Tyr Arg Asp Glu Ser Met 100 105 110 Arg Thr Ala Cys Ser Pro Asp Gly Leu Cys Ser Asp Gly Asn Gly Leu 115 120 125 Glu Leu Lys Cys Pro Phe Thr Ser Arg Asp Phe Met Lys Phe Arg Leu 130 135 140 Gly Gly Phe Glu Ala Ile Lys Ser Ala Tyr Met Ala Gln Val Gln Tyr 145 150 155 160 Ser Met Trp Val Thr Arg Lys Asn Ala Trp Tyr Phe Ala Asn Tyr Asp 165 170 175 Pro Arg Met Lys Arg Glu Gly Leu His Tyr Val Val Ile Glu Arg Asp 180 185 190 Glu Lys Tyr Met Ala Ser Phe Asp Glu Ile Val Pro Glu Phe Ile Glu 195 200 205 Lys Met Asp Glu Ala Leu Ala Glu Ile Gly Phe Val Phe Gly Glu Gln 210 215 220 Trp Arg 225 18760PRTMethanococcoides burtonii 18Met Met Ile Arg Glu Leu Asp Ile Pro Arg Asp Ile Ile Gly Phe Tyr 1 5 10 15 Glu Asp Ser Gly Ile Lys Glu Leu Tyr Pro Pro Gln Ala Glu Ala Ile 20 25 30 Glu Met Gly Leu Leu Glu Lys Lys Asn Leu Leu Ala Ala Ile Pro Thr 35 40 45 Ala Ser Gly Lys Thr Leu Leu Ala Glu Leu Ala Met Ile Lys Ala Ile 50 55 60 Arg Glu Gly Gly Lys Ala Leu Tyr Ile Val Pro Leu Arg Ala Leu Ala 65 70 75 80 Ser Glu Lys Phe Glu Arg Phe Lys Glu Leu Ala Pro Phe Gly Ile Lys 85 90 95 Val Gly Ile Ser Thr Gly Asp Leu Asp Ser Arg Ala Asp Trp Leu Gly 100 105 110 Val Asn Asp Ile Ile Val Ala Thr Ser Glu Lys Thr Asp Ser Leu Leu 115 120 125 Arg Asn Gly Thr Ser Trp Met Asp Glu Ile Thr Thr Val Val Val Asp 130 135 140 Glu Ile His Leu Leu Asp Ser Lys Asn Arg Gly Pro Thr Leu Glu Val 145 150 155 160 Thr Ile Thr Lys Leu Met Arg Leu Asn Pro Asp Val Gln Val Val Ala 165 170 175 Leu Ser Ala Thr Val Gly Asn Ala Arg Glu Met Ala Asp Trp Leu Gly 180 185 190 Ala Ala Leu Val Leu Ser Glu Trp Arg Pro Thr Asp Leu His Glu Gly 195 200 205 Val Leu Phe Gly Asp Ala Ile Asn Phe Pro Gly Ser Gln Lys Lys Ile 210 215 220 Asp Arg Leu Glu Lys Asp Asp Ala Val Asn Leu Val Leu Asp Thr Ile 225 230 235 240 Lys Ala Glu Gly Gln Cys Leu Val Phe Glu Ser Ser Arg Arg Asn Cys 245 250 255 Ala Gly Phe Ala Lys Thr Ala Ser Ser Lys Val Ala Lys Ile Leu Asp 260 265

270 Asn Asp Ile Met Ile Lys Leu Ala Gly Ile Ala Glu Glu Val Glu Ser 275 280 285 Thr Gly Glu Thr Asp Thr Ala Ile Val Leu Ala Asn Cys Ile Arg Lys 290 295 300 Gly Val Ala Phe His His Ala Gly Leu Asn Ser Asn His Arg Lys Leu 305 310 315 320 Val Glu Asn Gly Phe Arg Gln Asn Leu Ile Lys Val Ile Ser Ser Thr 325 330 335 Pro Thr Leu Ala Ala Gly Leu Asn Leu Pro Ala Arg Arg Val Ile Ile 340 345 350 Arg Ser Tyr Arg Arg Phe Asp Ser Asn Phe Gly Met Gln Pro Ile Pro 355 360 365 Val Leu Glu Tyr Lys Gln Met Ala Gly Arg Ala Gly Arg Pro His Leu 370 375 380 Asp Pro Tyr Gly Glu Ser Val Leu Leu Ala Lys Thr Tyr Asp Glu Phe 385 390 395 400 Ala Gln Leu Met Glu Asn Tyr Val Glu Ala Asp Ala Glu Asp Ile Trp 405 410 415 Ser Lys Leu Gly Thr Glu Asn Ala Leu Arg Thr His Val Leu Ser Thr 420 425 430 Ile Val Asn Gly Phe Ala Ser Thr Arg Gln Glu Leu Phe Asp Phe Phe 435 440 445 Gly Ala Thr Phe Phe Ala Tyr Gln Gln Asp Lys Trp Met Leu Glu Glu 450 455 460 Val Ile Asn Asp Cys Leu Glu Phe Leu Ile Asp Lys Ala Met Val Ser 465 470 475 480 Glu Thr Glu Asp Ile Glu Asp Ala Ser Lys Leu Phe Leu Arg Gly Thr 485 490 495 Arg Leu Gly Ser Leu Val Ser Met Leu Tyr Ile Asp Pro Leu Ser Gly 500 505 510 Ser Lys Ile Val Asp Gly Phe Lys Asp Ile Gly Lys Ser Thr Gly Gly 515 520 525 Asn Met Gly Ser Leu Glu Asp Asp Lys Gly Asp Asp Ile Thr Val Thr 530 535 540 Asp Met Thr Leu Leu His Leu Val Cys Ser Thr Pro Asp Met Arg Gln 545 550 555 560 Leu Tyr Leu Arg Asn Thr Asp Tyr Thr Ile Val Asn Glu Tyr Ile Val 565 570 575 Ala His Ser Asp Glu Phe His Glu Ile Pro Asp Lys Leu Lys Glu Thr 580 585 590 Asp Tyr Glu Trp Phe Met Gly Glu Val Lys Thr Ala Met Leu Leu Glu 595 600 605 Glu Trp Val Thr Glu Val Ser Ala Glu Asp Ile Thr Arg His Phe Asn 610 615 620 Val Gly Glu Gly Asp Ile His Ala Leu Ala Asp Thr Ser Glu Trp Leu 625 630 635 640 Met His Ala Ala Ala Lys Leu Ala Glu Leu Leu Gly Val Glu Tyr Ser 645 650 655 Ser His Ala Tyr Ser Leu Glu Lys Arg Ile Arg Tyr Gly Ser Gly Leu 660 665 670 Asp Leu Met Glu Leu Val Gly Ile Arg Gly Val Gly Arg Val Arg Ala 675 680 685 Arg Lys Leu Tyr Asn Ala Gly Phe Val Ser Val Ala Lys Leu Lys Gly 690 695 700 Ala Asp Ile Ser Val Leu Ser Lys Leu Val Gly Pro Lys Val Ala Tyr 705 710 715 720 Asn Ile Leu Ser Gly Ile Gly Val Arg Val Asn Asp Lys His Phe Asn 725 730 735 Ser Ala Pro Ile Ser Ser Asn Thr Leu Asp Thr Leu Leu Asp Lys Asn 740 745 750 Gln Lys Thr Phe Asn Asp Phe Gln 755 760 19707PRTCenarchaeum symbiosum 19Met Arg Ile Ser Glu Leu Asp Ile Pro Arg Pro Ala Ile Glu Phe Leu 1 5 10 15 Glu Gly Glu Gly Tyr Lys Lys Leu Tyr Pro Pro Gln Ala Ala Ala Ala 20 25 30 Lys Ala Gly Leu Thr Asp Gly Lys Ser Val Leu Val Ser Ala Pro Thr 35 40 45 Ala Ser Gly Lys Thr Leu Ile Ala Ala Ile Ala Met Ile Ser His Leu 50 55 60 Ser Arg Asn Arg Gly Lys Ala Val Tyr Leu Ser Pro Leu Arg Ala Leu 65 70 75 80 Ala Ala Glu Lys Phe Ala Glu Phe Gly Lys Ile Gly Gly Ile Pro Leu 85 90 95 Gly Arg Pro Val Arg Val Gly Val Ser Thr Gly Asp Phe Glu Lys Ala 100 105 110 Gly Arg Ser Leu Gly Asn Asn Asp Ile Leu Val Leu Thr Asn Glu Arg 115 120 125 Met Asp Ser Leu Ile Arg Arg Arg Pro Asp Trp Met Asp Glu Val Gly 130 135 140 Leu Val Ile Ala Asp Glu Ile His Leu Ile Gly Asp Arg Ser Arg Gly 145 150 155 160 Pro Thr Leu Glu Met Val Leu Thr Lys Leu Arg Gly Leu Arg Ser Ser 165 170 175 Pro Gln Val Val Ala Leu Ser Ala Thr Ile Ser Asn Ala Asp Glu Ile 180 185 190 Ala Gly Trp Leu Asp Cys Thr Leu Val His Ser Thr Trp Arg Pro Val 195 200 205 Pro Leu Ser Glu Gly Val Tyr Gln Asp Gly Glu Val Ala Met Gly Asp 210 215 220 Gly Ser Arg His Glu Val Ala Ala Thr Gly Gly Gly Pro Ala Val Asp 225 230 235 240 Leu Ala Ala Glu Ser Val Ala Glu Gly Gly Gln Ser Leu Ile Phe Ala 245 250 255 Asp Thr Arg Ala Arg Ser Ala Ser Leu Ala Ala Lys Ala Ser Ala Val 260 265 270 Ile Pro Glu Ala Lys Gly Ala Asp Ala Ala Lys Leu Ala Ala Ala Ala 275 280 285 Lys Lys Ile Ile Ser Ser Gly Gly Glu Thr Lys Leu Ala Lys Thr Leu 290 295 300 Ala Glu Leu Val Glu Lys Gly Ala Ala Phe His His Ala Gly Leu Asn 305 310 315 320 Gln Asp Cys Arg Ser Val Val Glu Glu Glu Phe Arg Ser Gly Arg Ile 325 330 335 Arg Leu Leu Ala Ser Thr Pro Thr Leu Ala Ala Gly Val Asn Leu Pro 340 345 350 Ala Arg Arg Val Val Ile Ser Ser Val Met Arg Tyr Asn Ser Ser Ser 355 360 365 Gly Met Ser Glu Pro Ile Ser Ile Leu Glu Tyr Lys Gln Leu Cys Gly 370 375 380 Arg Ala Gly Arg Pro Gln Tyr Asp Lys Ser Gly Glu Ala Ile Val Val 385 390 395 400 Gly Gly Val Asn Ala Asp Glu Ile Phe Asp Arg Tyr Ile Gly Gly Glu 405 410 415 Pro Glu Pro Ile Arg Ser Ala Met Val Asp Asp Arg Ala Leu Arg Ile 420 425 430 His Val Leu Ser Leu Val Thr Thr Ser Pro Gly Ile Lys Glu Asp Asp 435 440 445 Val Thr Glu Phe Phe Leu Gly Thr Leu Gly Gly Gln Gln Ser Gly Glu 450 455 460 Ser Thr Val Lys Phe Ser Val Ala Val Ala Leu Arg Phe Leu Gln Glu 465 470 475 480 Glu Gly Met Leu Gly Arg Arg Gly Gly Arg Leu Ala Ala Thr Lys Met 485 490 495 Gly Arg Leu Val Ser Arg Leu Tyr Met Asp Pro Met Thr Ala Val Thr 500 505 510 Leu Arg Asp Ala Val Gly Glu Ala Ser Pro Gly Arg Met His Thr Leu 515 520 525 Gly Phe Leu His Leu Val Ser Glu Cys Ser Glu Phe Met Pro Arg Phe 530 535 540 Ala Leu Arg Gln Lys Asp His Glu Val Ala Glu Met Met Leu Glu Ala 545 550 555 560 Gly Arg Gly Glu Leu Leu Arg Pro Val Tyr Ser Tyr Glu Cys Gly Arg 565 570 575 Gly Leu Leu Ala Leu His Arg Trp Ile Gly Glu Ser Pro Glu Ala Lys 580 585 590 Leu Ala Glu Asp Leu Lys Phe Glu Ser Gly Asp Val His Arg Met Val 595 600 605 Glu Ser Ser Gly Trp Leu Leu Arg Cys Ile Trp Glu Ile Ser Lys His 610 615 620 Gln Glu Arg Pro Asp Leu Leu Gly Glu Leu Asp Val Leu Arg Ser Arg 625 630 635 640 Val Ala Tyr Gly Ile Lys Ala Glu Leu Val Pro Leu Val Ser Ile Lys 645 650 655 Gly Ile Gly Arg Val Arg Ser Arg Arg Leu Phe Arg Gly Gly Ile Lys 660 665 670 Gly Pro Gly Asp Leu Ala Ala Val Pro Val Glu Arg Leu Ser Arg Val 675 680 685 Glu Gly Ile Gly Ala Thr Leu Ala Asn Asn Ile Lys Ser Gln Leu Arg 690 695 700 Lys Gly Gly 705 20720PRTThermococcus gammatolerans 20Met Lys Val Asp Glu Leu Pro Val Asp Glu Arg Leu Lys Ala Val Leu 1 5 10 15 Lys Glu Arg Gly Ile Glu Glu Leu Tyr Pro Pro Gln Ala Glu Ala Leu 20 25 30 Lys Ser Gly Ala Leu Glu Gly Arg Asn Leu Val Leu Ala Ile Pro Thr 35 40 45 Ala Ser Gly Lys Thr Leu Val Ser Glu Ile Val Met Val Asn Lys Leu 50 55 60 Ile Gln Glu Gly Gly Lys Ala Val Tyr Leu Val Pro Leu Lys Ala Leu 65 70 75 80 Ala Glu Glu Lys Tyr Arg Glu Phe Lys Glu Trp Glu Lys Leu Gly Leu 85 90 95 Lys Val Ala Ala Thr Thr Gly Asp Tyr Asp Ser Thr Asp Asp Trp Leu 100 105 110 Gly Arg Tyr Asp Ile Ile Val Ala Thr Ala Glu Lys Phe Asp Ser Leu 115 120 125 Leu Arg His Gly Ala Arg Trp Ile Asn Asp Val Lys Leu Val Val Ala 130 135 140 Asp Glu Val His Leu Ile Gly Ser Tyr Asp Arg Gly Ala Thr Leu Glu 145 150 155 160 Met Ile Leu Thr His Met Leu Gly Arg Ala Gln Ile Leu Ala Leu Ser 165 170 175 Ala Thr Val Gly Asn Ala Glu Glu Leu Ala Glu Trp Leu Asp Ala Ser 180 185 190 Leu Val Val Ser Asp Trp Arg Pro Val Gln Leu Arg Arg Gly Val Phe 195 200 205 His Leu Gly Thr Leu Ile Trp Glu Asp Gly Lys Val Glu Ser Tyr Pro 210 215 220 Glu Asn Trp Tyr Ser Leu Val Val Asp Ala Val Lys Arg Gly Lys Gly 225 230 235 240 Ala Leu Val Phe Val Asn Thr Arg Arg Ser Ala Glu Lys Glu Ala Leu 245 250 255 Ala Leu Ser Lys Leu Val Ser Ser His Leu Thr Lys Pro Glu Lys Arg 260 265 270 Ala Leu Glu Ser Leu Ala Ser Gln Leu Glu Asp Asn Pro Thr Ser Glu 275 280 285 Lys Leu Lys Arg Ala Leu Arg Gly Gly Val Ala Phe His His Ala Gly 290 295 300 Leu Ser Arg Val Glu Arg Thr Leu Ile Glu Asp Ala Phe Arg Glu Gly 305 310 315 320 Leu Ile Lys Val Ile Thr Ala Thr Pro Thr Leu Ser Ala Gly Val Asn 325 330 335 Leu Pro Ser Phe Arg Val Ile Ile Arg Asp Thr Lys Arg Tyr Ala Gly 340 345 350 Phe Gly Trp Thr Asp Ile Pro Val Leu Glu Ile Gln Gln Met Met Gly 355 360 365 Arg Ala Gly Arg Pro Arg Tyr Asp Lys Tyr Gly Glu Ala Ile Ile Val 370 375 380 Ala Arg Thr Asp Glu Pro Gly Lys Leu Met Glu Arg Tyr Ile Arg Gly 385 390 395 400 Lys Pro Glu Lys Leu Phe Ser Met Leu Ala Asn Glu Gln Ala Phe Arg 405 410 415 Ser Gln Val Leu Ala Leu Ile Thr Asn Phe Gly Ile Arg Ser Phe Pro 420 425 430 Glu Leu Val Arg Phe Leu Glu Arg Thr Phe Tyr Ala His Gln Arg Lys 435 440 445 Asp Leu Ser Ser Leu Glu Tyr Lys Ala Lys Glu Val Val Tyr Phe Leu 450 455 460 Ile Glu Asn Glu Phe Ile Asp Leu Asp Leu Glu Asp Arg Phe Ile Pro 465 470 475 480 Leu Pro Phe Gly Lys Arg Thr Ser Gln Leu Tyr Ile Asp Pro Leu Thr 485 490 495 Ala Lys Lys Phe Lys Asp Ala Phe Pro Ala Ile Glu Arg Asn Pro Asn 500 505 510 Pro Phe Gly Ile Phe Gln Leu Ile Ala Ser Thr Pro Asp Met Ala Thr 515 520 525 Leu Thr Ala Arg Arg Arg Glu Met Glu Asp Tyr Leu Asp Leu Ala Tyr 530 535 540 Glu Leu Glu Asp Lys Leu Tyr Ala Ser Ile Pro Tyr Tyr Glu Asp Ser 545 550 555 560 Arg Phe Gln Gly Phe Leu Gly Gln Val Lys Thr Ala Lys Val Leu Leu 565 570 575 Asp Trp Ile Asn Glu Val Pro Glu Ala Arg Ile Tyr Glu Thr Tyr Ser 580 585 590 Ile Asp Pro Gly Asp Leu Tyr Arg Leu Leu Glu Leu Ala Asp Trp Leu 595 600 605 Met Tyr Ser Leu Ile Glu Leu Tyr Lys Leu Phe Glu Pro Lys Glu Glu 610 615 620 Ile Leu Asn Tyr Leu Arg Asp Leu His Leu Arg Leu Arg His Gly Val 625 630 635 640 Arg Glu Glu Leu Leu Glu Leu Val Arg Leu Pro Asn Ile Gly Arg Lys 645 650 655 Arg Ala Arg Ala Leu Tyr Asn Ala Gly Phe Arg Ser Val Glu Ala Ile 660 665 670 Ala Asn Ala Lys Pro Ala Glu Leu Leu Ala Val Glu Gly Ile Gly Ala 675 680 685 Lys Ile Leu Asp Gly Ile Tyr Arg His Leu Gly Ile Glu Lys Arg Val 690 695 700 Thr Glu Glu Lys Pro Lys Arg Lys Gly Thr Leu Glu Asp Phe Leu Arg 705 710 715 720 21799PRTMethanospirillum hungatei 21Met Glu Ile Ala Ser Leu Pro Leu Pro Asp Ser Phe Ile Arg Ala Cys 1 5 10 15 His Ala Lys Gly Ile Arg Ser Leu Tyr Pro Pro Gln Ala Glu Cys Ile 20 25 30 Glu Lys Gly Leu Leu Glu Gly Lys Asn Leu Leu Ile Ser Ile Pro Thr 35 40 45 Ala Ser Gly Lys Thr Leu Leu Ala Glu Met Ala Met Trp Ser Arg Ile 50 55 60 Ala Ala Gly Gly Lys Cys Leu Tyr Ile Val Pro Leu Arg Ala Leu Ala 65 70 75 80 Ser Glu Lys Tyr Asp Glu Phe Ser Lys Lys Gly Val Ile Arg Val Gly 85 90 95 Ile Ala Thr Gly Asp Leu Asp Arg Thr Asp Ala Tyr Leu Gly Glu Asn 100 105 110 Asp Ile Ile Val Ala Thr Ser Glu Lys Thr Asp Ser Leu Leu Arg Asn 115 120 125 Arg Thr Pro Trp Leu Ser Gln Ile Thr Cys Ile Val Leu Asp Glu Val 130 135 140 His Leu Ile Gly Ser Glu Asn Arg Gly Ala Thr Leu Glu Met Val Ile 145 150 155 160 Thr Lys Leu Arg Tyr Thr Asn Pro Val Met Gln Ile Ile Gly Leu Ser 165 170 175 Ala Thr Ile Gly Asn Pro Ala Gln Leu Ala Glu Trp Leu Asp Ala Thr 180 185 190 Leu Ile Thr Ser Thr Trp Arg Pro Val Asp Leu Arg Gln Gly Val Tyr 195 200 205 Tyr Asn Gly Lys Ile Arg Phe Ser Asp Ser Glu Arg Pro Ile Gln Gly 210 215 220 Lys Thr Lys His Asp Asp Leu Asn Leu Cys Leu Asp Thr Ile Glu Glu 225 230 235 240 Gly Gly Gln Cys Leu Val Phe Val Ser Ser Arg Arg Asn Ala Glu Gly 245 250 255 Phe Ala Lys Lys Ala Ala Gly Ala Leu Lys Ala Gly Ser Pro Asp Ser 260 265 270 Lys Ala Leu Ala Gln Glu Leu Arg Arg Leu Arg Asp Arg Asp Glu Gly 275 280 285 Asn Val Leu Ala Asp Cys Val Glu Arg Gly Ala Ala Phe His His Ala 290 295 300 Gly Leu Ile Arg Gln Glu Arg Thr Ile Ile Glu Glu Gly Phe Arg Asn 305 310 315 320 Gly Tyr Ile Glu Val Ile Ala Ala Thr Pro Thr Leu Ala Ala Gly Leu 325 330 335 Asn Leu Pro Ala Arg Arg Val Ile Ile Arg Asp Tyr Asn Arg Phe Ala 340 345 350 Ser Gly Leu Gly Met Val Pro Ile Pro Val Gly Glu Tyr His Gln Met 355 360 365 Ala Gly Arg Ala Gly Arg Pro His Leu Asp Pro Tyr Gly Glu Ala Val 370

375 380 Leu Leu Ala Lys Asp Ala Pro Ser Val Glu Arg Leu Phe Glu Thr Phe 385 390 395 400 Ile Asp Ala Glu Ala Glu Arg Val Asp Ser Gln Cys Val Asp Asp Ala 405 410 415 Ser Leu Cys Ala His Ile Leu Ser Leu Ile Ala Thr Gly Phe Ala His 420 425 430 Asp Gln Glu Ala Leu Ser Ser Phe Met Glu Arg Thr Phe Tyr Phe Phe 435 440 445 Gln His Pro Lys Thr Arg Ser Leu Pro Arg Leu Val Ala Asp Ala Ile 450 455 460 Arg Phe Leu Thr Thr Ala Gly Met Val Glu Glu Arg Glu Asn Thr Leu 465 470 475 480 Ser Ala Thr Arg Leu Gly Ser Leu Val Ser Arg Leu Tyr Leu Asn Pro 485 490 495 Cys Thr Ala Arg Leu Ile Leu Asp Ser Leu Lys Ser Cys Lys Thr Pro 500 505 510 Thr Leu Ile Gly Leu Leu His Val Ile Cys Val Ser Pro Asp Met Gln 515 520 525 Arg Leu Tyr Leu Lys Ala Ala Asp Thr Gln Leu Leu Arg Thr Phe Leu 530 535 540 Phe Lys His Lys Asp Asp Leu Ile Leu Pro Leu Pro Phe Glu Gln Glu 545 550 555 560 Glu Glu Glu Leu Trp Leu Ser Gly Leu Lys Thr Ala Leu Val Leu Thr 565 570 575 Asp Trp Ala Asp Glu Phe Ser Glu Gly Met Ile Glu Glu Arg Tyr Gly 580 585 590 Ile Gly Ala Gly Asp Leu Tyr Asn Ile Val Asp Ser Gly Lys Trp Leu 595 600 605 Leu His Gly Thr Glu Arg Leu Val Ser Val Glu Met Pro Glu Met Ser 610 615 620 Gln Val Val Lys Thr Leu Ser Val Arg Val His His Gly Val Lys Ser 625 630 635 640 Glu Leu Leu Pro Leu Val Ala Leu Arg Asn Ile Gly Arg Val Arg Ala 645 650 655 Arg Thr Leu Tyr Asn Ala Gly Tyr Pro Asp Pro Glu Ala Val Ala Arg 660 665 670 Ala Gly Leu Ser Thr Ile Ala Arg Ile Ile Gly Glu Gly Ile Ala Arg 675 680 685 Gln Val Ile Asp Glu Ile Thr Gly Val Lys Arg Ser Gly Ile His Ser 690 695 700 Ser Asp Asp Asp Tyr Gln Gln Lys Thr Pro Glu Leu Leu Thr Asp Ile 705 710 715 720 Pro Gly Ile Gly Lys Lys Met Ala Glu Lys Leu Gln Asn Ala Gly Ile 725 730 735 Ile Thr Val Ser Asp Leu Leu Thr Ala Asp Glu Val Leu Leu Ser Asp 740 745 750 Val Leu Gly Ala Ala Arg Ala Arg Lys Val Leu Ala Phe Leu Ser Asn 755 760 765 Ser Glu Lys Glu Asn Ser Ser Ser Asp Lys Thr Glu Glu Ile Pro Asp 770 775 780 Thr Gln Lys Ile Arg Gly Gln Ser Ser Trp Glu Asp Phe Gly Cys 785 790 795 221756PRTEscherichia coli 22Met Met Ser Ile Ala Gln Val Arg Ser Ala Gly Ser Ala Gly Asn Tyr 1 5 10 15 Tyr Thr Asp Lys Asp Asn Tyr Tyr Val Leu Gly Ser Met Gly Glu Arg 20 25 30 Trp Ala Gly Lys Gly Ala Glu Gln Leu Gly Leu Gln Gly Ser Val Asp 35 40 45 Lys Asp Val Phe Thr Arg Leu Leu Glu Gly Arg Leu Pro Asp Gly Ala 50 55 60 Asp Leu Ser Arg Met Gln Asp Gly Ser Asn Lys His Arg Pro Gly Tyr 65 70 75 80 Asp Leu Thr Phe Ser Ala Pro Lys Ser Val Ser Met Met Ala Met Leu 85 90 95 Gly Gly Asp Lys Arg Leu Ile Asp Ala His Asn Gln Ala Val Asp Phe 100 105 110 Ala Val Arg Gln Val Glu Ala Leu Ala Ser Thr Arg Val Met Thr Asp 115 120 125 Gly Gln Ser Glu Thr Val Leu Thr Gly Asn Leu Val Met Ala Leu Phe 130 135 140 Asn His Asp Thr Ser Arg Asp Gln Glu Pro Gln Leu His Thr His Ala 145 150 155 160 Val Val Ala Asn Val Thr Gln His Asn Gly Glu Trp Lys Thr Leu Ser 165 170 175 Ser Asp Lys Val Gly Lys Thr Gly Phe Ile Glu Asn Val Tyr Ala Asn 180 185 190 Gln Ile Ala Phe Gly Arg Leu Tyr Arg Glu Lys Leu Lys Glu Gln Val 195 200 205 Glu Ala Leu Gly Tyr Glu Thr Glu Val Val Gly Lys His Gly Met Trp 210 215 220 Glu Met Pro Gly Val Pro Val Glu Ala Phe Ser Gly Arg Ser Gln Ala 225 230 235 240 Ile Arg Glu Ala Val Gly Glu Asp Ala Ser Leu Lys Ser Arg Asp Val 245 250 255 Ala Ala Leu Asp Thr Arg Lys Ser Lys Gln His Val Asp Pro Glu Ile 260 265 270 Arg Met Ala Glu Trp Met Gln Thr Leu Lys Glu Thr Gly Phe Asp Ile 275 280 285 Arg Ala Tyr Arg Asp Ala Ala Asp Gln Arg Thr Glu Ile Arg Thr Gln 290 295 300 Ala Pro Gly Pro Ala Ser Gln Asp Gly Pro Asp Val Gln Gln Ala Val 305 310 315 320 Thr Gln Ala Ile Ala Gly Leu Ser Glu Arg Lys Val Gln Phe Thr Tyr 325 330 335 Thr Asp Val Leu Ala Arg Thr Val Gly Ile Leu Pro Pro Glu Asn Gly 340 345 350 Val Ile Glu Arg Ala Arg Ala Gly Ile Asp Glu Ala Ile Ser Arg Glu 355 360 365 Gln Leu Ile Pro Leu Asp Arg Glu Lys Gly Leu Phe Thr Ser Gly Ile 370 375 380 His Val Leu Asp Glu Leu Ser Val Arg Ala Leu Ser Arg Asp Ile Met 385 390 395 400 Lys Gln Asn Arg Val Thr Val His Pro Glu Lys Ser Val Pro Arg Thr 405 410 415 Ala Gly Tyr Ser Asp Ala Val Ser Val Leu Ala Gln Asp Arg Pro Ser 420 425 430 Leu Ala Ile Val Ser Gly Gln Gly Gly Ala Ala Gly Gln Arg Glu Arg 435 440 445 Val Ala Glu Leu Val Met Met Ala Arg Glu Gln Gly Arg Glu Val Gln 450 455 460 Ile Ile Ala Ala Asp Arg Arg Ser Gln Met Asn Leu Lys Gln Asp Glu 465 470 475 480 Arg Leu Ser Gly Glu Leu Ile Thr Gly Arg Arg Gln Leu Leu Glu Gly 485 490 495 Met Ala Phe Thr Pro Gly Ser Thr Val Ile Val Asp Gln Gly Glu Lys 500 505 510 Leu Ser Leu Lys Glu Thr Leu Thr Leu Leu Asp Gly Ala Ala Arg His 515 520 525 Asn Val Gln Val Leu Ile Thr Asp Ser Gly Gln Arg Thr Gly Thr Gly 530 535 540 Ser Ala Leu Met Ala Met Lys Asp Ala Gly Val Asn Thr Tyr Arg Trp 545 550 555 560 Gln Gly Gly Glu Gln Arg Pro Ala Thr Ile Ile Ser Glu Pro Asp Arg 565 570 575 Asn Val Arg Tyr Ala Arg Leu Ala Gly Asp Phe Ala Ala Ser Val Lys 580 585 590 Ala Gly Glu Glu Ser Val Ala Gln Val Ser Gly Val Arg Glu Gln Ala 595 600 605 Ile Leu Thr Gln Ala Ile Arg Ser Glu Leu Lys Thr Gln Gly Val Leu 610 615 620 Gly His Pro Glu Val Thr Met Thr Ala Leu Ser Pro Val Trp Leu Asp 625 630 635 640 Ser Arg Ser Arg Tyr Leu Arg Asp Met Tyr Arg Pro Gly Met Val Met 645 650 655 Glu Gln Trp Asn Pro Glu Thr Arg Ser His Asp Arg Tyr Val Ile Asp 660 665 670 Arg Val Thr Ala Gln Ser His Ser Leu Thr Leu Arg Asp Ala Gln Gly 675 680 685 Glu Thr Gln Val Val Arg Ile Ser Ser Leu Asp Ser Ser Trp Ser Leu 690 695 700 Phe Arg Pro Glu Lys Met Pro Val Ala Asp Gly Glu Arg Leu Arg Val 705 710 715 720 Thr Gly Lys Ile Pro Gly Leu Arg Val Ser Gly Gly Asp Arg Leu Gln 725 730 735 Val Ala Ser Val Ser Glu Asp Ala Met Thr Val Val Val Pro Gly Arg 740 745 750 Ala Glu Pro Ala Ser Leu Pro Val Ser Asp Ser Pro Phe Thr Ala Leu 755 760 765 Lys Leu Glu Asn Gly Trp Val Glu Thr Pro Gly His Ser Val Ser Asp 770 775 780 Ser Ala Thr Val Phe Ala Ser Val Thr Gln Met Ala Met Asp Asn Ala 785 790 795 800 Thr Leu Asn Gly Leu Ala Arg Ser Gly Arg Asp Val Arg Leu Tyr Ser 805 810 815 Ser Leu Asp Glu Thr Arg Thr Ala Glu Lys Leu Ala Arg His Pro Ser 820 825 830 Phe Thr Val Val Ser Glu Gln Ile Lys Ala Arg Ala Gly Glu Thr Leu 835 840 845 Leu Glu Thr Ala Ile Ser Leu Gln Lys Ala Gly Leu His Thr Pro Ala 850 855 860 Gln Gln Ala Ile His Leu Ala Leu Pro Val Leu Glu Ser Lys Asn Leu 865 870 875 880 Ala Phe Ser Met Val Asp Leu Leu Thr Glu Ala Lys Ser Phe Ala Ala 885 890 895 Glu Gly Thr Gly Phe Thr Glu Leu Gly Gly Glu Ile Asn Ala Gln Ile 900 905 910 Lys Arg Gly Asp Leu Leu Tyr Val Asp Val Ala Lys Gly Tyr Gly Thr 915 920 925 Gly Leu Leu Val Ser Arg Ala Ser Tyr Glu Ala Glu Lys Ser Ile Leu 930 935 940 Arg His Ile Leu Glu Gly Lys Glu Ala Val Thr Pro Leu Met Glu Arg 945 950 955 960 Val Pro Gly Glu Leu Met Glu Thr Leu Thr Ser Gly Gln Arg Ala Ala 965 970 975 Thr Arg Met Ile Leu Glu Thr Ser Asp Arg Phe Thr Val Val Gln Gly 980 985 990 Tyr Ala Gly Val Gly Lys Thr Thr Gln Phe Arg Ala Val Met Ser Ala 995 1000 1005 Val Asn Met Leu Pro Ala Ser Glu Arg Pro Arg Val Val Gly Leu 1010 1015 1020 Gly Pro Thr His Arg Ala Val Gly Glu Met Arg Ser Ala Gly Val 1025 1030 1035 Asp Ala Gln Thr Leu Ala Ser Phe Leu His Asp Thr Gln Leu Gln 1040 1045 1050 Gln Arg Ser Gly Glu Thr Pro Asp Phe Ser Asn Thr Leu Phe Leu 1055 1060 1065 Leu Asp Glu Ser Ser Met Val Gly Asn Thr Glu Met Ala Arg Ala 1070 1075 1080 Tyr Ala Leu Ile Ala Ala Gly Gly Gly Arg Ala Val Ala Ser Gly 1085 1090 1095 Asp Thr Asp Gln Leu Gln Ala Ile Ala Pro Gly Gln Ser Phe Arg 1100 1105 1110 Leu Gln Gln Thr Arg Ser Ala Ala Asp Val Val Ile Met Lys Glu 1115 1120 1125 Ile Val Arg Gln Thr Pro Glu Leu Arg Glu Ala Val Tyr Ser Leu 1130 1135 1140 Ile Asn Arg Asp Val Glu Arg Ala Leu Ser Gly Leu Glu Ser Val 1145 1150 1155 Lys Pro Ser Gln Val Pro Arg Leu Glu Gly Ala Trp Ala Pro Glu 1160 1165 1170 His Ser Val Thr Glu Phe Ser His Ser Gln Glu Ala Lys Leu Ala 1175 1180 1185 Glu Ala Gln Gln Lys Ala Met Leu Lys Gly Glu Ala Phe Pro Asp 1190 1195 1200 Ile Pro Met Thr Leu Tyr Glu Ala Ile Val Arg Asp Tyr Thr Gly 1205 1210 1215 Arg Thr Pro Glu Ala Arg Glu Gln Thr Leu Ile Val Thr His Leu 1220 1225 1230 Asn Glu Asp Arg Arg Val Leu Asn Ser Met Ile His Asp Ala Arg 1235 1240 1245 Glu Lys Ala Gly Glu Leu Gly Lys Glu Gln Val Met Val Pro Val 1250 1255 1260 Leu Asn Thr Ala Asn Ile Arg Asp Gly Glu Leu Arg Arg Leu Ser 1265 1270 1275 Thr Trp Glu Lys Asn Pro Asp Ala Leu Ala Leu Val Asp Asn Val 1280 1285 1290 Tyr His Arg Ile Ala Gly Ile Ser Lys Asp Asp Gly Leu Ile Thr 1295 1300 1305 Leu Gln Asp Ala Glu Gly Asn Thr Arg Leu Ile Ser Pro Arg Glu 1310 1315 1320 Ala Val Ala Glu Gly Val Thr Leu Tyr Thr Pro Asp Lys Ile Arg 1325 1330 1335 Val Gly Thr Gly Asp Arg Met Arg Phe Thr Lys Ser Asp Arg Glu 1340 1345 1350 Arg Gly Tyr Val Ala Asn Ser Val Trp Thr Val Thr Ala Val Ser 1355 1360 1365 Gly Asp Ser Val Thr Leu Ser Asp Gly Gln Gln Thr Arg Val Ile 1370 1375 1380 Arg Pro Gly Gln Glu Arg Ala Glu Gln His Ile Asp Leu Ala Tyr 1385 1390 1395 Ala Ile Thr Ala His Gly Ala Gln Gly Ala Ser Glu Thr Phe Ala 1400 1405 1410 Ile Ala Leu Glu Gly Thr Glu Gly Asn Arg Lys Leu Met Ala Gly 1415 1420 1425 Phe Glu Ser Ala Tyr Val Ala Leu Ser Arg Met Lys Gln His Val 1430 1435 1440 Gln Val Tyr Thr Asp Asn Arg Gln Gly Trp Thr Asp Ala Ile Asn 1445 1450 1455 Asn Ala Val Gln Lys Gly Thr Ala His Asp Val Leu Glu Pro Lys 1460 1465 1470 Pro Asp Arg Glu Val Met Asn Ala Gln Arg Leu Phe Ser Thr Ala 1475 1480 1485 Arg Glu Leu Arg Asp Val Ala Ala Gly Arg Ala Val Leu Arg Gln 1490 1495 1500 Ala Gly Leu Ala Gly Gly Asp Ser Pro Ala Arg Phe Ile Ala Pro 1505 1510 1515 Gly Arg Lys Tyr Pro Gln Pro Tyr Val Ala Leu Pro Ala Phe Asp 1520 1525 1530 Arg Asn Gly Lys Ser Ala Gly Ile Trp Leu Asn Pro Leu Thr Thr 1535 1540 1545 Asp Asp Gly Asn Gly Leu Arg Gly Phe Ser Gly Glu Gly Arg Val 1550 1555 1560 Lys Gly Ser Gly Asp Ala Gln Phe Val Ala Leu Gln Gly Ser Arg 1565 1570 1575 Asn Gly Glu Ser Leu Leu Ala Asp Asn Met Gln Asp Gly Val Arg 1580 1585 1590 Ile Ala Arg Asp Asn Pro Asp Ser Gly Val Val Val Arg Ile Ala 1595 1600 1605 Gly Glu Gly Arg Pro Trp Asn Pro Gly Ala Ile Thr Gly Gly Arg 1610 1615 1620 Val Trp Gly Asp Ile Pro Asp Asn Ser Val Gln Pro Gly Ala Gly 1625 1630 1635 Asn Gly Glu Pro Val Thr Ala Glu Val Leu Ala Gln Arg Gln Ala 1640 1645 1650 Glu Glu Ala Ile Arg Arg Glu Thr Glu Arg Arg Ala Asp Glu Ile 1655 1660 1665 Val Arg Lys Met Ala Glu Asn Lys Pro Asp Leu Pro Asp Gly Lys 1670 1675 1680 Thr Glu Leu Ala Val Arg Asp Ile Ala Gly Gln Glu Arg Asp Arg 1685 1690 1695 Ser Ala Ile Ser Glu Arg Glu Thr Ala Leu Pro Glu Ser Val Leu 1700 1705 1710 Arg Glu Ser Gln Arg Glu Arg Glu Ala Val Arg Glu Val Ala Arg 1715 1720 1725 Glu Asn Leu Leu Gln Glu Arg Leu Gln Gln Met Glu Arg Asp Met 1730 1735 1740 Val Arg Asp Leu Gln Lys Glu Lys Thr Leu Gly Gly Asp 1745 1750 1755 23726PRTMethanococcoides burtonii 23Met Ser Asp Lys Pro Ala Phe Met Lys Tyr Phe Thr Gln Ser Ser Cys 1 5 10 15 Tyr Pro Asn Gln Gln Glu Ala Met Asp Arg Ile His Ser Ala Leu Met 20 25 30 Gln Gln Gln Leu Val Leu Phe Glu Gly Ala Cys Gly Thr Gly Lys Thr 35 40 45 Leu Ser Ala Leu Val Pro Ala Leu His Val Gly Lys Met Leu Gly Lys 50 55 60 Thr Val Ile Ile Ala Thr Asn Val His Gln Gln Met Val Gln Phe Ile 65 70 75

80 Asn Glu Ala Arg Asp Ile Lys Lys Val Gln Asp Val Lys Val Ala Val 85 90 95 Ile Lys Gly Lys Thr Ala Met Cys Pro Gln Glu Ala Asp Tyr Glu Glu 100 105 110 Cys Ser Val Lys Arg Glu Asn Thr Phe Glu Leu Met Glu Thr Glu Arg 115 120 125 Glu Ile Tyr Leu Lys Arg Gln Glu Leu Asn Ser Ala Arg Asp Ser Tyr 130 135 140 Lys Lys Ser His Asp Pro Ala Phe Val Thr Leu Arg Asp Glu Leu Ser 145 150 155 160 Lys Glu Ile Asp Ala Val Glu Glu Lys Ala Arg Gly Leu Arg Asp Arg 165 170 175 Ala Cys Asn Asp Leu Tyr Glu Val Leu Arg Ser Asp Ser Glu Lys Phe 180 185 190 Arg Glu Trp Leu Tyr Lys Glu Val Arg Ser Pro Glu Glu Ile Asn Asp 195 200 205 His Ala Ile Lys Asp Gly Met Cys Gly Tyr Glu Leu Val Lys Arg Glu 210 215 220 Leu Lys His Ala Asp Leu Leu Ile Cys Asn Tyr His His Val Leu Asn 225 230 235 240 Pro Asp Ile Phe Ser Thr Val Leu Gly Trp Ile Glu Lys Glu Pro Gln 245 250 255 Glu Thr Ile Val Ile Phe Asp Glu Ala His Asn Leu Glu Ser Ala Ala 260 265 270 Arg Ser His Ser Ser Leu Ser Leu Thr Glu His Ser Ile Glu Lys Ala 275 280 285 Ile Thr Glu Leu Glu Ala Asn Leu Asp Leu Leu Ala Asp Asp Asn Ile 290 295 300 His Asn Leu Phe Asn Ile Phe Leu Glu Val Ile Ser Asp Thr Tyr Asn 305 310 315 320 Ser Arg Phe Lys Phe Gly Glu Arg Glu Arg Val Arg Lys Asn Trp Tyr 325 330 335 Asp Ile Arg Ile Ser Asp Pro Tyr Glu Arg Asn Asp Ile Val Arg Gly 340 345 350 Lys Phe Leu Arg Gln Ala Lys Gly Asp Phe Gly Glu Lys Asp Asp Ile 355 360 365 Gln Ile Leu Leu Ser Glu Ala Ser Glu Leu Gly Ala Lys Leu Asp Glu 370 375 380 Thr Tyr Arg Asp Gln Tyr Lys Lys Gly Leu Ser Ser Val Met Lys Arg 385 390 395 400 Ser His Ile Arg Tyr Val Ala Asp Phe Met Ser Ala Tyr Ile Glu Leu 405 410 415 Ser His Asn Leu Asn Tyr Tyr Pro Ile Leu Asn Val Arg Arg Asp Met 420 425 430 Asn Asp Glu Ile Tyr Gly Arg Val Glu Leu Phe Thr Cys Ile Pro Lys 435 440 445 Asn Val Thr Glu Pro Leu Phe Asn Ser Leu Phe Ser Val Ile Leu Met 450 455 460 Ser Ala Thr Leu His Pro Phe Glu Met Val Lys Lys Thr Leu Gly Ile 465 470 475 480 Thr Arg Asp Thr Cys Glu Met Ser Tyr Gly Thr Ser Phe Pro Glu Glu 485 490 495 Lys Arg Leu Ser Ile Ala Val Ser Ile Pro Pro Leu Phe Ala Lys Asn 500 505 510 Arg Asp Asp Arg His Val Thr Glu Leu Leu Glu Gln Val Leu Leu Asp 515 520 525 Ser Ile Glu Asn Ser Lys Gly Asn Val Ile Leu Phe Phe Gln Ser Ala 530 535 540 Phe Glu Ala Lys Arg Tyr Tyr Ser Lys Ile Glu Pro Leu Val Asn Val 545 550 555 560 Pro Val Phe Leu Asp Glu Val Gly Ile Ser Ser Gln Asp Val Arg Glu 565 570 575 Glu Phe Phe Ser Ile Gly Glu Glu Asn Gly Lys Ala Val Leu Leu Ser 580 585 590 Tyr Leu Trp Gly Thr Leu Ser Glu Gly Ile Asp Tyr Arg Asp Gly Arg 595 600 605 Gly Arg Thr Val Ile Ile Ile Gly Val Gly Tyr Pro Ala Leu Asn Asp 610 615 620 Arg Met Asn Ala Val Glu Ser Ala Tyr Asp His Val Phe Gly Tyr Gly 625 630 635 640 Ala Gly Trp Glu Phe Ala Ile Gln Val Pro Thr Ile Arg Lys Ile Arg 645 650 655 Gln Ala Met Gly Arg Val Val Arg Ser Pro Thr Asp Tyr Gly Ala Arg 660 665 670 Ile Leu Leu Asp Gly Arg Phe Leu Thr Asp Ser Lys Lys Arg Phe Gly 675 680 685 Lys Phe Ser Val Phe Glu Val Phe Pro Pro Ala Glu Arg Ser Glu Phe 690 695 700 Val Asp Val Asp Pro Glu Lys Val Lys Tyr Ser Leu Met Asn Phe Phe 705 710 715 720 Met Asp Asn Asp Glu Gln 725 24439PRTEnterobacteria phage T4 24Met Thr Phe Asp Asp Leu Thr Glu Gly Gln Lys Asn Ala Phe Asn Ile 1 5 10 15 Val Met Lys Ala Ile Lys Glu Lys Lys His His Val Thr Ile Asn Gly 20 25 30 Pro Ala Gly Thr Gly Lys Thr Thr Leu Thr Lys Phe Ile Ile Glu Ala 35 40 45 Leu Ile Ser Thr Gly Glu Thr Gly Ile Ile Leu Ala Ala Pro Thr His 50 55 60 Ala Ala Lys Lys Ile Leu Ser Lys Leu Ser Gly Lys Glu Ala Ser Thr 65 70 75 80 Ile His Ser Ile Leu Lys Ile Asn Pro Val Thr Tyr Glu Glu Asn Val 85 90 95 Leu Phe Glu Gln Lys Glu Val Pro Asp Leu Ala Lys Cys Arg Val Leu 100 105 110 Ile Cys Asp Glu Val Ser Met Tyr Asp Arg Lys Leu Phe Lys Ile Leu 115 120 125 Leu Ser Thr Ile Pro Pro Trp Cys Thr Ile Ile Gly Ile Gly Asp Asn 130 135 140 Lys Gln Ile Arg Pro Val Asp Pro Gly Glu Asn Thr Ala Tyr Ile Ser 145 150 155 160 Pro Phe Phe Thr His Lys Asp Phe Tyr Gln Cys Glu Leu Thr Glu Val 165 170 175 Lys Arg Ser Asn Ala Pro Ile Ile Asp Val Ala Thr Asp Val Arg Asn 180 185 190 Gly Lys Trp Ile Tyr Asp Lys Val Val Asp Gly His Gly Val Arg Gly 195 200 205 Phe Thr Gly Asp Thr Ala Leu Arg Asp Phe Met Val Asn Tyr Phe Ser 210 215 220 Ile Val Lys Ser Leu Asp Asp Leu Phe Glu Asn Arg Val Met Ala Phe 225 230 235 240 Thr Asn Lys Ser Val Asp Lys Leu Asn Ser Ile Ile Arg Lys Lys Ile 245 250 255 Phe Glu Thr Asp Lys Asp Phe Ile Val Gly Glu Ile Ile Val Met Gln 260 265 270 Glu Pro Leu Phe Lys Thr Tyr Lys Ile Asp Gly Lys Pro Val Ser Glu 275 280 285 Ile Ile Phe Asn Asn Gly Gln Leu Val Arg Ile Ile Glu Ala Glu Tyr 290 295 300 Thr Ser Thr Phe Val Lys Ala Arg Gly Val Pro Gly Glu Tyr Leu Ile 305 310 315 320 Arg His Trp Asp Leu Thr Val Glu Thr Tyr Gly Asp Asp Glu Tyr Tyr 325 330 335 Arg Glu Lys Ile Lys Ile Ile Ser Ser Asp Glu Glu Leu Tyr Lys Phe 340 345 350 Asn Leu Phe Leu Gly Lys Thr Ala Glu Thr Tyr Lys Asn Trp Asn Lys 355 360 365 Gly Gly Lys Ala Pro Trp Ser Asp Phe Trp Asp Ala Lys Ser Gln Phe 370 375 380 Ser Lys Val Lys Ala Leu Pro Ala Ser Thr Phe His Lys Ala Gln Gly 385 390 395 400 Met Ser Val Asp Arg Ala Phe Ile Tyr Thr Pro Cys Ile His Tyr Ala 405 410 415 Asp Val Glu Leu Ala Gln Gln Leu Leu Tyr Val Gly Val Thr Arg Gly 420 425 430 Arg Tyr Asp Val Phe Tyr Val 435 25970PRTClostridium botulinum 25Met Leu Ser Val Ala Asn Val Arg Ser Pro Ser Ala Ala Ala Ser Tyr 1 5 10 15 Phe Ala Ser Asp Asn Tyr Tyr Ala Ser Ala Asp Ala Asp Arg Ser Gly 20 25 30 Gln Trp Ile Gly Asp Gly Ala Lys Arg Leu Gly Leu Glu Gly Lys Val 35 40 45 Glu Ala Arg Ala Phe Asp Ala Leu Leu Arg Gly Glu Leu Pro Asp Gly 50 55 60 Ser Ser Val Gly Asn Pro Gly Gln Ala His Arg Pro Gly Thr Asp Leu 65 70 75 80 Thr Phe Ser Val Pro Lys Ser Trp Ser Leu Leu Ala Leu Val Gly Lys 85 90 95 Asp Glu Arg Ile Ile Ala Ala Tyr Arg Glu Ala Val Val Glu Ala Leu 100 105 110 His Trp Ala Glu Lys Asn Ala Ala Glu Thr Arg Val Val Glu Lys Gly 115 120 125 Met Val Val Thr Gln Ala Thr Gly Asn Leu Ala Ile Gly Leu Phe Gln 130 135 140 His Asp Thr Asn Arg Asn Gln Glu Pro Asn Leu His Phe His Ala Val 145 150 155 160 Ile Ala Asn Val Thr Gln Gly Lys Asp Gly Lys Trp Arg Thr Leu Lys 165 170 175 Asn Asp Arg Leu Trp Gln Leu Asn Thr Thr Leu Asn Ser Ile Ala Met 180 185 190 Ala Arg Phe Arg Val Ala Val Glu Lys Leu Gly Tyr Glu Pro Gly Pro 195 200 205 Val Leu Lys His Gly Asn Phe Glu Ala Arg Gly Ile Ser Arg Glu Gln 210 215 220 Val Met Ala Phe Ser Thr Arg Arg Lys Glu Val Leu Glu Ala Arg Arg 225 230 235 240 Gly Pro Gly Leu Asp Ala Gly Arg Ile Ala Ala Leu Asp Thr Arg Ala 245 250 255 Ser Lys Glu Gly Ile Glu Asp Arg Ala Thr Leu Ser Lys Gln Trp Ser 260 265 270 Glu Ala Ala Gln Ser Ile Gly Leu Asp Leu Lys Pro Leu Val Asp Arg 275 280 285 Ala Arg Thr Lys Ala Leu Gly Gln Gly Met Glu Ala Thr Arg Ile Gly 290 295 300 Ser Leu Val Glu Arg Gly Arg Ala Trp Leu Ser Arg Phe Ala Ala His 305 310 315 320 Val Arg Gly Asp Pro Ala Asp Pro Leu Val Pro Pro Ser Val Leu Lys 325 330 335 Gln Asp Arg Gln Thr Ile Ala Ala Ala Gln Ala Val Ala Ser Ala Val 340 345 350 Arg His Leu Ser Gln Arg Glu Ala Ala Phe Glu Arg Thr Ala Leu Tyr 355 360 365 Lys Ala Ala Leu Asp Phe Gly Leu Pro Thr Thr Ile Ala Asp Val Glu 370 375 380 Lys Arg Thr Arg Ala Leu Val Arg Ser Gly Asp Leu Ile Ala Gly Lys 385 390 395 400 Gly Glu His Lys Gly Trp Leu Ala Ser Arg Asp Ala Val Val Thr Glu 405 410 415 Gln Arg Ile Leu Ser Glu Val Ala Ala Gly Lys Gly Asp Ser Ser Pro 420 425 430 Ala Ile Thr Pro Gln Lys Ala Ala Ala Ser Val Gln Ala Ala Ala Leu 435 440 445 Thr Gly Gln Gly Phe Arg Leu Asn Glu Gly Gln Leu Ala Ala Ala Arg 450 455 460 Leu Ile Leu Ile Ser Lys Asp Arg Thr Ile Ala Val Gln Gly Ile Ala 465 470 475 480 Gly Ala Gly Lys Ser Ser Val Leu Lys Pro Val Ala Glu Val Leu Arg 485 490 495 Asp Glu Gly His Pro Val Ile Gly Leu Ala Ile Gln Asn Thr Leu Val 500 505 510 Gln Met Leu Glu Arg Asp Thr Gly Ile Gly Ser Gln Thr Leu Ala Arg 515 520 525 Phe Leu Gly Gly Trp Asn Lys Leu Leu Asp Asp Pro Gly Asn Val Ala 530 535 540 Leu Arg Ala Glu Ala Gln Ala Ser Leu Lys Asp His Val Leu Val Leu 545 550 555 560 Asp Glu Ala Ser Met Val Ser Asn Glu Asp Lys Glu Lys Leu Val Arg 565 570 575 Leu Ala Asn Leu Ala Gly Val His Arg Leu Val Leu Ile Gly Asp Arg 580 585 590 Lys Gln Leu Gly Ala Val Asp Ala Gly Lys Pro Phe Ala Leu Leu Gln 595 600 605 Arg Ala Gly Ile Ala Arg Ala Glu Met Ala Thr Asn Leu Arg Ala Arg 610 615 620 Asp Pro Val Val Arg Glu Ala Gln Ala Ala Ala Gln Ala Gly Asp Val 625 630 635 640 Arg Lys Ala Leu Arg His Leu Lys Ser His Thr Val Glu Ala Arg Gly 645 650 655 Asp Gly Ala Gln Val Ala Ala Glu Thr Trp Leu Ala Leu Asp Lys Glu 660 665 670 Thr Arg Ala Arg Thr Ser Ile Tyr Ala Ser Gly Arg Ala Ile Arg Ser 675 680 685 Ala Val Asn Ala Ala Val Gln Gln Gly Leu Leu Ala Ser Arg Glu Ile 690 695 700 Gly Pro Ala Lys Met Lys Leu Glu Val Leu Asp Arg Val Asn Thr Thr 705 710 715 720 Arg Glu Glu Leu Arg His Leu Pro Ala Tyr Arg Ala Gly Arg Val Leu 725 730 735 Glu Val Ser Arg Lys Gln Gln Ala Leu Gly Leu Phe Ile Gly Glu Tyr 740 745 750 Arg Val Ile Gly Gln Asp Arg Lys Gly Lys Leu Val Glu Val Glu Asp 755 760 765 Lys Arg Gly Lys Arg Phe Arg Phe Asp Pro Ala Arg Ile Arg Ala Gly 770 775 780 Lys Gly Asp Asp Asn Leu Thr Leu Leu Glu Pro Arg Lys Leu Glu Ile 785 790 795 800 His Glu Gly Asp Arg Ile Arg Trp Thr Arg Asn Asp His Arg Arg Gly 805 810 815 Leu Phe Asn Ala Asp Gln Ala Arg Val Val Glu Ile Ala Asn Gly Lys 820 825 830 Val Thr Phe Glu Thr Ser Lys Gly Asp Leu Val Glu Leu Lys Lys Asp 835 840 845 Asp Pro Met Leu Lys Arg Ile Asp Leu Ala Tyr Ala Leu Asn Val His 850 855 860 Met Ala Gln Gly Leu Thr Ser Asp Arg Gly Ile Ala Val Met Asp Ser 865 870 875 880 Arg Glu Arg Asn Leu Ser Asn Gln Lys Thr Phe Leu Val Thr Val Thr 885 890 895 Arg Leu Arg Asp His Leu Thr Leu Val Val Asp Ser Ala Asp Lys Leu 900 905 910 Gly Ala Ala Val Ala Arg Asn Lys Gly Glu Lys Ala Ser Ala Ile Glu 915 920 925 Val Thr Gly Ser Val Lys Pro Thr Ala Thr Lys Gly Ser Gly Val Asp 930 935 940 Gln Pro Lys Ser Val Glu Ala Asn Lys Ala Glu Lys Glu Leu Thr Arg 945 950 955 960 Ser Lys Ser Lys Thr Leu Asp Phe Gly Ile 965 970 2643DNAArtificial SequenceSynthetic Polynucleotide 26tttttttttt cttttttttc ttttttggtt ggttgttggt tgg 432720DNAArtificial SequenceSynthetic Polynucleotide 27tttttttttt cttttttttt 202817DNAArtificial SequenceSynthetic Polynucleotide 28ggttggttgt tggttgg 172923DNAArtificial SequenceSynthetic Polynucleotide 29ttaatgctaa tcgtgatagg ggt 233028DNAArtificial SequenceSynthetic Polynucleotide 30gttctactaa accgtgtcaa tcagtgtc 28313560DNAArtificial SequenceSynthetic Polynucleotide 31gccatcagat tgtgtttgtt agtcgctttt tttttttgga attttttttt tggaattttt 60tttttgcgct aacaacctcc tgccgttttg cccgtgcata tcggtcacga acaaatctga 120ttactaaaca cagtagcctg gatttgttct atcagtaatc gaccttattc ctaattaaat 180agagcaaatc cccttattgg gggtaagaca tgaagatgcc agaaaaacat gacctgttgg 240ccgccattct cgcggcaaag gaacaaggca tcggggcaat ccttgcgttt gcaatggcgt 300accttcgcgg cagatataat ggcggtgcgt ttacaaaaac agtaatcgac gcaacgatgt 360gcgccattat cgcctagttc attcgtgacc ttctcgactt cgccggacta agtagcaatc 420tcgcttatat aacgagcgtg tttatcggct acatcggtac tgactcgatt ggttcgctta 480tcaaacgctt cgctgctaaa aaagccggag tagaagatgg tagaaatcaa taatcaacgt 540aaggcgttcc tcgatatgct ggcgtggtcg gagggaactg ataacggacg tcagaaaacc 600agaaatcatg gttatgacgt cattgtaggc ggagagctat ttactgatta ctccgatcac 660cctcgcaaac ttgtcacgct aaacccaaaa ctcaaatcaa caggcgccgg acgctaccag 720cttctttccc gttggtggga tgcctaccgc aagcagcttg gcctgaaaga cttctctccg 780aaaagtcagg acgctgtggc attgcagcag attaaggagc gtggcgcttt acctatgatt 840gatcgtggtg atatccgtca ggcaatcgac cgttgcagca atatctgggc ttcactgccg 900ggcgctggtt atggtcagtt cgagcataag gctgacagcc tgattgcaaa attcaaagaa 960gcgggcggaa cggtcagaga gattgatgta tgagcagagt caccgcgatt atctccgctc

1020tggttatctg catcatcgtc tgcctgtcat gggctgttaa tcattaccgt gataacgcca 1080ttacctacaa agcccagcgc gacaaaaatg ccagagaact gaagctggcg aacgcggcaa 1140ttactgacat gcagatgcgt cagcgtgatg ttgctgcgct cgatgcaaaa tacacgaagg 1200agttagctga tgctaaagct gaaaatgatg ctctgcgtga tgatgttgcc gctggtcgtc 1260gtcggttgca catcaaagca gtctgtcagt cagtgcgtga agccaccacc gcctccggcg 1320tggataatgc agcctccccc cgactggcag acaccgctga acgggattat ttcaccctca 1380gagagaggct gatcactatg caaaaacaac tggaaggaac ccagaagtat attaatgagc 1440agtgcagata gagttgccca tatcgatggg caactcatgc aattattgtg agcaatacac 1500acgcgcttcc agcggagtat aaatgcctaa agtaataaaa ccgagcaatc catttacgaa 1560tgtttgctgg gtttctgttt taacaacatt ttctgcgccg ccacaaattt tggctgcatc 1620gacagttttc ttctgcccaa ttccagaaac gaagaaatga tgggtgatgg tttcctttgg 1680tgctactgct gccggtttgt tttgaacagt aaacgtctgt tgagcacatc ctgtaataag 1740cagggccagc gcagtagcga gtagcatttt tttcatggtg ttattcccga tgctttttga 1800agttcgcaga atcgtatgtg tagaaaatta aacaaaccct aaacaatgag ttgaaatttc 1860atattgttaa tatttattaa tgtatgtcag gtgcgatgaa tcgtcattgt attcccggat 1920taactatgtc cacagccctg acggggaact tctctgcggg agtgtccggg aataattaaa 1980acgatgcaca cagggtttag cgcgtacacg tattgcatta tgccaacgcc ccggtgctga 2040cacggaagaa accggacgtt atgatttagc gtggaaagat ttgtgtagtg ttctgaatgc 2100tctcagtaaa tagtaatgaa ttatcaaagg tatagtaata tcttttatgt tcatggatat 2160ttgtaaccca tcggaaaact cctgctttag caagattttc cctgtattgc tgaaatgtga 2220tttctcttga tttcaaccta tcataggacg tttctataag atgcgtgttt cttgagaatt 2280taacatttac aaccttttta agtcctttta ttaacacggt gttatcgttt tctaacacga 2340tgtgaatatt atctgtggct agatagtaaa tataatgtga gacgttgtga cgttttagtt 2400cagaataaaa caattcacag tctaaatctt ttcgcacttg atcgaatatt tctttaaaaa 2460tggcaacctg agccattggt aaaaccttcc atgtgatacg agggcgcgta gtttgcatta 2520tcgtttttat cgtttcaatc tggtctgacc tccttgtgtt ttgttgatga tttatgtcaa 2580atattaggaa tgttttcact taatagtatt ggttgcgtaa caaagtgcgg tcctgctggc 2640attctggagg gaaatacaac cgacagatgt atgtaaggcc aacgtgctca aatcttcata 2700cagaaagatt tgaagtaata ttttaaccgc tagatgaaga gcaagcgcat ggagcgacaa 2760aatgaataaa gaacaatctg ctgatgatcc ctccgtggat ctgattcgtg taaaaaatat 2820gcttaatagc accatttcta tgagttaccc tgatgttgta attgcatgta tagaacataa 2880ggtgtctctg gaagcattca gagcaattga ggcagcgttg gtgaagcacg ataataatat 2940gaaggattat tccctggtgg ttgactgatc accataactg ctaatcattc aaactattta 3000gtctgtgaca gagccaacac gcagtctgtc actgtcagga aagtggtaaa actgcaactc 3060aattactgca atgccctcgt aattaagtga atttacaata tcgtcctgtt cggagggaag 3120aacgcgggat gttcattctt catcactttt aattgatgta tatgctctct tttctgacgt 3180tagtctccga cggcaggctt caatgaccca ggctgagaaa ttcccggacc ctttttgctc 3240aagagcgatg ttaatttgtt caatcatttg gttaggaaag cggatgttgc gggttgttgt 3300tctgcgggtt ctgttcttcg ttgacatgag gttgccccgt attcagtgtc gctgatttgt 3360attgtctgaa gttgttttta cgttaagttg atgcagatca attaatacga tacctgcgtc 3420ataattgatt atttgacgtg gtttgatggc ctccacgcac gttgtgatat gtagatgata 3480atcattatca ctttacgggt cctttccggt gaaaaaaaag gtaccaaaaa aaacatcgtc 3540gtgagtagtg aaccgtaagc 35603285DNAArtificial SequenceSynthetic Polynucleotide 32gccatcagat tgtgtttgtt agtcgctttt tttttttgga attttttttt tggaattttt 60tttttgcgct aacaacctcc tgccg 853372DNAArtificial SequenceSynthetic Polynucleotide 33gcttacggtt cactactcac gacgatgttt tttttggtac cttttttttc accggaaagg 60acccgtaaag tg 723446DNAArtificial SequenceSynthetic Polynucleotide 34tttttttttt tttttttttt tttttttttt tttttttttt tttttt 463527DNAArtificial SequenceSynthetic Polynucleotide 35ggttgtttct gttggtgctg atattgc 273627DNAArtificial SequenceSynthetic Polynucleotide 36gccatcagat tgtgtttgtt agtcgct 273727DNAArtificial SequenceSynthetic Polynucleotide 37acactgattg acacggttta gtagaac 273827DNAArtificial SequenceSynthetic Polynucleotide 38gcttacggtt cactactcac gacgatg 27393587DNAArtificial SequenceSynthetic Polynucleotide 39gccatcagat tgtgtttgtt agtcgctgcc atcagattgt gtttgttagt cgcttttttt 60ttttggaatt ttttttttgg aatttttttt ttgcgctaac aacctcctgc cgttttgccc 120gtgcatatcg gtcacgaaca aatctgatta ctaaacacag tagcctggat ttgttctatc 180agtaatcgac cttattccta attaaataga gcaaatcccc ttattggggg taagacatga 240agatgccaga aaaacatgac ctgttggccg ccattctcgc ggcaaaggaa caaggcatcg 300gggcaatcct tgcgtttgca atggcgtacc ttcgcggcag atataatggc ggtgcgttta 360caaaaacagt aatcgacgca acgatgtgcg ccattatcgc ctagttcatt cgtgaccttc 420tcgacttcgc cggactaagt agcaatctcg cttatataac gagcgtgttt atcggctaca 480tcggtactga ctcgattggt tcgcttatca aacgcttcgc tgctaaaaaa gccggagtag 540aagatggtag aaatcaataa tcaacgtaag gcgttcctcg atatgctggc gtggtcggag 600ggaactgata acggacgtca gaaaaccaga aatcatggtt atgacgtcat tgtaggcgga 660gagctattta ctgattactc cgatcaccct cgcaaacttg tcacgctaaa cccaaaactc 720aaatcaacag gcgccggacg ctaccagctt ctttcccgtt ggtgggatgc ctaccgcaag 780cagcttggcc tgaaagactt ctctccgaaa agtcaggacg ctgtggcatt gcagcagatt 840aaggagcgtg gcgctttacc tatgattgat cgtggtgata tccgtcaggc aatcgaccgt 900tgcagcaata tctgggcttc actgccgggc gctggttatg gtcagttcga gcataaggct 960gacagcctga ttgcaaaatt caaagaagcg ggcggaacgg tcagagagat tgatgtatga 1020gcagagtcac cgcgattatc tccgctctgg ttatctgcat catcgtctgc ctgtcatggg 1080ctgttaatca ttaccgtgat aacgccatta cctacaaagc ccagcgcgac aaaaatgcca 1140gagaactgaa gctggcgaac gcggcaatta ctgacatgca gatgcgtcag cgtgatgttg 1200ctgcgctcga tgcaaaatac acgaaggagt tagctgatgc taaagctgaa aatgatgctc 1260tgcgtgatga tgttgccgct ggtcgtcgtc ggttgcacat caaagcagtc tgtcagtcag 1320tgcgtgaagc caccaccgcc tccggcgtgg ataatgcagc ctccccccga ctggcagaca 1380ccgctgaacg ggattatttc accctcagag agaggctgat cactatgcaa aaacaactgg 1440aaggaaccca gaagtatatt aatgagcagt gcagatagag ttgcccatat cgatgggcaa 1500ctcatgcaat tattgtgagc aatacacacg cgcttccagc ggagtataaa tgcctaaagt 1560aataaaaccg agcaatccat ttacgaatgt ttgctgggtt tctgttttaa caacattttc 1620tgcgccgcca caaattttgg ctgcatcgac agttttcttc tgcccaattc cagaaacgaa 1680gaaatgatgg gtgatggttt cctttggtgc tactgctgcc ggtttgtttt gaacagtaaa 1740cgtctgttga gcacatcctg taataagcag ggccagcgca gtagcgagta gcattttttt 1800catggtgtta ttcccgatgc tttttgaagt tcgcagaatc gtatgtgtag aaaattaaac 1860aaaccctaaa caatgagttg aaatttcata ttgttaatat ttattaatgt atgtcaggtg 1920cgatgaatcg tcattgtatt cccggattaa ctatgtccac agccctgacg gggaacttct 1980ctgcgggagt gtccgggaat aattaaaacg atgcacacag ggtttagcgc gtacacgtat 2040tgcattatgc caacgccccg gtgctgacac ggaagaaacc ggacgttatg atttagcgtg 2100gaaagatttg tgtagtgttc tgaatgctct cagtaaatag taatgaatta tcaaaggtat 2160agtaatatct tttatgttca tggatatttg taacccatcg gaaaactcct gctttagcaa 2220gattttccct gtattgctga aatgtgattt ctcttgattt caacctatca taggacgttt 2280ctataagatg cgtgtttctt gagaatttaa catttacaac ctttttaagt ccttttatta 2340acacggtgtt atcgttttct aacacgatgt gaatattatc tgtggctaga tagtaaatat 2400aatgtgagac gttgtgacgt tttagttcag aataaaacaa ttcacagtct aaatcttttc 2460gcacttgatc gaatatttct ttaaaaatgg caacctgagc cattggtaaa accttccatg 2520tgatacgagg gcgcgtagtt tgcattatcg tttttatcgt ttcaatctgg tctgacctcc 2580ttgtgttttg ttgatgattt atgtcaaata ttaggaatgt tttcacttaa tagtattggt 2640tgcgtaacaa agtgcggtcc tgctggcatt ctggagggaa atacaaccga cagatgtatg 2700taaggccaac gtgctcaaat cttcatacag aaagatttga agtaatattt taaccgctag 2760atgaagagca agcgcatgga gcgacaaaat gaataaagaa caatctgctg atgatccctc 2820cgtggatctg attcgtgtaa aaaatatgct taatagcacc atttctatga gttaccctga 2880tgttgtaatt gcatgtatag aacataaggt gtctctggaa gcattcagag caattgaggc 2940agcgttggtg aagcacgata ataatatgaa ggattattcc ctggtggttg actgatcacc 3000ataactgcta atcattcaaa ctatttagtc tgtgacagag ccaacacgca gtctgtcact 3060gtcaggaaag tggtaaaact gcaactcaat tactgcaatg ccctcgtaat taagtgaatt 3120tacaatatcg tcctgttcgg agggaagaac gcgggatgtt cattcttcat cacttttaat 3180tgatgtatat gctctctttt ctgacgttag tctccgacgg caggcttcaa tgacccaggc 3240tgagaaattc ccggaccctt tttgctcaag agcgatgtta atttgttcaa tcatttggtt 3300aggaaagcgg atgttgcggg ttgttgttct gcgggttctg ttcttcgttg acatgaggtt 3360gccccgtatt cagtgtcgct gatttgtatt gtctgaagtt gtttttacgt taagttgatg 3420cagatcaatt aatacgatac ctgcgtcata attgattatt tgacgtggtt tgatggcctc 3480cacgcacgtt gtgatatgta gatgataatc attatcactt tacgggtcct ttccggtgaa 3540aaaaaaggta ccaaaaaaaa catcgtcgtg agtagtgaac cgtaagc 3587403560DNAArtificial SequenceSynthetic Polynucleotide 40gcttacggtt cactactcac gacgatgttt tttttggtac cttttttttc accggaaagg 60acccgtaaag tgataatgat tatcatctac atatcacaac gtgcgtggag gccatcaaac 120cacgtcaaat aatcaattat gacgcaggta tcgtattaat tgatctgcat caacttaacg 180taaaaacaac ttcagacaat acaaatcagc gacactgaat acggggcaac ctcatgtcaa 240cgaagaacag aacccgcaga acaacaaccc gcaacatccg ctttcctaac caaatgattg 300aacaaattaa catcgctctt gagcaaaaag ggtccgggaa tttctcagcc tgggtcattg 360aagcctgccg tcggagacta acgtcagaaa agagagcata tacatcaatt aaaagtgatg 420aagaatgaac atcccgcgtt cttccctccg aacaggacga tattgtaaat tcacttaatt 480acgagggcat tgcagtaatt gagttgcagt tttaccactt tcctgacagt gacagactgc 540gtgttggctc tgtcacagac taaatagttt gaatgattag cagttatggt gatcagtcaa 600ccaccaggga ataatccttc atattattat cgtgcttcac caacgctgcc tcaattgctc 660tgaatgcttc cagagacacc ttatgttcta tacatgcaat tacaacatca gggtaactca 720tagaaatggt gctattaagc atatttttta cacgaatcag atccacggag ggatcatcag 780cagattgttc tttattcatt ttgtcgctcc atgcgcttgc tcttcatcta gcggttaaaa 840tattacttca aatctttctg tatgaagatt tgagcacgtt ggccttacat acatctgtcg 900gttgtatttc cctccagaat gccagcagga ccgcactttg ttacgcaacc aatactatta 960agtgaaaaca ttcctaatat ttgacataaa tcatcaacaa aacacaagga ggtcagacca 1020gattgaaacg ataaaaacga taatgcaaac tacgcgccct cgtatcacat ggaaggtttt 1080accaatggct caggttgcca tttttaaaga aatattcgat caagtgcgaa aagatttaga 1140ctgtgaattg ttttattctg aactaaaacg tcacaacgtc tcacattata tttactatct 1200agccacagat aatattcaca tcgtgttaga aaacgataac accgtgttaa taaaaggact 1260taaaaaggtt gtaaatgtta aattctcaag aaacacgcat cttatagaaa cgtcctatga 1320taggttgaaa tcaagagaaa tcacatttca gcaatacagg gaaaatcttg ctaaagcagg 1380agttttccga tgggttacaa atatccatga acataaaaga tattactata cctttgataa 1440ttcattacta tttactgaga gcattcagaa cactacacaa atctttccac gctaaatcat 1500aacgtccggt ttcttccgtg tcagcaccgg ggcgttggca taatgcaata cgtgtacgcg 1560ctaaaccctg tgtgcatcgt tttaattatt cccggacact cccgcagaga agttccccgt 1620cagggctgtg gacatagtta atccgggaat acaatgacga ttcatcgcac ctgacataca 1680ttaataaata ttaacaatat gaaatttcaa ctcattgttt agggtttgtt taattttcta 1740cacatacgat tctgcgaact tcaaaaagca tcgggaataa caccatgaaa aaaatgctac 1800tcgctactgc gctggccctg cttattacag gatgtgctca acagacgttt actgttcaaa 1860acaaaccggc agcagtagca ccaaaggaaa ccatcaccca tcatttcttc gtttctggaa 1920ttgggcagaa gaaaactgtc gatgcagcca aaatttgtgg cggcgcagaa aatgttgtta 1980aaacagaaac ccagcaaaca ttcgtaaatg gattgctcgg ttttattact ttaggcattt 2040atactccgct ggaagcgcgt gtgtattgct cacaataatt gcatgagttg cccatcgata 2100tgggcaactc tatctgcact gctcattaat atacttctgg gttccttcca gttgtttttg 2160catagtgatc agcctctctc tgagggtgaa ataatcccgt tcagcggtgt ctgccagtcg 2220gggggaggct gcattatcca cgccggaggc ggtggtggct tcacgcactg actgacagac 2280tgctttgatg tgcaaccgac gacgaccagc ggcaacatca tcacgcagag catcattttc 2340agctttagca tcagctaact ccttcgtgta ttttgcatcg agcgcagcaa catcacgctg 2400acgcatctgc atgtcagtaa ttgccgcgtt cgccagcttc agttctctgg catttttgtc 2460gcgctgggct ttgtaggtaa tggcgttatc acggtaatga ttaacagccc atgacaggca 2520gacgatgatg cagataacca gagcggagat aatcgcggtg actctgctca tacatcaatc 2580tctctgaccg ttccgcccgc ttctttgaat tttgcaatca ggctgtcagc cttatgctcg 2640aactgaccat aaccagcgcc cggcagtgaa gcccagatat tgctgcaacg gtcgattgcc 2700tgacggatat caccacgatc aatcataggt aaagcgccac gctccttaat ctgctgcaat 2760gccacagcgt cctgactttt cggagagaag tctttcaggc caagctgctt gcggtaggca 2820tcccaccaac gggaaagaag ctggtagcgt ccggcgcctg ttgatttgag ttttgggttt 2880agcgtgacaa gtttgcgagg gtgatcggag taatcagtaa atagctctcc gcctacaatg 2940acgtcataac catgatttct ggttttctga cgtccgttat cagttccctc cgaccacgcc 3000agcatatcga ggaacgcctt acgttgatta ttgatttcta ccatcttcta ctccggcttt 3060tttagcagcg aagcgtttga taagcgaacc aatcgagtca gtaccgatgt agccgataaa 3120cacgctcgtt atataagcga gattgctact tagtccggcg aagtcgagaa ggtcacgaat 3180gaactaggcg ataatggcgc acatcgttgc gtcgattact gtttttgtaa acgcaccgcc 3240attatatctg ccgcgaaggt acgccattgc aaacgcaagg attgccccga tgccttgttc 3300ctttgccgcg agaatggcgg ccaacaggtc atgtttttct ggcatcttca tgtcttaccc 3360ccaataaggg gatttgctct atttaattag gaataaggtc gattactgat agaacaaatc 3420caggctactg tgtttagtaa tcagatttgt tcgtgaccga tatgcacggg caaaacggca 3480ggaggttgtt agcgcaaaaa aaaaattcca aaaaaaaaat tccaaaaaaa aaaagcgact 3540aacaaacaca atctgatggc 35604129DNAArtificial SequenceSynthetic Polynucleotide 41gcaatatcag caccaacaga aacaacctt 2942103DNAArtificial SequenceSynthetic Polynucleotide 42tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60tttttttttt ttttttggtt gtttctgttg gtgctgatat tgc 10343606DNAArtificial SequenceSynthetic Polynucleotide 43gccatcagat tgtgtttgtt agtcgctttt tttttttgga attttttttt tggaattttt 60tttttgacgc tcagtaatgt gacgatagct gaaaactgta cgataaacgg tacgctgagg 120gcggaaaaaa tcgtcgggga cattgtaaag gcggcgagcg cggcttttcc gcgccagcgt 180gaaagcagtg tggactggcc gtcaggtacc cgtactgtca ccgtgaccga tgaccatcct 240tttgatcgcc agatagtggt gcttccgctg acgtttcgcg gaagtaagcg tactgtcagc 300ggcaggacaa cgtattcgat gtgttatctg aaagtactga tgaacggtgc ggtgatttat 360gatggcgcgg cgaacgaggc ggtacaggtg ttctcccgta ttgttgacat gccagcgggt 420cggggaaacg tgatcctgac gttcacgctt acgtccacac ggcattcggc agatattccg 480ccgtatacgt ttgccagcga tgtgcaggtt atggtgatta agaaacaggc gctgggcatc 540agcgtggtct gagtgtgaaa aaaaaggtac caaaaaaaac atcgtcgtga gtagtgaacc 600gtaagc 60644606DNAArtificial SequenceSynthetic Polynucleotide 44gcttacggtt cactactcac gacgatgttt tttttggtac cttttttttc acactcagac 60cacgctgatg cccagcgcct gtttcttaat caccataacc tgcacatcgc tggcaaacgt 120atacggcgga atatctgccg aatgccgtgt ggacgtaagc gtgaacgtca ggatcacgtt 180tccccgaccc gctggcatgt caacaatacg ggagaacacc tgtaccgcct cgttcgccgc 240gccatcataa atcaccgcac cgttcatcag tactttcaga taacacatcg aatacgttgt 300cctgccgctg acagtacgct tacttccgcg aaacgtcagc ggaagcacca ctatctggcg 360atcaaaagga tggtcatcgg tcacggtgac agtacgggta cctgacggcc agtccacact 420gctttcacgc tggcgcggaa aagccgcgct cgccgccttt acaatgtccc cgacgatttt 480ttccgccctc agcgtaccgt ttatcgtaca gttttcagct atcgtcacat tactgagcgt 540caaaaaaaaa attccaaaaa aaaaattcca aaaaaaaaaa gcgactaaca aacacaatct 600gatggc 6064528DNAArtificial SequenceSynthetic Polynucleotide 45gcaatatcag caccaacaga aacaacct 284610DNAArtificial SequenceSynthetic Polynucleotide 46tttttttttt 10473560DNAArtificial SequenceSynthetic Polynucleotide 47gcttacggtt cactactcac gacgatgttt tttttggtac cttttttttc accggaaagg 60acccgtaaag tgataatgat tatcatctac atatcacaac gtgcgtggag gccatcaaac 120cacgtcaaat aatcaattat gacgcaggta tcgtattaat tgatctgcat caacttaacg 180taaaaacaac ttcagacaat acaaatcagc gacactgaat acggggcaac ctcatgtcaa 240cgaagaacag aacccgcaga acaacaaccc gcaacatccg ctttcctaac caaatgattg 300aacaaattaa catcgctctt gagcaaaaag ggtccgggaa tttctcagcc tgggtcattg 360aagcctgccg tcggagacta acgtcagaaa agagagcata tacatcaatt aaaagtgatg 420aagaatgaac atcccgcgtt cttccctccg aacaggacga tattgtaaat tcacttaatt 480acgagggcat tgcagtaatt gagttgcagt tttaccactt tcctgacagt gacagactgc 540gtgttggctc tgtcacagac taaatagttt gaatgattag cagttatggt gatcagtcaa 600ccaccaggga ataatccttc atattattat cgtgcttcac caacgctgcc tcaattgctc 660tgaatgcttc cagagacacc ttatgttcta tacatgcaat tacaacatca gggtaactca 720tagaaatggt gctattaagc atatttttta cacgaatcag atccacggag ggatcatcag 780cagattgttc tttattcatt ttgtcgctcc atgcgcttgc tcttcatcta gcggttaaaa 840tattacttca aatctttctg tatgaagatt tgagcacgtt ggccttacat acatctgtcg 900gttgtatttc cctccagaat gccagcagga ccgcactttg ttacgcaacc aatactatta 960agtgaaaaca ttcctaatat ttgacataaa tcatcaacaa aacacaagga ggtcagacca 1020gattgaaacg ataaaaacga taatgcaaac tacgcgccct cgtatcacat ggaaggtttt 1080accaatggct caggttgcca tttttaaaga aatattcgat caagtgcgaa aagatttaga 1140ctgtgaattg ttttattctg aactaaaacg tcacaacgtc tcacattata tttactatct 1200agccacagat aatattcaca tcgtgttaga aaacgataac accgtgttaa taaaaggact 1260taaaaaggtt gtaaatgtta aattctcaag aaacacgcat cttatagaaa cgtcctatga 1320taggttgaaa tcaagagaaa tcacatttca gcaatacagg gaaaatcttg ctaaagcagg 1380agttttccga tgggttacaa atatccatga acataaaaga tattactata cctttgataa 1440ttcattacta tttactgaga gcattcagaa cactacacaa atctttccac gctaaatcat 1500aacgtccggt ttcttccgtg tcagcaccgg ggcgttggca taatgcaata cgtgtacgcg 1560ctaaaccctg tgtgcatcgt tttaattatt cccggacact cccgcagaga agttccccgt 1620cagggctgtg gacatagtta atccgggaat acaatgacga ttcatcgcac ctgacataca 1680ttaataaata ttaacaatat gaaatttcaa ctcattgttt agggtttgtt taattttcta 1740cacatacgat tctgcgaact tcaaaaagca tcgggaataa caccatgaaa aaaatgctac 1800tcgctactgc gctggccctg cttattacag gatgtgctca acagacgttt actgttcaaa 1860acaaaccggc agcagtagca ccaaaggaaa ccatcaccca tcatttcttc gtttctggaa 1920ttgggcagaa gaaaactgtc gatgcagcca aaatttgtgg cggcgcagaa aatgttgtta 1980aaacagaaac ccagcaaaca ttcgtaaatg gattgctcgg ttttattact ttaggcattt 2040atactccgct ggaagcgcgt gtgtattgct cacaataatt gcatgagttg cccatcgata 2100tgggcaactc tatctgcact gctcattaat atacttctgg gttccttcca gttgtttttg 2160catagtgatc agcctctctc tgagggtgaa

ataatcccgt tcagcggtgt ctgccagtcg 2220gggggaggct gcattatcca cgccggaggc ggtggtggct tcacgcactg actgacagac 2280tgctttgatg tgcaaccgac gacgaccagc ggcaacatca tcacgcagag catcattttc 2340agctttagca tcagctaact ccttcgtgta ttttgcatcg agcgcagcaa catcacgctg 2400acgcatctgc atgtcagtaa ttgccgcgtt cgccagcttc agttctctgg catttttgtc 2460gcgctgggct ttgtaggtaa tggcgttatc acggtaatga ttaacagccc atgacaggca 2520gacgatgatg cagataacca gagcggagat aatcgcggtg actctgctca tacatcaatc 2580tctctgaccg ttccgcccgc ttctttgaat tttgcaatca ggctgtcagc cttatgctcg 2640aactgaccat aaccagcgcc cggcagtgaa gcccagatat tgctgcaacg gtcgattgcc 2700tgacggatat caccacgatc aatcataggt aaagcgccac gctccttaat ctgctgcaat 2760gccacagcgt cctgactttt cggagagaag tctttcaggc caagctgctt gcggtaggca 2820tcccaccaac gggaaagaag ctggtagcgt ccggcgcctg ttgatttgag ttttgggttt 2880agcgtgacaa gtttgcgagg gtgatcggag taatcagtaa atagctctcc gcctacaatg 2940acgtcataac catgatttct ggttttctga cgtccgttat cagttccctc cgaccacgcc 3000agcatatcga ggaacgcctt acgttgatta ttgatttcta ccatcttcta ctccggcttt 3060tttagcagcg aagcgtttga taagcgaacc aatcgagtca gtaccgatgt agccgataaa 3120cacgctcgtt atataagcga gattgctact tagtccggcg aagtcgagaa ggtcacgaat 3180gaactaggcg ataatggcgc acatcgttgc gtcgattact gtttttgtaa acgcaccgcc 3240attatatctg ccgcgaaggt acgccattgc aaacgcaagg attgccccga tgccttgttc 3300ctttgccgcg agaatggcgg ccaacaggtc atgtttttct ggcatcttca tgtcttaccc 3360ccaataaggg gatttgctct atttaattag gaataaggtc gattactgat agaacaaatc 3420caggctactg tgtttagtaa tcagatttgt tcgtgaccga tatgcacggg caaaacggca 3480ggaggttgtt agcgcaaaaa aaaaattcca aaaaaaaaat tccaaaaaaa aaaagcgact 3540aacaaacaca atctgatggc 3560

Claims

1. A method for determining the presence, absence or one or more characteristics of two or more analytes in two or more samples, comprising: (a) coupling a first analyte in a first sample to a membrane using one or more anchors; (b) allowing the first analyte to interact with a detector present in the membrane and thereby determining the presence, absence or one or more characteristics of the first analyte; (c) uncoupling the first analyte from the membrane; (d) coupling a second analyte in a second sample to the membrane using one or more anchors; and (e) allowing the second analyte to interact with a detector in the membrane and thereby determining the presence, absence or one or more characteristics of the second analyte.

2. A method according to claim 1, wherein (i) step (c) is performed before step (d), (ii) step (d) is performed before step (c) or (iii) steps (c) and (d) are performed at the same time.

3. A method according to claim 1, wherein the one or more anchors comprise a polypeptide anchor and/or a hydrophobic anchor.

4. A method according to claim 3, wherein the hydrophobic anchor comprises a lipid, fatty acid, sterol, carbon nanotube or amino acid.

5. A method according to claim 1, wherein step (c) comprises uncoupling the first analyte from the membrane by removing the one or more anchors from the membrane.

6. A method according to claim 5, wherein step (c) comprises contacting the one or more anchors with an agent which has a higher affinity for the one or more anchors than the anchors have for the membrane.

7. A method according to claim 6, wherein (i) the one or more anchors comprises cholesterol and the agent is a cyclodextrin or a derivative thereof or a lipid; (ii) the one or more anchors comprises streptavidin, biotin or desthiobiotin and the agent is biotin, desthiobiotin or streptavidin; or (iii) the one or more anchors comprises a protein and the agent is an antibody or fragment thereof which specifically binds to the protein.

8. A method according to claim 1, wherein step (c) comprises contacting the one or more anchors with an agent which reduces their ability to couple to the membrane.

9. A method according to claim 8, wherein (i) the one or more anchors comprises cholesterol and the agent is cholesterol dehydrogenase; (ii) the one or more anchors comprises a lipid and the agent is a phospholipase; or (iii) the one or more anchors comprises a protein and the agent is a proteinase or urea.

10. A method according to claim 1, wherein step (c) comprises uncoupling the first analyte from the membrane by separating the first analyte from the one or more anchors.

11. A method according to claim 1, wherein step (c) comprises uncoupling the first analyte from the membrane by contacting the first analyte and the one or more anchors with an agent which competes with the first analyte for binding to the one or more anchors.

12. A method according to claim 11, wherein the agent is a polynucleotide which competes with the first analyte for hybridisation to the one or more anchors.

13. A method according to claim 10, wherein step (c) comprises (i) contacting the first analyte and the one or more anchors with urea, tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT), streptavidin or biotin, UV light, an enzyme or a binding agent; (ii) heating the first analyte and one or more anchors; or (iii) altering the pH.

14. (canceled)

15. (canceled)

16. A method according to claim 10, wherein step (d) comprises coupling the second analyte to the membrane using the one or more anchors that were separated from the first analyte.

17. A method according to claim 16, wherein steps (c) and (d) comprise uncoupling the first analyte from the membrane by contacting the membrane with the second analyte such that the second analyte competes with the first analyte for binding to the one or more anchors and replaces the first analyte.

18. (canceled)

19. A method according to claim 1, wherein between steps (c) and (d) the method comprises removing at least some of the first sample from the membrane.

20.-26. (canceled)

27. A method according to claim 1, wherein the detector comprises a transmembrane pore.

28.-40. (canceled)

41. A method for uncoupling from a membrane an analyte coupled to the membrane using cholesterol, comprising contacting the analyte with a cyclodextrin or a derivative thereof and thereby uncoupling the analyte from the membrane.

42.-44. (canceled)

45. A kit for determining the presence, absence or one or more characteristics of two or more analytes in two or more samples comprising (a) two or more anchors which are capable of coupling the two or more analytes to a membrane and (b) one or more agents which are capable of uncoupling at least one of the two or more analytes from the membrane.

46.-48. (canceled)

49. A method according to claim 1, wherein the first and the second analytes are polynucleotides and wherein the method is for identifying or estimating the sequence of the first polynucleotide and/or the second polynucleotide.